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Abstract
Transfer RNAs (tRNAs) physically link the genetic code to an amino acid sequence,
by recruiting amino acids to three-nucleotide codons in messenger RNAs. To ensure that the
genetic code is translated as intended, tRNAs must be accurately aminoacylated and
faithfully recognize codons in the ribosome during protein synthesis. Given the critical
function of tRNAs, it has often been assumed that mutations in human tRNA genes would be
either lethal to cells or not significantly impair tRNA function. My goal was to rigorously test
this assumption in mammalian cell models, prompted by the recent discovery of
unprecedented variation in human tRNA gene sequences.
First, I review existing knowledge on links between human cytosolic tRNA biology
and disease. Next, I demonstrate that synthetic tRNA mutants can elicit significant levels of
amino acid misincorporation in human cells, which is surprisingly well tolerated. I then test
the effects of mistranslation by synthetic and natural tRNA variants on cellular models of
neurodegenerative disease, based on our hypothesis that mistranslation would exacerbate
protein-folding stress-associated diseases. I find that a natural tRNA variant occurring in
~2% of the sequenced human population has significant potential to modify the progression
and severity of Huntington’s disease, amyotrophic lateral sclerosis, and potentially other
diseases. Lastly, I investigate methodological approaches which could aid in the
characterization of other natural human tRNA variants, while demonstrating that even
identical tRNA variants may differ in phenotypic severity and effected tissues depending on
local sequence context of the tRNA gene.

Keywords
Transfer RNA, tRNA, mistranslation, amino acid misincorporation, human disease,
neurodegenerative disease, Huntington’s disease, HTT, amyotrophic lateral sclerosis, FUS,
protein aggregation, fluorescence, microscopy.
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Summary for Lay Audience
Transfer RNAs, commonly known as tRNAs, are like assembly-line workers for the
cell. Their job is to carry amino acids—the building blocks of proteins—to the ribosome,
which assembles amino acids into a protein sequence. Proteins carry out most cellular
functions. From providing structural support to the cell, to pumping ions across the cell
membrane, their functions are astoundingly diverse. Hence, the job of tRNAs is critical to
ensure that every protein is produced precisely as encoded by the human genome.
Given the critical function of tRNAs, it has often been assumed that mutations in
tRNA genes would be either lethal to cells or not significantly impair tRNA function.
However, since tRNAs are genetically encoded molecules themselves, they too are subject to
mutation, and some mutations cause tRNAs to carry the wrong amino acids to the ribosome,
or misread the genetic code, resulting in the erroneous incorporation of amino acids in
proteins. Further, it was recently discovered that tRNA gene sequence variants are common
in the human population, with the average individual harboring ~60-70 variants in tRNA
genes compared to the human reference genome.
My thesis explores tRNA genes as an underappreciated source of variability in human
diseases. First, I found that synthetic tRNA mutants can cause significant levels of amino
acid misincorporation (~2-3%) without severely impacting cell viability. Next, I found that a
naturally occurring tRNA variant found in ~2% of the sequenced human population had
potent modifying effects on cellular models of Huntington’s disease and amyotrophic lateral
sclerosis, demonstrating that tRNA variants have potential to modify the outcomes of
neurodegenerative diseases. Lastly, I investigated several methodological approaches to
characterize the many human tRNA sequence variants in the human population, while
finding that even identical tRNA gene mutations can have differing severity of effects and in
different cell types depending on which identical copy of a tRNA gene is mutated in the
genome. Altogether, my work shines a new light on tRNA variants as potentially
underappreciated modifiers of human disease and outlines new methods to study them.
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Chapter 1
1. Pathways to disease from natural variations in human cytoplasmic
tRNAs1
1.1 Introduction
Protein synthesis is an evolutionarily conserved process that is required by all life. In the interpretation
of the genetic code, transfer RNAs (tRNAs) play a central role as they physically link amino acids to
codons. Crick’s adaptor hypothesis predicted the existence of tRNAs in 1955: “each amino acid would
combine chemically, at a special enzyme, with a small molecule which, having a specific hydrogenbonding surface, would combine specifically with the nucleic acid template.” (1). Just three years later,
the first tRNAs were discovered as soluble RNAs involved in protein synthesis (2). Working in yeast,
Holley isolated tRNAs and determined the first tRNA sequence (3). The first codons were mapped to
amino acids using repeating poly-ribonucleotides as templates for protein synthesis (4,5). The labs of
Nirenberg (6) and Khorana (7) then raced to solve the complete codon catalogue using a technique that
monitored the binding of radiolabeled aminoacyl-tRNAs to ribosomes separately prepared with each of
the possible 64 trinucleotide codons. These efforts established the standard genetic code table for which
Holley, Khorana, and Nirenberg were awarded the Nobel prize in Physiology or Medicine in 1968.
Fascinatingly, by the time the prize was awarded, exceptions to the genetic code had already been
identified. In 1966, Yanofsky and colleagues demonstrated tRNA mutants enabled missense suppression
or amino acid mis-incorporation using a defective tryptophan synthase A gene in Escherichia coli (8).
Early in 1968, Atkins identified the first exception to triplet decoding with the discovery of frame-shifting
in Salmonella typhimurium (9). Indeed, while the genetic code is nearly universal in the living world,
several exceptions to the standard code occur in diverse organisms (10). Genome sequences, genetic and
biochemical data reveal that in organisms from microbes to humans, codons can be ambiguously decoded
(8,11-13), reassigned (14,15), or site-specifically recoded (16-18) to incorporate unexpected amino acids
or amino acids beyond the standard set of 20.

1

Work in this chapter was published in: Lant, J.T., Berg, M.D., Heinemann, I.U., Brandl, C.J.,
O’Donoghue, P. (2019). Pathways to disease from natural variations in human cytoplasmic tRNAs.
Journal of Biological Chemistry.
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Given the importance of cytosolic tRNAs to facilitate accurate synthesis of the proteome,
surprisingly few examples have linked a cytosolic tRNA mutation to human disease thus far. Yet, recent
examples directly connecting cytosolic tRNA mutations to disease in humans (19) and separately to
neurodegeneration (20,21) and cancer (22) in mice suggest that cytosolic tRNA variants play a greater
role in disease than previously imagined. It is possible that significant changes to tRNA function are not
usually tolerated in the genome or that defective tRNA alleles may be genetically buffered by multiple
copies of each iso-decoder. Nevertheless, two empirical observations suggest tRNAs have a larger role
in disease than previously recognized: i) the unexpectedly large number of tRNA variants in the human
population (Tables 1.1, 1.2, 1.3, S1.1) and ii) the fact that even a single nucleotide change in a single
tRNA gene can cause mistranslation or stall translation leading to molecular and cellular defects (e.g.,
(13,21,23)). The majority of research connecting human tRNA function to disease is focused on
mutations in aminoacyl-tRNA synthetases (AARSs) (reviewed in (24)), on proteins that modify
nucleotides in cytosolic tRNAs (25,26), or on the smaller pool of mitochondrial tRNAs (27-29). Two
major reasons for this are a relative lack in available sequence data for cytosolic tRNAs, and a long-held
assumption that excessive tRNA copy number should ‘buffer’ potential phenotypes resulting from a
single mutant.
In this review, we outline the complexity of cytosolic tRNA function and regulation in eukaryotic
cells. We then summarize recent studies demonstrating examples of single nucleotide tRNA variants that
elicit significant levels of amino acid mis-incorporation, which can be surprisingly well-tolerated in
eukaryotic cells. Using data from the 1000 Genomes Project, we analyzed the location and frequency of
naturally occurring human tRNA variants. These data reveal an abundance of mistranslating tRNAs in
the human population. Finally, we summarize recent evidence linking tRNA mutations and de-regulated
tRNA expression and nucleotide modification to disease in humans and model systems. Some of the
studies point to the idea that tRNA mutations, which are otherwise tolerated or benign, contribute to
disease in the context of other coincidental cellular defects.
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1.2 tRNA function and regulation

Figure 1.1. tRNA structure. (A) Transfer RNAs fold into an L-shaped 3-dimensional structure with
extensive intramolecular base-pairing. This tRNAPhe structure (PDB: 1OB5) (134) is aminoacylated with
phenylalanine (AA). (B) In a two-dimensional representation, tRNA resembles a cloverleaf. In both
diagrams, the tRNA is colored by structural elements: acceptor stem (red), dihydrouridine (D)-arm
(green), anticodon stem (cyan), anticodon (bases 34, 35, 36 in purple), variable loop (yellow), TΨC (T)
arm (navy), and the conserved CCA-3’ end (white). A schematic mRNA is shown below the tRNA
diagram to indicate the tRNA nucleotides that base pair with each codon position.

1.2.1 The role of tRNA in decoding the genetic code.
Transfer RNAs are best known for their role in translation of RNA messages into proteins. tRNAs
are relatively small RNA molecules, typically consisting of 76 - 90 nucleotides, and fold into a conserved
three-dimensional structure in the shape of an upside-down L (Fig. 1.1A). The anticodon resides at the
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long end of the L-shape and binds to cognate codons in the messenger RNA (mRNA) on the ribosome.
On the opposite end of the tRNA, the amino acid is ligated to the 3’ terminal adenosine residue in the
acceptor stem. Accurate tRNA aminoacylation and high-fidelity decoding of codons on the ribosome are
key determinants to accurate protein production.
Codon recognition is determined by the tRNA anticodon, which base-pairs with tri-nucleotide
codons in mRNAs during protein synthesis (Fig. 1.1B). The essential interaction between codon and
anticodon is established not only by Watson-Crick base pairing, but also by nucleotide modifications in
tRNAs (30,31), competition between cognate and near-cognate decoding (32,33), and wobble decoding.
Generally, the first two positions of a codon form Watson-Crick pairs with the tRNA, while the third
position is more flexible (30). In back-to-back publications, Crick hypothesized (34) what Söll et al.
determined experimentally (35), that the third position of a codon can involve G:U or U:G wobble pairing
with the 1st position of the anticodon at tRNA nucleotide 34. Indeed, the initial discoveries also included
examples of extended wobble decoding in yeast arginine and alanine tRNAs that read codons ending in
U, C, or A (35). Extended wobble decoding is facilitated by post-transcriptional tRNA modification,
where adenosine residues at position 34 are modified to inosine, which pairs with U, C, or A in the third
codon position (30). Additional nucleotide modifications in the anticodon loop (particularly at positions
34 and 37) also impact translation fidelity and reading-frame maintenance (36,37). For example, in yeast,
a 5-methoxycarbonylmethyl-2-thiouridine modification at anti-codon base U34 represses +1 frameshifting. Lack of the modification or hypo-modification at this site in a variety of tRNAs leads to 1.5 to
3.0-fold increases in ribosomal frame-shifting (38). Similarly, absence of the modified base N6threonylcarbamoyladenosine (t6A) at the anticodon adjacent position 37 also increases frame-shifting in
yeast by 2-fold (39).
The standard genetic code is comprised of 61 sense codons which encode 20 amino acids and 3
codons (UGA, UAG and UAA) that usually signal termination of protein synthesis. Since certain tRNAs
decode up to three or four different codons, the theoretical minimum number of tRNAs for an organism
to encode 20 amino acids is 32 (34). Söll et al. observed (35) that the “minimum number of sRNA [tRNA]
molecules required for recognition of all of the meaningful codons is relatively small, and this conclusion
in turn raises the question of redundancy in the sRNA pool of a cell.” This question, raised the year after
the code was solved, is still unanswered today. As a result of the genome sequencing revolution, we
know now that nature contains examples of organisms with tRNA gene complements that are well below
and vastly greater than this apparent minimal requirement. There are examples of organelles (e.g., human
mitochondria with 22 tRNA genes) and even parasitic microbes (e.g., Mycoplasma mobile with 28 tRNA
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genes (40)) with fewer than 32 tRNA genes. Their survival depends on importing the missing tRNAs
from a different cellular compartment (41) or presumably a host cell.

Figure 1.2 Phylogenetic relationships of human and yeast tRNA Ala. The tree is based on an alignment
of all known human and yeast tRNAAla iso-acceptors. The vastly expanded number and greater diversity
of human tRNAAla genes compared to their yeast counterparts is evident. The tRNAs are labeled
according to gene names in the genomic tRNA database (43), which include anticodon sequence
followed by a numbering system where the first number indicates similar sequences, and the second a
gene copy identifier. The human reference genome contains a misannotated tRNA Ala, which was used to
root the tree. This gene, tRNAAla-GGC-19-3, is a tRNAThr with a mutation (T36C) endowing the tRNA
with an alanine anticodon. This is the only example of the alanine GGC anticodon in humans. Scale bar
indicates the number of nucleotide changes per site in the tRNA sequences. The tree was calculated
similarly as before (135). Briefly, a starting tree computed in MultiSeq 2.0 (136) was optimized to
identify the maximum likelihood tree using PhyML 3.1 (137). Statistical branch support (out of 100) was
calculated based on an approximate likelihood ratio test method (138) as implemented in PhyML.
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Escherichia coli encodes 88 tRNA genes, while yeast has a small tRNAome for a eukaryote at
275 tRNA genes. Eukaryotes typically have hundreds of tRNA genes that display a general trend to
increase in number and sequence diversity with the complexity of the organism (42). Unicellular
protozoans encode near the theoretical minimum of tRNA genes, such as the malaria parasite
Plasmodium falciparum, which has only 35 tRNA genes (43). P. falciparum was recently found to import
additional tRNAs from its host (44). Some species of fish have astoundingly high tRNA gene numbers
(Table S1.2), such as the elephant shark (Callorhinchus milii), which encodes 13,724 tRNAs (43). As
exemplified in a phylogenetic comparison of yeast and human alanine tRNAs (Fig. 1.2), the sequence
variations among tRNA iso-acceptors appears to increase with complexity as well. Yeast has 16 tRNA Ala
iso-acceptors including 11 identical genes with the AGC anticodon and 5 identical genes with the TGC
anticodon. In contrast, humans encode 45 tRNAAla iso-acceptors with markedly greater sequence
diversity than their yeast counterparts including examples with CGC anticodons not seen in yeast (Fig
1.2).

1.2.2 tRNA regulation in human cells.
The number of expressed tRNA genes in human cells is not well defined. Of the 610 tRNA genes
in humans, the genomic tRNA database predicts 417 genes in their high confidence set, indicating the
tRNA is likely to function in protein synthesis (43). Comprehensive profiling of RNAs in human serum
suggests 411 expressed tRNA genes (45). According to CHIP-seq analysis of RNA Polymerase III and
transcription factor occupancy, ~350 tRNA genes are actively transcribed in a single human cell line
(IMR90hTert) (46). Gogakos et al. (98) reported the expression of 288-349 tRNAs in HEK 293 cells
based on two different RNA sequencing methods (47). Together the data suggest 300-400 tRNA genes
are expressed in any individual human cell.
The degree to which each human tRNA contributes to protein synthesis has not been determined,
but evidence that cells regulate tRNA expression to control protein production is emerging. First,
expression of individual tRNA genes varies between tissues (48,49). Further, the steady-state level of
different tRNAs correlates with the expression of matched-codon biased mRNA transcripts (48). The
observation suggests that cells can fine-tune tRNA expression profiles to match codon usage in expressed
mRNAs. Indeed, the fact that efficient protein expression requires tRNA levels and decoding capacity
match the distribution of codons in mRNA is well known. Multiple E. coli strains and bioinformatic tools
for codon adaptation were developed based on this principle to enhance the production of eukaryotic and
other recombinant proteins in bacteria (50).
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Once transcribed, tRNAs are processed via the removal and addition of nucleotides to produce a
mature tRNA. Introns, 5’-leader and 3’-trailer sequences in the original transcript are removed (51).
Next, the CCA-adding enzyme elongates the pre-tRNA with the conserved CCA 3’-end. CCA-adding
enzymes can append a second CCA to certain tRNAs with mismatches or excessive G:U pairs in their
acceptor stems (52). The double CCA addition primes tRNAs for exonucleolytic digestion via the rapid
tRNA decay pathway (53). The human CCA adding enzyme (TRNT1) is implicated in disease. Complete
loss-of-function in TRNT1 is embryonic lethal, and partial loss-of-function mutations cause congenital
sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD) (54).
tRNAs are further processed with a variety of post-transcriptional nucleotide modifications,
including 2’ O-methylation of the ribose, N-acetylation and N-methylation of the nucleotide bases as
well as more complex modifications that form bases such as Wybutosine (reviewed in (55)).
In eukaryotes, tRNAHis is post-transcriptionally edited to add an extra guanine (G-1) to the 5’-end
of the tRNA, a unique feature recognized and required by the cognate histidyl-tRNA synthetase (56).
Depleting the tRNAHis guanylyltransferase that catalyzes G-1 addition leads to accumulation of unaminoacylated and un-guanylated, yet hyper-methylated tRNA His in the nucleus (57). Subsequent studies
point to tRNAHis m5C hypermethylation as a response to growth arrest in S. cerevisiae, although the
significance of the increase in m5C methylation is yet unclear (58). Monomethylation of the 5′monophsosphate of tRNAHis by Bicoid interacting 3 domain containing RNA methyltransferase
(BCDIN3D) is thought to protect tRNAHis from degradation. BCDIN3D is overexpressed in breast cancer
cells, and monomethylated tRNAHis is more abundant in breast cancer cells, yet the overall level of
tRNAHis is not impacted (59). It is thought that monomethylation contributes to the formation of tRNA Hisderived fragments in breast cancer cells, which in turn regulates tumorigenic genes involved in breast
cancers (60).
In fact, tRNAs are the most frequently modified non-coding RNA known, containing an average
of 13 modifications per molecule (61). The combined number of expressed tRNA genes and their
multiple modification states imply the existence of a large combinatorial number of tRNA microspecies
in the human cell (62). Since tRNA modifications are important for translation fidelity and reading frame
maintenance (34,36,37,63), these microspecies have the potential to impact cellular function and disease.
Modifications are also essential for regulating tRNA turnover (64) and for proper structure, folding, and
stability of the tRNA (55). Indeed, many tRNA modifying enzymes are already linked to disease (26).
As described below, tRNA modification can also dynamically up- or down-regulate sets of tRNAs (6567).
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The mature and active tRNA is a substrate for amino acid ligation catalyzed by the AARS
enzymes in an ATP-dependent reaction (68). Each AARS enzyme has specificity both for an amino acid
and a distinct set of cognate tRNA iso-acceptors. Amino acids are ligated to the 3’-end of tRNAs,
requiring the presence of a CCA 3’-tail. To ensure tRNA recognition fidelity, AARSs make essential
contacts with nucleotides in their cognate tRNAs, called identity elements (69). Aminoacyl-tRNAs are
then substrates for protein synthesis. The likelihood that a given aminoacyl-tRNA acts in translation
depends upon many factors including the stability of the tRNA, the number of aminoacylated-tRNAs
competing for the same codon, and the expression of mRNAs containing codons read by the tRNA.
tRNAs unfit for translation are degraded by rapid tRNA decay pathway (70). Cytoplasmic tRNA levels
are also regulated by export processes to other cellular compartments, including into mitochondria (71),
or retrograde transport into the nucleus (72). As reviewed elsewhere (62), tRNAs perform additional
functions outside of translation, either as whole tRNAs (73) or tRNA-derived fragments (74).

1.3 Phenotypes of mistranslating cells
Mistranslation occurs in all cells (75) as a result of multiple different mechanisms. Considering
the small size, multitude of protein partners and essential cellular role of tRNAs, single nucleotide
changes can have a profound impact on their function and on the efficiency and fidelity of protein
synthesis (12,13,23,69). Proteins encoded by mRNAs containing rare codons or strongly biased codon
compositions are most susceptible to the effects of tRNA variants. Loss-of-function mutations in tRNAs
can cause ribosome stalling to de-regulate protein synthesis, while gain-of-function mutations in tRNAs
can lead to mis-aminoacylation and mistranslation (12,21).
Mistranslating tRNAs can arise from surprisingly minor changes to the nucleotide sequence.
Although many tRNAs harbor major identity determinants in their anticodon, coupling aminoacylation
fidelity to codon assignment; alanyl-, leucyl-, and seryl-tRNA synthetases do not recognize the anticodon nucleotides on their cognate tRNAs. Anticodon mutations in these tRNAs often elicit amino acid
mis-incorporation (69). The accumulation of highly active tRNASer anticodon mutants is toxic to yeast
cells, causing proteome wide mistranslation (23). In yeast, the degree of anticodon mutant toxicity varies,
depending on competition with wild type tRNAs, chemical properties of the amino acids and tRNA
modifications (76).
Santos et al. analyzed tRNASer variants containing Ala or Leu anticodons in murine NIH 3T3
cells grown in culture and subsequently xenografted to live mice (22). As determined by mass
spectrometry in tumor samples recovered from the mice, the rate of mistranslation increased by ~2-fold
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in the cells expressing tRNASer containing an alanine anticodon, but only marginally in cells expressing
tRNASer with a leucine anticodon. Mistranslation was not toxic to the NIH 3T3 cells when grown in
culture as determined by cellular viability, necrosis, and proliferation assays, indicating that increased
cytosolic tRNA-dependent mistranslation was initially well-tolerated. Interestingly, expressing the
mistranslating tRNAs promoted the formation of foci in vitro, suggesting a link to tumorigenesis (22).
Briefly, foci formation occurs when cancer-like cells form dense clusters resembling early-stage tumors
on a petri dish (77). Mistranslating tRNAs promoted the activation of the oncogenic factors protein
kinase B (Akt) and p38 when cells were treated with tumor necrosis factor alpha (TNF-α), to a greater
extent than cells expressing the wildtype tRNAs. Furthermore, cells mistranslating alanine codons with
serine promoted angiogenesis in a chick chorioallantoic membrane assay (CAM) and were highly
tumorigenic when introduced in mice. In comparison to the parent cells in culture, expression of the
mistranslating tRNAs increased ~8-fold in cells recovered from mouse tumors. Although mistranslating
tRNAs variants had undetectable cytotoxicity in cells in culture, the mutant tRNAs exacerbated or
accelerated cellular pathways to cancer in a mammalian model of disease (22).
Identity element mutations are another route to mistranslating tRNAs. The phenotypic
consequences of a single tRNA variant of this type are the subject of a number of recent studies. AlaRS
recognizes two critical identity determinants at the 3rd base pair in the acceptor stem (G3:U70) (78), and
also aminoacylates tRNAs bearing GU pair at the 4th acceptor stem base pair (76). tRNA variants that
convert non-alanine tRNAs to alanine accepting tRNAs by creating these identity elements are common
in mammalian genomes (79). Some human tRNACys and tRNAThr species with G4:U69 base pairs are
natural alanine acceptors, and cysteine to alanine mistranslation was detected in HEK 293 cells (79). An
Animalia specific tRNA deacylase was recently discovered that co-occurs with tRNA Thr G4:U69 variants
in animal genomes and de-acylates mis-charged Ala-tRNAThr (80). This enzyme may protect human cells
from alanine mistranslation at threonine codons.
In our work on tRNA-dependent mistranslation, we expressed a mutant of human tRNA Pro
containing a G3:U70 base pair in human cells. The human tRNA Pro mutant was an efficient alanine
acceptor in vitro that no longer accepted proline. Our previous work in yeast demonstrated that a
homologous tRNAPro mutant mistranslated multiple proline codons with alanine (13). We developed a
green fluorescent protein reporter (D129P) that fluoresces in response to mistranslation at the Pro129
codon. In HEK 293 cells (12), we did not observe significant mistranslation in rich media compared to
cells expressing wildtype tRNAPro. When the cells were starved of serum and glucose over a period of
days, mistranslation accumulated to 2-5% according to the GFP reporter. Strikingly, and similar to the
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report of Santos et al. (22), we did not observe a loss in cellular viability or induction of the heat shock
response compared to cells expressing the wildtype tRNA, indicating that this level of mistranslation was
well tolerated. In yeast, a mistranslating tRNA did show synthetic slow growth when coupled with
deletion mutants lacking the proteome regulatory transcription factor Rpn4 (13). The above examples
illustrate how phenotypes driven by a mistranslating tRNA variant can remain hidden; yet, in conditions
of stress or in models of disease, an otherwise neutral tRNA variant can interact synthetically with a
stressor or a second mutation to cause phenotypic defects.
Errors in protein synthesis are normally thought to be deleterious, yet mistranslation is an
adaptive response in diverse organisms from bacteria (81) to yeast (13) to human cells (82). In some of
these cases mistranslation provides a selective advantage. As reviewed elsewhere (83), a recurrent
finding is that stress conditions reduce aminoacylation fidelity (84). For example, upon oxidative stress,
methionyl-tRNA synthetase increases its mis-aminoacylation of non-cognate tRNAs up to 10-fold in
bacteria and mammalian cells (82,85,86); the additional methionine in proteins is thought to protect the
proteome from oxidative damage.

1.4 tRNA variation in humans
Human tRNA variants that likely mistranslate can be readily identified in publicly available sequence
data (43) (Tables 1.1, 1.2, S1.1). Some of these natural variants (79) or similar variants designed in the
laboratory (12,22) do in fact cause mistranslation in human cells. In addition, tRNA variants which
simply impair tRNA folding or function also impact the proteome. The absence of even a single tRNA
gene product can alter the tRNA pool and limit the rate of protein synthesis by causing ribosome stalling
(21). In both capacities, mutations in tRNA encoding genes represent an important class of potential
disease modifiers that could increase the severity of other disease-causing alleles.
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Figure 1.3 Transfer RNA variants observed in the 1000 Genomes Project. (A) Variants that occur
within tRNA genes (defined by GtRNAdb(128)) were downloaded from the 1000 Genomes Project phase
3 dataset (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/). Insertions and deletions were
removed, as were variants with no allele frequency available. Each variant was mapped to its
corresponding tRNA position, according to standardized numbering (139), using an in-house Perl script.
High confidence tRNAs were defined as tRNAs with a tRNAscan-SE score > 50 (128). For the high
confidence tRNA set, unique mutations are mapped to each position in the tRNA. (B) The same data in
(A) is plotted for the high-confidence set (cyan dashed line) and for all human tRNA sequences (red
line). (C) The allele frequencies (log2 scale) of all variants that occur at each tRNA position are
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represented in box and whisker plots. Boxes outline quartiles of the allele frequency distribution, filled
circles depict the median allele frequency, whiskers show 1.5 × quartile range, and hollow circles depict
raw data, i.e., the allele frequencies for each unique tRNA variant at the indicated position.
To visualize the nature and extent of human tRNA variation, we analyzed data from the 1000
Genomes Project and plotted the number of unique variants at each position in an alignment of all human
tRNA genes (Fig. 1.3A,B). The number of unique variants were mapped on the tRNA secondary structure
(Fig 1.3A). We also plotted the frequency of occurrence of each of these tRNA mutations in the human
population (Fig. 1.3C). Some tRNAs, such as those for leucine, serine, and selenocysteine have
significantly larger variable loops; variation from these regions was not included. No position in human
tRNA genes is immune to variation, yet some positions are far more variable than others (Fig. 1.3A, B).
The allele frequency of these variants indicates that common (> 5% allele frequency) and rare variants
(< 5% allele frequency) are distributed across nearly all sites in the tRNA (Fig. 1.3C). Some sites,
however, lack common variants. Although restricted to rare variants, variation is observed at position
73; this ‘discriminator’ base is a key identity element for many AARSs. The anticodon shows variation
at all 3 bases, albeit reduced compared to other regions of the tRNA. The data from 1000 Genomes
Project suggests that across all ~600 tRNA loci, there are 25-30 unique nucleotide variants at each anticodon base and these include both common and rare variants in the population (Fig. 1.3C).
Positions within the acceptor stem contain large numbers of unique variants. Many AARSs
recognize acceptor stem nucleotides to ensure aminoacylation fidelity (69), thus, acceptor stem variants
have the potential to elicit mistranslation or lead to a defective tRNA. Another compelling observation
is that several important sites of tRNA modification display significant variation (e.g., position 37 in the
anticodon loop) (Fig. 1.3). Consistent with this observation, mutations in tRNA-modifying enzymes that
act at these positions are implicated in disease (26).
As mentioned above, most human AARSs recognize identity determinants in the tRNA anticodon
except for AlaRS, LeuRS, and SerRS (69), thus, non-synonymous anticodon variants in Ala, Leu, and
Ser tRNAs are likely to mistranslate. Correspondingly, the tRNA variants that have already been shown
to elicit mistranslation in human cells have mutations in the tRNA anticodon or create the identity
determinants for AlaRS (12,78,79). Anticodon mutations in other tRNAs typically reduce or ablate
amino-acylation (69). However, the degree of amino-acylation loss is not known for all anticodon
positions in all tRNAs, and in some cases efficient amino-acylation can be retained even when some
identity determinants are mutated (87).
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Certainly, mistranslating tRNAs can arise from a variety of mechanisms. In terms of mutations
in the tRNA, substitutions at aminoacylation identity elements or anti-determinants that normally exclude
non-cognate aminoacylation in nearly any tRNA have the potential to lead to mis-aminoacylated tRNAs
and mistranslation. Although such mutants likely occur in the human population, there is a paucity of
biochemical data regarding human tRNA identity elements and anti-determinants, thus challenging
confident identification of such variants as mistranslating tRNAs from sequence alone. Anti-codon
mutations in Ser, Ala, and Leu, however, will undoubtedly lead to amino acid mis-incorporation. For this
reason, our discussion of specific mistranslating tRNA examples from human genomes focused on these
‘obvious’ mistranslating tRNAs.
To assess the prevalence of likely tRNA mistranslators in the human population, we searched the
Genomic tRNA database (GtRNAdb) for high-confidence Ala, Leu, and Ser tRNAs with anticodon
mutations (Table 1.1) or mutations in the 3rd or 4th acceptor stem base pair that create the G3:U70 (Table
1.2) or G4:U69 (Table S1.1) AlaRS identity element. In total, among the human Ala, Leu, and Ser isoacceptor groups reported in GtRNAdb there are 27 unique anti-codon variants. Of these, there are 14
unique non-synonymous (Table 1.1) and 13 synonymous anticodon variants. Most non-synonymous
anticodon variants are rare, but three variants occur in >1% of the population. One alanine tRNA variant
containing a glycine anticodon occurs in over 6% of sequenced individuals. The common occurrence of
these mutations in cytosolic tRNAs is striking; analogous variants in mitochondrial tRNAs are embryonic
lethal (27). Although we found a similar number of unique synonymous anti-codon variants, none were
found in > 1% of sequenced individuals. While still encoding the ‘correct’ amino acid, such mutants may
more or less efficiently read synonymous codons for a particular amino acid, altering translation rates.
Further complicating this scenario, certain apparently synonymous anticodon variants may
become mis-translators through nucleotide modification. For example, tRNAs normally containing an
A34 are modified to inosine (I34) by the action of adenine deaminases acting on tRNAs (ADATs) (88).
As noted above, I34 enables expanded wobble decoding to codons ending in U, C or A, thus, A34
containing tRNAs are normally restricted to those amino acids with synonymous codons ending in U, C,
and A. However, human genomes include examples of tRNAs bearing A34 that, if modified to I34,
would lead to mis-translation (e.g., tRNA-Ser-GCT-5-1 single nucleotide polymorphism (SNP)
rs550301646; tRNA-Asn-ATT-1-1 and tRNA-Tyr-ATA-1-1 are in the human reference genome). In the
case of tRNAAsn, A34I would incorporate Asn at Lys AAA codons. This type of phenomenon was
recently examined with anticodon variants of Methanocaldococcus jannaschii tRNATyr expressed in E.
coli (89,90). In this case, a tRNATyr mutant with an AUG anticodon decoded both histidine CAU and
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CAC codons with tyrosine at approximately equal efficiency (2-3%); the mutant tRNA Tyr AUG
anticodon was indeed partially modified to IUG (89). Perhaps as a natural defense against mistranslation
and resulting of abundant Gln-tRNAGln1UUG, mis-incorporation of tyrosine at glutamine CAA codons was
not detected in E. coli (89).
Adding to the complexity of human tRNA variation, tRNA genes are particularly susceptible to
transcription-associated mutagenesis (TAM) (91), and thus, their sequence can change more rapidly than
other genes. Thornlow et al. demonstrated that tRNA genes experience 7- to 10- fold higher rates of
TAM compared to the genome-wide average (91). TAM occurs when DNA strands are separated during
transcription and the non-template strand becomes temporarily isolated, and more accessible to mutagens
(92). While tRNA variation is generally selected against on a population scale, this implies that the
sequence of tRNA genes within individual cells could change throughout life and that perturbations that
increase a tRNAs expression could further increase mutation rates.
Table 1.1 Human tRNA anticodon variants
tRNA gene

variant

MAF

variant

MAF

variant

tRNA

codon

tRNA

expression

(%)a

counta

(%)b

countb

scorec

identity

identity

ARMd CHIPe

Ala-AGC-2-2

G35A

0.02

1

-

-

84.7

Val

Ala

+

+

Ala-AGC-6-1

G35C

6.55

328

6.47

8130

74.1

Gly

Ala

+

+

Ala-AGC-15-1

C36T

0.04

2

0.03

42

56.7

Thr

Ala

+

-

Ala-AGC-16-1

G35A

2.2

11

2.1

269

53.1

Val

Ala

+

-

Ala-CGC-1-1

G35T

-

-

0.0008

1

79.7

Glu

Ala

+

+

Ala-TGC-1-1

G35A

-

-

-

-

80.5

Val

Ala

+

+

Leu-CAA-3-1

A35C

-

-

0.0008

1

77.3

Trp

Leu

+

+

Ser-AGA-2-2

G35A

0.02

1

0.003

4

89.6

Phe

Ser

+

+

Ser-AGA-2-3

G35A

1.82

91

1.87

2347

89.6

Phe

Ser

+

+

Ser-AGA-2-4

G35C

-

-

0.003

4

89.6

Cys

Ser

+

+

Ser-AGA-2-5

_35T

-

-

0.0008

1

89.6

-

-

+

+

Ser-CGA-2-1

_36T

-

-

0.03

34

94

-

-

+

-

Ser-TGA-2-1

G35A

0.04

2

0.02

22

90.4

Leu

Ser

+

+

Ser-TGA-3-1

_36T

-

-

0.0008

1

89.7

-

-

+

+

MAF; minor allele frequency. _##N; inserted nucleotide. aData from 1000 Genomes Project (127,128);
b

Data from TOPMED sequencing project (128,129); ctRNA score was calculated using tRNA-Scan SE

(128); dARM = ARM-seq data suggesting expression (128,130); eCHIP = CHIP-seq hits for at least 3 of
4 core transcription proteins (RPC155, POLR3G, BRF1, BDP1) (46,129,131-133).
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Table 1.2. Human tRNA variants that introduce a G3:U70 base pair
tRNA gene

variant

MAF

variant

MAF

variant

tRNA

expression

(%)a

counta

(%)b

countb

scorec

ARMd CHIPe

Arg-ACG-1-3

C70U

-

-

0.002

2

68

+

+

Cys-GCA-2-3

C70U

-

-

0.02

29

82

+

+

Cys-GCA-1-1

C70U

0.02

1

0.07

86

84

+

-

Cys-GCA-17-1

C70U

-

-

0.002

2

71

+

+

Cys-GCA-12-1

C70U

0.02

1

0.01

16

72

+

+

Gly-CCC-2-1

G70U

-

-

0.05

64

75

+

+

Gly-GCC-2-4

A3G

0.08

4

0.05

63

81

+

-

Gly-GCC-2-5

A3G

0.02

1

0.005

6

81

+

-

Gly-GCC-2-1

A3G

0.02

1

0.02

20

81

+

+

Gly-GCC-2-3

A3G

-

-

-

-

81

+

+

Gly-GCC-1-5

A3G

1.2

61

1.3

1633

81

+

+

Gly-GCC-5-1

A3G

0.02

1

0.1

129

55

-

-

Gly-TCC-2-6

C70U

0.03

14

0.09

111

74

+

+

Ser-AGA-2-6

A3G

-

-

0.01

12

90

+

+

MAF; minor allele frequency. aData from 1000 Genomes Project (127,128); bData from TOPMED
sequencing project (128,129); ctRNA score was calculated using tRNA-Scan SE (128); dARM = ARMseq data suggesting expression (128,130); eCHIP = CHIP-seq hits for at least 3 of 4 core transcription
proteins (RPC155, POLR3G, BRF1, BDP1) (46,129,131-133).

1.5 tRNA variation and disease
Like the involvement of mitochondrial tRNA variants in disease (28), recent studies have identified
specific cytosolic tRNA mutants as drivers or modifiers of disease in humans and mice. In addition,
tRNA mis-modification and imbalanced tRNA expression also contribute to disease. Here we highlight
examples of defective tRNA function in genetic disorders, cancers, and neurodegeneration.

1.5.1 tRNA mutants linked to disease
Kobayashi et al. identified the first human tRNA associated with disease in 1990 (90). The mutation, a
variant of a mitochondrial tRNALeu gene, leads to the degradation of the tRNA and causes a rare disorder
characterized by stroke and dementia: mitochondrial myopathy, encephalopathy, lactic acidosis and
stroke-like episodes (MELAS). Shortly after, a mutation in mitochondrial tRNA Lys was found to cause
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another rare neurological disorder: myoclonic epilepsy and ragged-red fiber disease (MERRF) (93).
Several other mitochondrial tRNA variants are implicated in major human diseases, including heart
disease (94), hypertension (95), metabolic disease (96), and deafness (97).
Two clear examples have emerged where a cytosolic tRNA variant either contributes to or
directly causes disease. One case (described in the section tRNA variants in neurodegeneration) involves
a mutation in a single tRNAArg gene which causes widespread neurodegeneration in mice when
associated with a second mutation in a protein coding gene that sensitizes cells to ribosome stalling (21).
The other case (detailed in the section tRNA modification defects in disease) is a single nucleotide
mutation in the only functional human tRNASec gene (98,99) that causes abdominal pain, fatigue, muscle
weakness and low plasma selenium levels in a homozygous patient (19). In this case, the tRNA Sec variant
appears to be the primary driver of disease (19).

1.5.2 Imbalanced tRNA expression and disease
tRNA copy number variation. The copy number of tRNA genes varies between individuals. Iben and
Maraia assessed copy number variation among nuclear encoded tRNAs from whole genome sequencing
data obtained in the 1000 Genomes Project (100). Their study focused on two sets of two parents and a
child, from which > 15-fold read coverage was obtained. While the high similarity of tRNA iso-acceptors
complicates this type of analysis, significant copy number variation in at least 11 tRNA gene loci among
the six individuals was reported. Further, they validated a homozygous deletion encoding tRNA LysCUU
on chromosome 7 in one individual. Interestingly, modification defects in this tRNA associate with type
2 diabetes in mice. The deletion is common in the human population, and has no known indication of an
associated phenotypic defect (101).
Tissue specific tRNA expression. Dittmar et al. demonstrated the tissue-dependency of tRNA expression
using a tRNA microarray which probed 42 nuclear encoded and 21 mitochondrial encoded tRNAs from
8 different tissues (48). They revealed that human tissues express different sets of cytosolic tRNAs.
Comprehensive analysis based on RNA polymerase III occupancy of tRNA genes in mice support this
finding (102).
The relevance of tissue-specific tRNA expression to disease was demonstrated by the link
between tRNA abundance and cystic fibrosis (103). In this work, Kirchner et al. characterized a
synonymous single nucleotide polymorphism in the cystic fibrosis transmembrane conductance regulator
(CFTR), which substitutes an ACT Thr codon with ACG. This synonymous mutation results in a cell
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type-dependent alteration of CFTR protein levels that are not explained by a change in mRNA stability
or splicing. The authors discovered that tRNAThrCGU is a low abundance tRNA in the cystic fibrosis model
and human bronchial epithelial cell lines. The polymorphism not only reduces CFTR expression in
human bronchial epithelial cells, but also impairs the folding, localization, and membrane conductance
of CFTR. The findings point to a translation rate-dependent mechanism, where ribosome stalling on the
ACG codon, which is read by a low abundance tRNA, causes the protein product to mis-fold and
malfunction.
Phenotypic defects from synonymous codon mutations are observed in numerous other diseaserelevant protein coding genes (reviewed in (104)). Examples include multidrug resistance 1 (MDR1)
(105), Estrogen receptor α (ERα) (106,107), and surfactant protein-D (SFTPD) (108). Thus, expression
of specific tRNA iso-decoders is an important consideration when synonymous mutations result in a
phenotype, particularly if the protein synthesis burden is shifted to a low abundance or possibly defective
tRNA. Conceivably tRNA synonymous anticodon variants (noted above) could have a similar effect on
translation rates and cellular phenotypes.
De-regulated tRNA expression. tRNA expression can change dynamically in disease. Pavon-Eternod et
al. (107) demonstrated that tRNA expression increases from 3- to 10-fold in breast cancer tumors (109).
Oncogenic transcription factors such as Ras and c-Myc promote RNA polymerase (Pol) III transcription,
whereas tumor suppressors such as Rb and p53 inhibit Pol III transcription, providing a link between
common cancer mechanisms and Pol III-dependent tRNA expression (reviewed in (110)). Although
cause or effect has not been established in these cases, tRNA expression changes in cancer may occur
through global tRNA upregulation to facilitate increased protein synthesis requirements in tumor cells
(111).
Dysregulation of specific tRNA iso-acceptors is also implicated in cancer. Overexpression of the
initiator tRNAMet promotes translation reprogramming and cell proliferation in the human breast
epithelial cell lines 184A1 and MCF10A (109). This was corroborated in a comprehensive study that
quantified tRNA expression profiles using tRNA microarrays and histone modification mapping across
470 patient-derived tissue samples representing various states of proliferation (112). Gingold et al.
demonstrated that tRNAiMet expression is highest in the most proliferating samples and lowest in the
differentiating cells.
In contrast, reduced tRNASec expression was observed in many proliferating and especially
cancerous cell samples (112). tRNASec is required for the production of selenocysteine-containing
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proteins. Depending on the context, selenoprotein synthesis can either prevent or promote cancer (113),
thus, up or down-regulation of tRNASec may have relevance to disease. tRNA expression changes can
also promote cancer through roles for tRNAs beyond protein synthesis. A recent review highlighted
examples of tRNAs or tRNA-derived fragments from at least 16 iso-acceptor groups that are specifically
de-regulated in cancer (110).
The tRNA expression profile in a particular cell will lead to more or less efficient translation of
certain mRNAs depending on codon usage (114,115). Differential expression of tRNAs also promotes
cancer through favoring particular “translation programs.” The study of Gingold et al. (112) profiled
codon usage in transcripts associated with cell cycle versus differentiation. The authors observed a
dichotomy where codons with A or U in the 3rd codon position are generally more common in
proliferation-associated mRNAs, and G- or C-ending codons more common in differentiation-associated
mRNA transcripts (112). The emerging view is that cells dynamically switch between ‘programs’ of
protein synthesis, in part by coordinating the transcription of tRNAs with anticodons matching the codon
bias in expressed mRNAs.
Differential expression of specific tRNA iso-decoders. The expression of specific tRNA iso-decoders
promotes metastasis in breast cancer model cell lines (112). The authors measured the relative abundance
of different tRNA iso-decoders in cell lines selected for high rates of metastasis (MDA-LM2, CN-LM1)
and parental cell lines (MDA-231, CN34). Two tRNAs (tRNAArgCCG and tRNAGluUUC) were highly
upregulated in both metastatic lines. These tRNAs were overexpressed in MDA-231 cells to assess
changes in the proteome resulting from their increased expression. The abundance of proteins encoded
by transcripts enriched in the matching codons (GGC and GAR) increased. As measured by ribosome
profiling, two such mRNAs (encoding EXOSC2 and GRIPAP1) showed higher rates of active translation
in the cells over-expressing tRNAGluUUC. RNAi mediated knockdown of these mRNAs reduced in vitro
invasion capacity of the cells, suggesting that EXOSC2 and GRIPAP1 are required for tRNA GluUUCpromoted metastasis. Hence, the coordinated expression of tRNA iso-decoders facilitates translational
reprogramming in cancer cells and is implicated in the promotion of proliferation as well as metastasis.

1.5.3 tRNA modification defects in disease
As mentioned previously, post-transcriptional modifications are important for tRNA function and
stability. Hypo-modification can lead to rapid tRNA decay (116), and many tRNAs require anticodon
modifications to ensure faithful codon recognition (34,63). Over 50 different nucleotide modifications
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occur in eukaryotic tRNAs (117), and in humans, tRNAs contain an average of 13 modifications per
molecule (61). Accordingly, tRNA modification defects are implicated in numerous diseases, including
neurological, cardiac, respiratory, and metabolic diseases, as well as cancer and mitochondrial-linked
disorders (26). Most diseases that result from defects in tRNA modification are due to mutations in
protein coding genes or in mitochondrial tRNA genes, rather than cytosolic tRNA genes.
A recent example, however, provides compelling evidence of a cytosolic tRNA mutant and deregulated nucleotide modification in human disease. A C65G mutation in tRNA SecUCA was identified in
a patient exhibiting abdominal pain, fatigue, muscle weakness and low plasma selenium levels (28).
Although humans encode 2 tRNASec genes, apparently only one is functional. A mutation in this gene
has the potential to impact all 25 human selenoproteins, that are essential for normal development (118).
Selenoproteins may be categorized into two groups: housekeeping and stress-related. Synthesis of
housekeeping selenoproteins depends on a 5-methoxycarbonylmethyluridine (mcm 5U) modification at
position 34 of tRNASec, whereas further modification to 5-methoxycarbonylmethyl-2′-O-methyluridine
(mcm5Um) promotes synthesis of stress-related selenoproteins (119). The tRNA Sec C65G variant only
impaired expression of stress-related selenoproteins. This is attributed to the fact that the variant has
markedly reduced levels of both the mcm5Um modification at position 34 and the N6-isopentenyl
adenosine (i6A) modification at position 37 (19). The finding underscores the complexity of nucleotide
modification in tRNA function by showing that a mutation at one site in tRNA can impact modification
at other locations in the tRNA body. In this case, a single nucleotide variant in the T-arm altered
modifications in the anticodon stem loop (Fig. 1.1). Although the mechanism is not yet defined,
presumably the C65G mutant inhibits or reduces the methyl-transferase activity of the multi-function
ALKBH8 gene product that catalyzes conversion of mcm 5U to mcm5Um at position 34 (120).
Modifications can also drive or favor specific translation programs (65,66). For example,
melanomas harboring the V600E mutation in the proto-oncogene B-Raf depend on translational
reprogramming controlled by upregulation of U34 tRNA-modifying enzymes (67). Similar to the
modulation of tRNA expression in metastatic breast cancer (121), the mechanism relies on coordinated
regulation of both tRNAs and associated codon-biased transcripts. These modification tunable transcripts
(MoTTs) are sensitive to particular tRNA modification states (65). U 34 tRNA modification promotes
decoding of the ‘-AA’ ending codons AAA, GAA, and CAA (122). Remarkably, upregulation of U 34
modifying enzymes promote survival of melanomas dependent on hypoxia-inducible factor (HIF) 1α
metabolism. Elevated levels of HIF-1 correlate with tumor metastasis and poor patient prognosis as well
as tumor resistance to therapy (123). Indeed, the HIF1A mRNA is enriched in AAA, GAA, and CAA
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codons (67). When U34 modifying enzymes ELP3, CTU1, or CTU2 were knocked down, HIF1α protein
levels decreased even though HIF1A mRNA levels were unchanged. Cancer cells, thus, are able to
regulate tRNA modification enzymes to ultimately tune protein synthesis rates and protein levels in favor
of oncogenesis.

1.5.4 tRNA variants in neurodegeneration
A common attribute of disorders linked to defective protein homeostasis is the accumulation of
mistranslated or misfolded proteins in cells (20,124). In many cell types, this problem can be
counteracted through apoptosis or cell division (124). However, post-mitotic cells such as those found
in the heart and brain are incapable of diluting misfolded proteins through division, and lack the
regenerative capacity to replace apoptotic cells readily (124). Further, protein quality control decreases
in post-mitotic tissues with age (125). Post-mitotic tissues may be particularly vulnerable to the
consequences of tRNA variants and increasingly so with age.
Girstmair et al. (122) proposed a role for cytosolic tRNAs in Huntington disease (HD). HD is
caused by an expanded Gln repeat in the huntingtin protein (htt), encoded by a stretch of 40 to 100
repeated CAG codons (126). In some cases, shorter CAG repeats appear to also cause HD, suggesting
there are additional disease modifiers. Continuous translation of the repeat depletes charged tRNA GlnCUG,
which results in more frequent frameshifting in the translation of the HTT gene, possibly exacerbating
the disease phenotype (122). Although tRNAGlnCUG variants are not yet known to exacerbate HD, these
findings illustrate the importance of tRNA function and abundance in pathologies of the brain.
Indeed, naturally occurring tRNA variants have the potential to deplete the abundance of a brainspecific tRNA that is essential for health. Ishimura et al. (21) uncovered a synthetic toxic effect involving
a single cytosolic tRNA variant that causes wide-spread neurodegeneration in mice (21). A pair of
mutations in GTPBP2 (encoding a protein that rescues stalled ribosomes) and Tr20 (encoding
tRNAArgUCU) were found to co-occur in mice identified in a phenotypic screen for neurodegeneration.
Mice carrying both mutations exhibit rapid neurodegeneration and die at 8-9 weeks. At 3 weeks, the
mutant mice are indistinguishable from wildtype. The C50T mutation (n-Tr20) prevents tRNAArgUCU
maturation and, in combination with the loss of GTPBP2, leads to ribosome stalling. Despite many
‘redundant’ tRNAArg iso-decoders in the cell, the lack of function of this single tRNA causes ribosome
stalling. The authors measured a 3-fold increase in AGA pauses in the n-Tr20 mutant compared to a
mouse containing the wild-type tRNA. Fascinatingly, tRNA Arg C50T variants also occur in the human
population, including in a TCT iso-acceptor (Table 1.3).

21
Table 1.3. Human tRNAArg C50T variants
tRNA gene

SNP id

MAF
(%)

a

a

variant
count

a

MAF

variant

tRNA

b

b

c

(%)

count

score

expression
ARMd CHIPe

Arg-ACG-1-1

rs6939540

2.42

121

2.2

2765

67.6

+

+

Arg-ACG-1-2

rs186104107

0.02

1

0.01

14

67.6

+

+

Arg-TCG-6-1

rs113170043

16.6

831

20.2

24374

53.7

+

-

Arg-TCT-5-1

rs143334272

0.8

41

0.6

711

61.4

+

-

Data from 1000 genomes project; bData from TOPMED sequencing project (128,129); ctRNA score was

calculated using tRNA-Scan SE (128); dARM = ARM-seq data suggesting expression (128,130); eCHIP
= CHIP-seq hits for at least 3 of 4 core transcription proteins (RPC155, POLR3G, BRF1, BDP1)
(46,129,131-133).
This work exemplifies the ways in which tRNA variants can exacerbate pathways to disease. Two
observations from this work may have broader applicability to understanding the roles for tRNA variants
in disease. Firstly, the phenotype was tissue specific, since expression of the n-Tr20 encoded tRNA is
only observed in the central nervous system. Further, a co-incident mutation in another gene sensitized
cells to the loss-of-function mutation in a single tRNA gene. Together these mutations caused disease in
the animal model.

1.6 Conclusion
Humans display a remarkable array of both common and rare tRNA mutants, some with the obvious
potential to mistranslate the genetic code (Tables 1.1, 1.2, S1.1) or create defective tRNAs (e.g., Table
1.3). Indeed, such tRNA variants can elicit significant levels of mistranslation in the human cell, and
influence protein synthesis and protein homeostasis (Fig. 1.4). Above, we highlighted recent examples
showing how tRNA variants and defective tRNA genes contribute to disease. In addition to causing
disease, tRNAs variants also act synergistically with other disease-causing alleles by placing additional
stress on protein quality control mechanisms or biasing translation programs that drive disease. Further,
tissue-specific tRNA expression and de-regulated tRNA expression or modification contributes to
disease and phenotypic defects at the cellular level. Together these observations suggest that cytosolic
tRNA mutations may have greater importance in disease than previously recognized. We hope that the
evidence provided in this review will stimulate new interest in considering cytoplasmic tRNA variants
as an important factor in human genetic variation and disease.
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Figure 1.4 Phenotypic consequences of tRNA variation. Transfer RNA variation can impact
expression, aminoacylation, or processing and maturation of tRNAs, including nucleotide
modification and tRNA folding. Alterations in the functional tRNA pool can impact mRNA
translation by causing mistranslation, frame-shifting, ribosome stalling, or increased expression of
codon-biased transcripts. These alterations can in turn alter the amino acid sequence, folding, and
abundance of proteins across the entire proteome.
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1.8 Supplemental information
1.8.1 Supplemental tables
Table S1.1 Human tRNA variants that introduce a G4:U69 base pair
tRNA

variant effect MAF (%)a

variant

MAF

variant

counta

(%)b

countb

tRNA Scorec

Expression
ARMd CHIPe

Cys-GCA-2-3

C69U G4:U69

0.02

1

0.00004

5

81.9

+

+

Cys-GCA-9-3

C69U G4:U69

18.9

948

0.1329

16689

77.2

+

-

Cys-GCA-9-4

C69U G4:U69

1.5

76

0.0166

2090

77.2

+

+

Cys-GCA-14-1

C69U G4:U69

0.02

1

-

-

71.6

+

+

Ser-AGA-2-3

C69U G4:U69

0.02

1

0.00002

2

89.6

+

+

Ser-CGA-2-1

C69U G4:U69

0.02

1

0.000008

1

94.0

+

+

Ser-GCT-1-1

C69U G4:U69

-

-

0.00002

2

91.9

+

-

Ser-GCT-4-2

C69U G4:U69

0.02

1

0.00003

4

88.4

+

+

Ser-GCT-4-1

C69U G4:U69

0.02

1

0.0003

37

88.4

+

+

Ser-GCT-2-1

C69U G4:U69

0.02

1

0.0002

21

91

+

+

Ser-TGA-2-1

C69U G4:U69

0.06

3

0.0002

21

90.4

+

+

iMet-CAT-1-1

A4G

G4:U69

0.02

1

-

-

60.4

+

+

iMet-CAT-1-3

A4G

G4:U69

-

-

0.00005

6

60.4

+

+

iMet-CAT-1-4

A4G

G4:U69

0.5

25

0.0015

185

60.4

+

+

iMet-CAT-1-6

A4G

G4:U69

0.02

1

0.0005

67

60.4

+

+

Phe-GAA-1-4

C69U G4:U69

-

-

0.00003

4

88.9

+

+

Phe-GAA-1-2

C69U G4:U69

-

-

-

-

88.9

+

+

Phe-GAA-2-1

C69U G4:U69

-

-

0.00007

9

87.9

+

+

Phe-GAA-3-1

C69U G4:U69

-

-

0.00006

7

88.3

+

+

Cys-GCA-23-1

Reference genome = G4:U69

59.1

+

-

Thr-AGT-1-1

Reference genome = G4:U69

82.6

+

+

Thr-AGT-1-2

Reference genome = G4:U69

82.6

+

+

Thr-AGT-1-3

Reference genome = G4:U69

82.6

+

+

Thr-AGT-5-1

Reference genome = G4:U69

80.1

+

-

Thr-CGT-2-1

Reference genome = G4:U69

79.6

+

+

Thr-CGT-4-1

Reference genome = G4:U69

78.3

+

+

Val-AAC-6-1

Reference genome = G4:U69

69.9

+

+

MAF; minor allele frequency. _##N; inserted nucleotide. aData from 1000 genomes project (1,2);
b
Data from TOPMED sequencing project (2,3); ctRNA score was calculated using tRNA-Scan
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SE (2); dARM = ARM-seq data suggesting expression (2,4); eCHIP = CHIP-seq hits for at least 3
of 4 core transcription proteins (RPC155, POLR3G, BRF1, BDP1) (3,5-8).
Table S1.2. List of tRNA counts in selected genomes.
Species

Number of tRNA genes

Number of tRNA genes
(high confidence)

E. coli K12

89

86

S. cerevisiae

275

275

M. musculus

471

468

H. sapiens

596

417

C. elegans

596

596

A. thaliana

700

684

G. max (soybean)

738

738

O. sativa (rice)

764

738

S. purpuratus (sea urchin)

1068

1065

Z. mays (maize)

1202

1198

G. morhua (atlantic cod)

1502

1490

P. marinus (lamprey)

2491

2484

X. tropicalis (frog)

2653

2638

Danio rerio (zebrafish)

12292

12244

C. milii (elephant shark)

13758

13724
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Chapter 2
2. Visualizing tRNA-dependent mistranslation in human cells 1
2.1 Introduction
A highly accurate proteome is not required for life. In the years preceding and immediately
following the elucidation of the genetic code1, 2, it was argued that mis-interpretation of the genetic
code and the resulting mistranslation would lead to an error catastrophe 3 in the proteome that could
not support life. Crick used the same logic to argue that the code could not evolve further or tolerate
significant errors because modern proteomes are composed of “so many highly evolved protein
molecules that any change to these would be highly disadvantageous unless accompanied by many
simultaneous mutations to correct the ‘mistakes’ produced by altering the code 4.” There is now
ample evidence that the code does indeed continue to evolve through codon reassignments, codon
recoding, and natural genetic code expansion in species representing the complete diversity of
life5.
In contrast to the concept of a highly accurate proteome, diverse organisms show robustness to
genetic code changes and mistranslation. A series of landmark studies, in Escherichia coli6, yeast7,
and mammalian cells8 reshaped our view of the level of accuracy required to produce a functional
proteome. Errors in protein synthesis are estimated to occur at a rate of 1 mis-incorporated amino
acid in 104 to 105 codons9, 10, which suggests that between 0.01 and 0.001% of codons are misread
in the human proteome. E. coli can tolerate remarkably high levels of mistranslation. Indeed, Ruan
et al.6 showed that E. coli grow similarly to wildtype even when 10% of genetically encoded
asparagine residues were mistranslated as aspartic acid. The heat-shock response, and the
expression of cellular proteases were essential to maintain wild-type like growth in these cells
despite proteome-wide mistranslation6.
In Saccharomyces cerevisiae, we selected a mutant tRNA that suppressed a stress-sensitive
phenotype by inducing proline to alanine mistranslation at a rate of ~6% 11. Yeast cells tolerated
this tRNA-dependent mistranslation by inducing heat-shock, again without a significant growth
defect. In the mistranslating yeast strain, we also observed synthetic slow growth with a deletion
of a gene (rpn4) encoding a transcription factor that regulates proteasome gene expression,
2

Work in this chapter was published in: Lant, J.T., Berg, M.D. Sze, D.H.W., Hoffman, K.S.,
Akinpelu, I.C., Turk, M., Heinemann, I.U., Duennwald, M.L., Brandl, C.J., and
O’Donoghue, P. (2017) Visualizing tRNA-dependent mistranslation in human cells. RNA
Biology.
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implicating the proteasome and protein degradation as critical mechanisms the cell uses to tolerate
mistranslation11. In mammalian cells, tyrosine limitation leads to proteome-wide mistranslation of
tyrosine codons with phenylalanine at a rate of ~1%, again without a significant impact on cellular
viability12.
Not only can cells tolerate mistranslation robustly, but mistranslation may also be advantageous
in conditions of stress. Mistranslation in bacteria13 and mammalian cells14, 15 protects cells from
reactive oxygen species. In an E. coli strain with a ribosomal protein mutant (RpsD) that enhances
mistranslation, a stop codon suppression assay indicated ~5-fold increase in translation errors
above the basal level. This mistranslation increased expression of a general stress response
activator (RpoS) that in turn up-regulated antioxidant gene expression, making the cell more
resistant to peroxide treatment13. In HEK 293T cells, mis-aminoacylation of tRNAGlu with
methionine accounts for a ~0.5% basal level of mistranslation 16. Immune or chemical induction of
oxidative stress increased this rate up to 10-fold17. The current model suggests that oxidative stress
leads to extracellular signal–regulated kinase (ERK) dependent phosphorylation of the
methionine-tRNA synthetase, which makes the enzyme more promiscuous for non-cognate
tRNAs18. The additional methionine incorporated in the proteome at non-methionine positions is
thought to act as a ‘sink’ for ROS, and methionine mistranslation increased resistance to ROS in
cell culture17. These studies demonstrate that cells are capable not only of tolerating proteomewide mistranslation, but can derive a selective advantage from mistranslation under certain stress
conditions.
We recently devised a selection in yeast that requires mistranslation at proline codons for the
organism to survive under stress. The selection relied on a stress-sensitive allele of the PIK kinase
chaperon, Tti211, 19, 20. Single base mutations in tRNAPro were selected that resulted in a C70U
mutation in the acceptor stem of the tRNA, yielding the essential G3:U70 identity element for
alanyl-tRNA synthetase (AlaRS). Unlike many tRNA synthetases, AlaRS does not recognize the
anticodon of its cognate tRNA (Fig 2.1). Rather it establishes critical interactions with both major
and minor groove sides of the G3:U70 base pair in the acceptor stem of tRNA Ala

21

. These

interactions orient the 5’ amino acid accepting CCA-end of the tRNA in the AlaRS active site (Fig
2.1). Although AlaRS does not tolerate the reverse U:G pair or other mutations at this position 22,
the human AlaRS shows significant activity with tRNAs that encode a G4:U69 pair 23, of which
there are several in the human reference genome. Taken together, these studies suggest that
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because of its minimal identity requirements, the generation of tRNA mutations that are
mischarged with Ala may be more prevalent in nature, including in humans, than previously
assumed.

Figure 2.1. Structure of AlaRS and tRNAAla complex. The zoomed in view (A) focuses on the
interaction of the tRNAAla acceptor stem with the AlaRS active site (PDB code 3WQY 21). The 3’
terminal CCA bases of the tRNA are labeled. An alanyl-adenylate analog (*) is also shown. The
major AlaRS identity element G3:U70 is highlighted. AlaRS residues (R371, N359, D450, S451)
form a hydrogen bond network (gray dashes) that contacts and ‘reads’ the GU pair from both the
major and minor grove sides of the tRNA are annotated. The complete dimeric AlaRS is shown
in complex with tRNAAla (B). The three bases of the anticodon (U34, G35, C36; green) are not
recognized by the AlaRS.
Here we produced and characterized a mutant human tRNA Pro with the G3:U70 base pair (Fig
2.2A). With biochemical experiments and live cell imaging, we quantified and visualized tRNAdependent mistranslation in human cells, finding that the mutant tRNA Pro is an efficient alanine
acceptor that promotes mistranslation in human cells in culture.
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2.2 Materials and methods
2.2.1 Plasmids and strains.
Plasmid manipulations were performed with E. coli DH5α cells (Invitrogen, Carlsbad, CA,
USA). For in vitro amino-acylation assays, tRNA genes were ordered as single stranded DNA
oligomers from Sigma-Aldrich (Darmstadt, Germany) with overhangs to BamHI/XbaI sites.
Single-stranded oligomers were phosphorylated using T4 polynucleotide kinase (New England
Biolabs (NEB), Ipswich, MA, USA) and annealed by gradual cooling from 95C to 55C.
Annealed oligomers were cloned into pUC19 BamHI/XbaI sites using BamHI, XbaI, and T4 DNA
ligase (NEB). pUC19-derived plasmids were purified by mini-prep (GeneAid, New Taipei City,
Taiwan) and used as template for in vitro transcription. For expression in human cell culture, EGFP
D129A or D129P genes were cloned into pcDNA3.1 HindIII/EcoRI sites. Transfer RNA genes
were fused to a human U6 promoter sequence and 6x thymidine termination sequence by overlap
extension PCR (pfu polymerase, Agilent Technologies), then ligated into pcDNA3.1 at the NruI
site. Plasmid DNA was isolated from 100 ml E. coli cultures by midi-prep (GeneAid) followed by
phenol chloroform extraction and ethanol precipitation, then re-suspended in sterile Milli-Q water.
All plasmids were diluted to equimolar (+/- 20 ng/μl) concentrations before transfection.

2.2.2 In vitro tRNA transcription and radiolabeling.
In vitro transcription and radiolabeling of tRNAs for in vitro aminoacylation experiments
was performed as previously described24 (see Supporting Information for tRNA sequences and
details).

2.2.3 In vitro tRNA aminoacylation.
For the aminoacylation assays we purchased recombinant human AlaRS (Abcam, ab73442,
Cambridge, UK) and human glutamyl-prolyl-tRNA synthetase (EPRS, Origene, TP317559,
Rockville, MD). 50 μl reactions with 5 μM tRNA, 300 nM 32P-labelled tRNA, 10 mM amino acid
(Ala or Pro as indicated), 5 mM ATP and 1 μM tRNA synthetase were incubated at 37C for 0, 20
and 40 minutes. Reactions were digested with nuclease P1, spotted on a polyethyleneiminecellulose thin layer chromatography (TLC) plate (EMD Millipore, Billerica, MA, USA) and
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chromatographed in 5% acetic acid and 100 mM ammonium acetate. TLC plates were exposed to
a phosphor screen, which was imaged using a Storm 860 Phosphorimager (GE Healthcare Life
Science, Little Chalfont, UK).

2.2.4 HEK 293T cell transfection.
Transfections were performed in 24-well or 6-well plates using 1.25 μg or 2.5 μg of DNA,
respectively. Cells were cultured in high glucose Dulbecco’s modified Eagle medium (DMEM,
4.5 g/L glucose) containing penicillin, streptomycin (P/S), and 10% fetal bovine serum (FBS)
(Gibco by Life Technologies, Carlsbad, MA). At 70-80% cell confluency, media was replaced
with standard DMEM (no FBS, P/S) and cells transfected with pcDNA3.1-derived plasmids using
lipofectamine 2000 (Invitrogen). Cells were returned to +P/S, +10% FBS media to recover for at
least 1 day before analysis. Cell fluorescence was quantitated daily as described below. For
experiments in low serum, low glucose media, after ‘day 1’ quantitation, media was replaced with
1% FBS, 1 g/L glucose DMEM (Corning Cellgro, Corning, NY, USA). Geneticin selections were
maintained in DMEM (4.5 g/L glucose, 10% serum, P/S) containing 500 µg/ml geneticin (G418;
Gibco by Life Technologies).

2.2.5 Fluorescence quantitation of enhanced GFP (EGFP) reporter.
To quantify EGFP fluorescence, images were captured using an EVOS FL auto fluorescent
microscope (Thermo Fisher Scientific, Waltham, MA, USA) at 20X magnification and GFP foci
outlined using the ellipse measurement tool. The EVOS microscope measures GFP fluorescence
with 470/525 nm excitation/emission wavelengths. Our negative control and experimental cultures
(EGFP D129P) were exposed for 163 ms with a 65 unit light setting and our positive (EGFP
D129A) was exposed for 163 ms with a 23 unit light setting. In each field of view, the 15 brightest
foci were outlined and data collected as a mean pixel intensity within each ellipse. At least 135
foci were measured from each experiment daily across three biological replicates and three fieldsof-view per replicate. On the final day, an additional two fields-of-view were collected per
transfection, totaling 225 foci. The average of five empty space measurements was subtracted
from all values in each field of view to account for inconsistencies in light scattering between
fields. Percentage mistranslation was estimated using the means of each data set and p-values were
calculated pairwise using single-factor ANOVA with Microsoft Excel.
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2.2.6 Western blotting.
Cells were harvested by pipetting and centrifuged in 1.5 ml microcentrifuge tubes at 1500
 g for 3 min at 4°C. Supernatant was removed and cells washed with ice cold Phosphate Buffered
Saline (1  PBS pH 7.4; Corning Cellgro) and centrifuged again. PBS was aspirated off and cells
were suspended in 50 μl of ice-cold Lysis buffer: 50 mM Tris-HCl (pH 7.4), 1% Triton X-100,
150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), and 1 mM Phenylmethylsulfonyl fluoride.
The re-suspended cells were incubated on ice for 5 min then centrifuged at 4C, 30,000  g for 10
minutes. Lysates were separated on standard SDS-polyacrylamide gel electrophoresis (PAGE)
(15% acrylamide) and transferred to Polyvinylidene fluoride membranes using a Trans-Blot Turbo
Transfer System (BioRad, Hercules, CA, USA). Membranes were cut horizontally according to
protein standards to enable multiple antibodies to be assayed in parallel. Membranes were
incubated for 1 hr in blocking solution (3% bovine serum albumin (BSA), 0.1% Tween 20, 1%
PBS) before adding primary antibodies at a 1:5000 final dilution (α-HSP70, Invitrogen, MA3-006;
α-HSP90, Protein Tech, Rosemont, IL, USA, 13171-1-AP; α-GFP, abcam, ab32146; α-GAPDH,
Sigma-Aldrich, MAB374). Membranes were incubated overnight at 4°C, washed for 3  10 min
in washing solution (1% BSA, 0.1% Tween 20, 1% PBS), then incubated with anti-mouse (Thermo
Fisher Scientific, MA1-21315) or anti-rabbit (Sigma, GENA9340) horse radish peroxidase-linked
secondary antibodies for 2 hr at 1:2000 final dilution. Membranes were then washed with 1  PBS
with 0.1% Tween 20 three times for 10 minutes, followed one wash for 10 minute in 1  PBS.
Protein markers were visualized using Clarity Western enhanced chemiluminescence (ECL)
Substrates (Bio-Rad) following the manufacturer’s instructions and imaged with a ChemiDoc
XRS+ System (Bio-Rad).

2.2.7 Cell viability assay.
HEK 293T cell cultures were seeded at equivalent cell densities and grown overnight in high
glucose DMEM, then transfected in triplicate and assayed either one day post-transfection or
switched to low serum, low glucose DMEM for 4 days. Cellular viability was determined using a
CellTiter-Glo Luminescent Cell Viability Assay following the manufacturer’s instructions
(Promega, Madison, WI). Each transfection was assayed in triplicate, totaling three biological and
nine technical replicates per experiment.

42

2.3 Results
2.3.1 Biochemical characterization of a mistranslating human tRNAPro
(G3:U70).
We first investigated human tRNAPro G3:U70 for mis-acylation activity with Ala (Fig 2.2).
We produced and purified human tRNAPro, tRNAAla, and tRNAPro G3:U70 by in vitro transcription
using recombinant T7 RNA polymerase. Recombinant human AlaRS (Abcam) and human
glutamyl-prolyl-tRNA synthetase (GluProRS, Origene) were purchased. The ProRS activity in
human cells is encoded as a single polypeptide fused to GluRS. We performed aminoacylation
assays according to standard protocols (see Methods) as previously24. The level of aminoacyltRNA formed at specific time points was measured using 32P radiolabeled tRNA variants (see SI
Methods). Following nuclease P1 digestion, unreacted tRNA and aminoacylated-tRNA product
were separated by thin layer chromatography and visualized by autoradiography (Fig 2.2B). The
aminoacylation assays confirmed significant activity of human GluProRS in Pro-tRNA Pro
formation, and efficient aminoacylation by human AlaRS of tRNA Ala with Ala (Fig 2.2B). Like
our previous findings with the homologous yeast AlaRS and ProRS 11, ProRS activity is weaker
than that observed with AlaRS. Pro accepting activity was not detected with the tRNA Pro G3:U70
mutant and human GluProRS, indicating that the single base pair mutation is a sufficient antideterminant for GluProRS. In the presence of AlaRS and Ala, however, a gain-of-function was
observed as the mutant tRNA was charged with Ala, though to a lesser extent than tRNA Ala (Fig.
2.2B). These results demonstrate tRNAPro (G3:U70) is an efficient Ala acceptor in vitro and the
mutation is sufficient to disable ProRS activity.
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Figure 2.2. In vitro amino-acylation of tRNAPro (G3:U70). Cloverleaf diagrams (A) of human
tRNAProUGG WT and G3:U70. Mutations in the acceptor stem are outlined with a rectangle.
Purified 32P-radiolabeled tRNAs were aminoacylated with Ala by human AlaRS or Pro by
human GluProRS as indicated in Methods. The autoradiographs show reaction progress
(accumulation of aminoacylated-tRNA) for each reaction over a 40-minute time course.

2.3.2 GFP reporter illuminates mistranslation in living cells.
We recently established a novel EGFP mistranslation reporter in yeast 11. The GFP reporter
contains a mutation, D129P, which is thought to cause a kink in the backbone of GFP’s β-barrel
structure11. When the Pro codon at position 129 in the EGFP reporter is translated accurately as
Pro, the resulting EGFP, although stably produced, lacks fluorescence. The mutant D129A,
however, fluoresces similarly to wild type EGFP. In our studies in yeast, this reporter was a
sensitive measure of mistranslation activity in live cells. We reported a level of ~6% mistranslation
of the critical Pro129 codon to Ala in a yeast strain that co-expressed the mistranslating tRNA Pro
(G3:U70)11.
To define how human cells in culture respond to mistranslation, we conducted a series of
transient transfection experiments in HEK 293T cells. Each cell line harbored a pCDNA3.1
plasmid containing separate EGFP and tRNA expression cassettes. Our EGFP reporter (D129A or
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D129P) was expressed under the control of a pCMV constitutive promoter. We chose to test a
CCA codon for mistranslation by tRNAProUGG G3:U70, consistent with our study in yeast 11. The
tRNA expression cassette was designed to include an upstream U6 constitutive promoter and
followed by a downstream poly-T terminator sequence (see Methods).
Having established our Pro-codon sensitive EGFP mistranslation reporter for use in human
cells, we transfected HEK 293T cells in triplicate with plasmids co-expressing EGFP D129P or
D129A and the wild type (C3:G70) or mistranslating (G3:U70) human tRNA Pro (Figs 2.3, S2.3).
Based on 3 biological replicates, transfection efficiencies were initially ~50-60% as determined
from the number of cells fluorescing in our EGFP D129A positive control, but declined to ~2040% by the end of our multi-day experiment due to plasmid dilution by cell division.
Mistranslation was quantified by fluorescence microscopy (Fig. 2.3, see Methods).

Figure 2.3. tRNA-dependent mistranslation increases under glucose and serum starvation.
HEK 293T cell cultures were transfected in triplicate with plasmid harboring tRNA Pro and EGFP
D129P (WT); tRNAPro G3:U70 and EGFP D129P (G3:U70); or tRNAPro and EGFP D129A (+).
Cells were grown for 1 day post-transfection in high glucose media (high), then media was
replaced with low serum, low glucose (low) and fluorescence was measured daily by
fluorescence microscopy (see Methods). Box and whisker plots (A) of EGFP foci intensity.
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Horizontal demarcations depict quartiles with median centered. Means are depicted with an X.
Dots represent the general distribution of at least 135 foci measured in each plot across 3
biological and at least 9 technical replicates. Mistranslation levels were estimated based on
means of the three populations on each day and the p-value of a difference between the WT and
G3:U70 populations is reported base on single-factor ANOVA. Representative images (B) of
mistranslating cells. HEK 293T cell images were captured at 20X magnification using light
(phase) or fluorescence (GFP; ex/em = 470/525 nm) microscopy. Scale bars depict 200 µm.
In standard, high glucose media, we did not detect a significant difference in EGFP D129P
fluorescence between cells expressing tRNAPro versus tRNAPro (G3:U70). We reasoned, based on
the literature (e.g., 13-15), that mistranslation would be enhanced in conditions of stress. Therefore,
the transfected cell lines were transferred to a low serum and low glucose medium and monitored
daily. For cells expressing wild type and mutant tRNAPro, we analyzed GFP fluorescence up to 5
days following transfection. Under glucose and serum starvation, a trend of accumulating
mistranslation was observed in cells expressing the mutant tRNAPro over the course of the
experiment. The estimate of mistranslation was calculated based on the relative fluorescence of
EGFP D129P and D129A expressing controls (Figs 2.3, S2.4). Following recovery (~1 day after
switching media), we observed a reproducible, and statistically significant, 4-6% (p-value < 10 -8)
increased rate of mistranslation on days 4 and 5 in the cells expressing tRNA Pro (G3:U70).
Equivalent GFP expression in all cell lines was confirmed by immunoblotting and compared to a
glyceraldehyde 3-phosphate dehydrogenase loading control (Fig 2.4). The mistranslationdependent effect began to taper on day 5 due to gradual plasmid loss. Cells were lysed at this stage
for further analysis by western blotting.
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Figure 2.4. Mistranslation caused no detectable induction of heat shock response. Western
blotting of HEK 293T cell lysates (A) with antibodies detecting EGFP, heat shock markers
(HSP70, HSP90), and a GAPDH loading control. Lysates were harvested after one day incubation
in high glucose media (A, left panel) or changed to low serum, low glucose media (A, right panel)
for four days before harvesting. Lysates were separated by SDS-PAGE; loading quantities were
balanced according to triplicate Bradford assays. Densitometry based on triplicate western blots
of HSP90 (B) and HSP70 (C) levels normalized to the GAPDH control. Error bars indicated 1
standard deviation of the mean. (B, C) Lysates harvested on day 5 low serum, low glucose media
from three independent transfections. None of the values reported were statistically significantly
different (ANOVA).

2.3.3 Mistranslation following antibiotic selection.
In an attempt to control for transfection efficiency in these experiments, we also observed
elevated mistranslation in cells following selection on geneticin. The selected cells maintained the
pCDNA plasmid bearing the GFP reporter and either the wild type or mistranslating tRNA Pro.
Following selection, there was no obvious change in morphology when the tRNA Pro (G3:U70)
mutant was expressed compared to tRNAPro, though morphological heterogeneity could be seen in
both cell lines (Fig S2.1). Since geneticin inhibits bacterial growth by interfering with ribosome
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function, and similar aminoglycosides decrease ribosome fidelity in bacterial 25 and mammalian26
translation systems, we anticipated the potential for elevated mistranslation in these cells.
Although we did not observe elevated mistranslation in cells expressing the wild type tRNA Pro,
analysis by fluorescence microscopy suggested that GFP D129P fluorescence was restored at a
low level (~3%, p-value = 1.2 x 10-8) by tRNAPro (G3:U70)-dependent mistranslation with Ala
(Fig S2.2). This result is concordant with our observations in nutrient deprived cells (Fig 2.3) as
the cells under antibiotic selection are also undergoing stress.

2.3.4 Mistranslation by tRNAPro (G3:U70) does not induce a heat-shock
response.
In our previous studies of mistranslation induced by tRNA Pro (G3:U70) in yeast, the heatshock response was observed in mistranslating cells 11. Here, HEK 293T cells were harvested
following 4 days of growth on low serum and low glucose medium where mistranslation was
observed. Using GAPDH as a loading control, we immunoblotted to detect markers for the heat
shock response (HSP70, HSP90). Despite the fact that cells were mistranslating Pro codons with
Ala at a rate of ~5%, we were unable to detect significant differences in the levels of HSP70 or
HSP90 in comparison to cells expressing the wild type tRNA Pro (Fig 2.4).

Figure 2.5. Viability of mistranslating cells. HEK 293T cell cultures were transfected in
triplicate with lipofectamine only (No Vector, NV), or plasmid harboring tRNA Pro and EGFP
D129P (WT); tRNAPro G3:U70 and EGFP D129P (G3:U70); or tRNAPro and EGFP D129A (+).
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Transfected cells were assayed one day post-transfection (A) or after four days incubation in low
serum, low glucose media (B). Viability assays were performed following manufacturer’s
instructions (see Methods) using three technical replicates per transfection. Plots show mean
luminescence, which correlates with cellular ATP levels. Error bars indicated 1 standard deviation
of the mean. Stars depict the indicated statistically significant differences according to singlefactor ANOVA (**** = p < 0.0001; *** = p < 0.001; n.s. = p > 0.05).

2.3.5 Viability of mistranslating cells.
Using a standard assay for cell viability, based on the production of ATP in metabolically
active cells (see Methods), we determined the impact of tRNAPro and tRNAPro G3:U70 expression
on the viability of HEK 293T cells in culture. Cells were transfected with the indicated EGFP and
tRNAPro expressing pCDNA 3.1 plasmids (Fig 2.5) and grown in rich media or in low nutrient
conditions. Expression of the EGFP protein reduced cell viability marginally in comparison to the
un-transfected control cells (p < 0.0001, Fig 2.5A). In agreement with our measurements of the
mistranslation as indicated by the GFP reporter, cell viability in rich media was unaffected by
expression of tRNAPro in comparison to the mistranslating tRNAPro G3:U70 mutant (Fig 2.5A). In
low serum, low glucose medium, the viability of all cultures decreased, yet cells expressing
tRNAPro G3:U70 were equally as viable as cells expressing the wildtype tRNA Pro (Fig 2.5B).

2.4 Discussion
2.4.1 Transfer RNA genes occur in excess.
Translation of the 61 sense codons in the genetic code table requires a theoretical minimum of
32 tRNAs to translate all 20 amino acids27. There are examples of organelles (human mitochondria,
22 tRNAs), parasites (Borrelia burgdorferi, 32 tRNAs; Mycoplasma pulmonis, 28 tRNAs), and
obligate symbiotic microbes (Sulcia muelleri, 31 tRNAs) with a small number of tRNA genes,
some of which fall below the ‘theoretical’ limit based on wobble decoding 28. In the case of
organelles, a complete set of tRNAs for protein synthesis is achieved via tRNA import from
nuclear encoded tDNAs29 or perhaps super-wobbling (i.e., one tRNA reading 4 codons) as
demonstrated with tRNAGly in tobacco plants30. The fact that no free-living organisms has less
than 32 tRNAs already indicates that the coding problem is more complex or more elaborate than
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the simple mechanics of matching codon to anticodon and wobble decoding. In free living
microbes, the smallest sets of tRNA genes are found in the model minimal genome of Mycoplasma
genitalium (36 tRNA genes), while the hyperthemophile Methanopyrus kandleri encodes just 34
tRNAs genes.
The number and diversity of tRNA genes expands in correlation with the complexity of the
organism31. For example, yeast encodes 275 tRNAs whereas humans have 610 tRNA genes 28.
None of the human tRNA genes are predicted as pseudogenes28. Most human tRNA genes are
expressed in some cells or tissues28, and tRNA genes show tissue32 and cell-line specific expression
patterns33. Even individual tissues express a large number of these tRNA genes. For example, in
human primary liver tissue, 223 tRNA genes are actively transcribed 34. The reason for the overabundance of tRNA genes in human and higher eukaryotes has remained a mystery.

2.4.2 A single tRNA mutant induces mistranslation in human cells.
Among the human population, tRNA mutations are common. Based on sequence data from the
1000-genomes project, more than half of individuals (54%) contain at least 1 mutant tRNA and
20% of individuals harbor two or more mutant tRNAs35. Fascinatingly, tRNA gene copy number
also varies even among a small group of individuals 36.
Mistranslating tRNAs are present in the reference human genome. Recent work demonstrated
tRNA variants with a G4:U69 pair enable aminoacylation with Ala. G4:U69 mutants are common
in eukaryotic genomes and 1 of the 30 copies of tRNACys in the human genome contains such a
GU pair. The mutation confers Ala accepting identity on this tRNA Cys variant in vitro and in HEK
293T cells in culture23.
Given the complexity of the human tRNAome and its diversity in the human population, we set
out to determine if a single tRNA mutant would induce mistranslation in human cells in culture,
and to characterize the consequences of this mistranslation. In our previous studies in yeast,
expression of a mutant tRNA caused ~6% mis-incorporation at Pro codons in cells grown in
nutrient rich conditions11. Here we expressed a homologous mistranslating tRNAPro mutant in
human cells in culture, and we were unable to detect mistranslation in rich media. Only upon
subjecting the cells to stresses, including nutrient deprivation or antibiotic selection, did we
observe a similar level of mistranslation (5%) induced by the tRNA Pro G3:U70 mutant. The results
suggest that the human cell is potentially more resistant to mistranslation caused by a single tRNA
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gene. However, under conditions of stress or nutrient deprivation, mis-made protein could be
readily detected. We speculate that under stress conditions human cells are either less able to
degrade mis-made protein, deacylate mis-charged tRNAs37, 38 at a lower frequency, or more readily
use the mis-aminoacylated tRNA in translation.

2.4.3 tRNA-dependent mistranslation linked to disease.
There is growing evidence connecting mistranslation to disease 19, 39-41. Many efforts focus
on AARSs, either affected by mutations or oxidative damage 13, that promote mis-aminoacylation
of their cognate tRNAs12,
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or of non-cognate tRNAs43, both of which can then lead to

mistranslation. The relevance of analyzing the role of tRNA mutants in disease was highlighted
by a recent study that identified a mutation in a single tRNA gene specifically expressed in the
central nervous system. The tRNA mutation caused a synthetic neurodegenerative phenotype in
mice also lacking the gene GTPB2, which is involved in ribosome recycling 44. In agreement with
our findings, the impact of the tRNA mutation alone, in the absence of stress or a synthetic defect,
was not sufficient to cause significant mistranslation. This recently established link between tRNA
mutations and disease suggests that further studies will uncover a greater role for human tRNA
variants in health and disease.

2.4.4 Detecting tRNA-dependent mistranslation in live cells.
A key difference between our work and previous work with editing defective tRNA synthetases
is that the AARS mutants mis-aminoacylate (to some level) all tRNA isoacceptors for the cognate
amino acid. In our experiments, we expressed a single tRNA Pro mutant. Although this tRNA is
specifically mis-aminoacylated with Ala, it then competes with properly aminoacylated tRNA Pro
isoacceptors expressed from 46 genetic loci in the diploid human genome. This contrasts with our
previous studies in yeast, where mistranslating tRNAPro competes with only 10 tRNAPro genes.
This difference in tRNA copy number may explain why the tRNA Pro G3:U70 readily mistranslates
in yeast cells in rich media, whereas in human cells, stress was required to enhance tRNA Pro
G3:U70 induced mistranslation. It may be that the large number of human tRNA genes serves as
a ‘buffer’ against mistranslation induced by single gene tRNA mutants.
In this work, we demonstrated the use of a novel mistranslation reporter that is specifically
sensitive to mistranslation at Pro codons in human cells. Given the sensitivity of GFP to mutations
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at key positions, a number of other groups have developed GFP-based reporters for different types
of mistranslation. GFP (M72Q) has been used extensively in mammalian cells to detect natural
levels of methionine mis-incorporation, which increases 10-fold in response to oxidative stress 16,
43

. GFP (E222Q)45 and GFP (T65V)46 are examples of reporters that detect mistranslation of

glutamine and valine codons, respectively. Our GFP (D129P) reporter extends the range of GFPbased reporters for use in live human cells to include a new type of mistranslation.
A complementary approach involves using quantitative mass spectrometry to identify
mistranslation in a GFP reporter47. In this approach, the fluorescence output of GFP was not used
to detect mistranslation, rather a particular residue in GFP was chosen such that tryptic peptides
that include the site are ideal for detection by MS. The technique, referred to as MS-READ, is
unbiased as it can detect any type of mistranslation event, including detection of exceedingly low
levels of amino acid mis-incorporation. Although this quantitative method cannot be applied in
live cell imaging, it can be used in a kinetic mode to chart mistranslation in cells at specified time
points. Taken together, these mistranslation reporters provide the opportunity to comprehensively
identify mistranslation induced by natural and disease-linked tRNA variants.

2.4.5 Cellular adaptation to mistranslation.
In yeast, tRNAPro G3:U70 induces a heat shock response11. Robust proteasomal activity
was also required to maintain wild-type like growth with this proteome-wide mistranslation 11. In
the current study, we were unable to detect a significant impact of tRNA-dependent mistranslation
on the heat shock response or on cell viability in HEK 293T cells. In contrast to the view of a
highly accurate proteome, there are many examples in bacteria and eukaryotic cells (see
Introduction), where levels of mistranslation of 5-10% have a negligible impact on cell growth and
viability. For example, yeast cells expressing an editing defective phenylalanyl-tRNA synthetase
(PheRS) in complete media showed no phenotypic defect, despite mis-incorporation of tyrosine at
phenylalanine codons7. When these mistranslating yeast cells were grown under conditions of
amino acid stress, i.e., in media containing a 1/400 ratio of Phe/Tyr, ~5% of phenylalanine codons
were mistranslated, which resulted in viable cells with a 50% reduction in growth rate. The strain
failed to mount a heat shock response despite proteome wide mistranslation. The growth defect
resulted from the fact that the PheRS editing defective yeast strain was ineffective in activating
amino acid and protein stress response pathways to this particular type of mistranslation 7. These
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striking observations reveal the complex and varied cellular responses that manifest as a result of
distinct types of mistranslation, and highlight the need for a greater understanding of mistranslation
in the context of cellular physiology and disease.

2.5 Conclusion
All cells have an inherent level of mistranslation8, 14. Cells, from bacteria to humans, have evolved
mechanisms to cope with not only this inherent level of mistranslation, but, also elevated levels
resulting from a variety sources including oxidative and nutrient stress as well as AARS and tRNA
mutations. The study noted above7 and similar studies (reviewed in48) are beginning to shed light
on the pathways activated in response to mistranslation, and of particular interest is the interaction
of mistranslation with cell stress. These advances are motivating our on-going work to further
characterize the mammalian cellular response to Pro codon mistranslation in stress conditions and
cellular models of disease. In addition, our approach represents a feasible high-throughput cellbased screen for tRNA function. We anticipate that the GFP reporter we developed here will have
application in mapping the function of human tRNA variants in the natural population and in
elucidating tRNA mutations implicated as drivers or perhaps suppressors of disease.
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2.7 Supplemental information
2.7.1 Supporting methods
Production of T7 RNA polymerase.
T7 RNA polymerase (6xHis-tagged T7 RNAP) was expressed from pT7-911 vector in 1L
E. coli culture at 37⁰C in LB + 100 g/mL ampicillin. Cultures were induced with 1 mM Isopropyl
β-D-1-thiogalactopyranoside at OD600 = 0.6 and incubated for 3 hours at 20°C before harvesting
cells by centrifugation. Recombinant T7 RNAP was purified by Ni-NTA affinity chromatography.
The column was washed with 20 column volumes wash buffer (10 mM imidazole, 50 mM TrisHCl pH 8.0, 100 mM NaCl, 5% glycerol, 5 mM β-mercaptoethanol) and eluted with 10 column
volumes elution buffer (500 mM imidazole, 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 5% glycerol,
5 mM β-mercaptoethanol). Elution fractions were analyzed by coomassie-stained SDS-PAGE and
fractions containing T7 RNA polymerase at the correct molecular weight were pooled for dialysis.
Pooled elution fractions were dialyzed overnight at 4°C in storage buffer (20 mM HEPES-KOH
pH 8.0, 1 mM EDTA, 100 mM NaCl, 3 mM dithiothreitol, 50% glycerol) and stored at -20°C.

In vitro tRNA transcription and radiolabeling.
Transcription reactions were performed as previously1 in a reaction containing 200 ng/l
DNA template in the presence 40 mM HEPES-KOH pH 8.0, 22 mM MgCl 2, 5 mM dithiothreitol,
1 mM spermidine, 4 mM of NTPs (ATP, GTP, CTP, and UTP), and 30 nM T7 RNAP. Samples
were run on 12% urea (7M) polyacrylamide gels at 40 W. Correct-sized bands were visualized
with a UV transilluminator and excised. Gel plugs were vortexed and dissolved in 10 ml of 3 M
sodium acetate (pH 5.2) at 4°C for 2 hours or overnight. The solubilized tRNAs solution was then
filter sterilized (2 m). Filtrates from three reactions (2  2-hour, 1  overnight incubation in 3 M
sodium acetate pH 5.2) were pooled together and precipitated with an equal volume of 100%
isopropanol at -80°C overnight. Samples were centrifuged at 10,000  g for one hour, supernatant
was decanted, and the pellet was washed with 70% ethanol. Centrifugation was then repeated,
supernatant was removed and pellets were air-dried before re-suspension in sterile milli-Q water.
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Folding and radiolabeling of tRNA.
tRNAs were denatured in a 95°C water bath for 5 min then cooled gradually to room
temperature. At 65°C, MgCl2 was added to a final concentration of 10 mM to assist with folding.
50 l reactions were prepared with 1 μM tRNA, 100 mM Tris-HCl pH 8.0, 10 mM dithiothreitol,
40 mM MgCl2, 10 μM NaPPi, 200 nCi of α-32[P]-ATP (PerkinElmer) and 5 μl of CCA adding
enzyme (produced as previously1). The reaction was incubated at 37°C for 1 hour. Radio-labelled
tRNAs were purified using Biospin30 column (Bio-Rad).

2.7.2 Supporting tables
Table S2.1. Sequences of tRNA construct oligos
Sequence (5' to 3')
tRNAAla Watson strand

CTAGATAATACGACTCACTATAGGGGGTATAGCTCAGTGG
TAGAGCGCGTGCTTAGCATGCACGAGGTCCTGGGTTCGA
TCCCCAGTACCTCCACCATGCATG

tRNAAla Crick strand

GATCCATGCATGGTGGAGGTACTGGGGATCGAACCCAGG
ACCTCGTGCATGCTAAGCACGCGCTCTACCACTGAGCTAT
ACCCCCTATAGTGAGTCGTATTAT

tRNAPro Watson strand

CTAGATAATACGACTCACTATAGGCTCGTTGGTCTAGTGG
TATGATTCTCGCTTTGGGTGCGAGAGGTCCCGGGTTCAA
ATCCCGGACGAGCCCCCATGCATG

tRNAPro Crick strand

GATCCATGCATGGGGGCTCGTCCGGGATTTGAACCCGGG
ACCTCTCGCACCCAAAGCGAGAATCATACCACTAGACCA
ACGAGCCTATAGTGAGTCGTATTAT

tRNAPro mutant Watson strand

CTAGATAATACGACTCACTATAGGCTCGTTGGTCTAGTGG
TATGATTCTCGCTTTGGGTGCGAGAGGTCCCGGGTTCAA
ATCCCGGACGATCCCCCATGCATG

Pro

tRNA

mutant Crick strand

GATCCATGCATGGGGGATCGTCCGGGATTTGAACCCGGG
ACCTCTCGCACCCAAAGCGAGAATCATACCACTAGACCA
ACGAGCCTATAGTGAGTCGTATTAT
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Table S2.2. Sequences of primers for template PCR
Sequence (5' to 3')
Upstrean T7 promoter forward

GTTGGGAAGGGCGATCGGTG

tRNAAla forward

CTAGATAATACGACTCACTATAGGGGG

tRNAAla reverse

TGGTGGAGGTACTGGGGAT

tRNAPro forward

CTAGATAATACGACTCACTATAGGC

Pro

tRNA

reverse

TGGGGGCTCGTCCGGGA

tRNAPro mutant forward

TAATACGACTCACTATAGGGTCG

tRNAPro mutant reverse

TGGGGGATCGTCCGGGA

2.7.3 Supporting figures

Phase

GFP
tRNAPro G3:U70
EGFP D129P

200 µm

WT tRNAPro
EGFP D129P (-)

Figure S2.1. Overexpression of tRNAPro G3:U70 had no obvious effect on cell morphology
compared to wild-type tRNAPro. Images captured by light (phase) or fluorescence (GFP; ex/em
= 470/525 nm) microscopy on day three low serum, low glucose media (see main text, Fig. 2.3).
Scale bars depict 200 m distance.
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Figure S2.2. Visualizing mistranslation after selection in Geneticin. HEK 293T cell cultures
were transfected with plasmid harboring tRNAPro and EGFP D129P (WT); tRNAPro G3:U70 and
EGFP D129P (G3:U70); or tRNAPro and EGFP D129A (+). All plasmids have a pCDNA 3.1 (+)
backbone containing the bacterial NeoR gene. Selection cultures were maintained in Geneticin
(G418) containing media for 25 days prior to quantification. (A) representative images captured
by light (phase) or fluorescence (GFP; ex/em = 470/525) microscopy at 4  magnification. Scale
bars represent 400 µm distance. (B) Box and whisker plots of EGFP foci intensity. Horizontal
demarcations depict quartiles with median centered. Dots represent the general distribution of 100
foci measured in each plot. Stars indicate statistically significant differences according to singlefactor ANOVA (**** = p < 0.0001). Means are noted below each blot.
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WT
Phase

G3:U70
GFP

Phase

GFP

200 µm

Figure S2.3. Additional images from low serum low glucose growth, experiment day 5. HEK
293T cell cultures were transfected with plasmid harboring tRNAPro and EGFP D129P (WT); or
tRNAPro G3:U70 and EGFP D129P (G3:U70). Images captured by light (phase) or fluorescence
(GFP; ex/em = 470/525) microscopy at 20  magnification. Scale bars represent 200 µm distance.
See main text (Fig. 2.3 and methods) for experimental details.
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Figure S2.4. Mistranslation under glucose and serum starvation. Box and whisker plots
showing data from figure 2.3 (main text) with EGFP D129A data set removed and vertical axis
zoomed in to more clearly show differences caused by mistranslating tRNA in comparison to the
wild type tRNA. HEK 293T cell cultures were transfected with plasmid harboring tRNA Pro and
EGFP D129P (WT); or tRNAPro G3:U70 and EGFP D129P (G3:U70). See main text (Fig. 2.3 and
methods) for experimental details.
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Chapter 3
3. Formation and persistence of polyglutamine aggregates in
mistranslating cells1
3.1 Introduction
High-fidelity translation of messenger RNAs (mRNAs) was considered essential for life by
assuring the functional reproduction of ‘so many highly evolved protein molecules’ (1). In fact,
translation of mRNAs is the most erroneous step on the path from gene expression to protein
synthesis in cells (2-5). Errors in protein synthesis can result from ribosome stalling or pausing,
frameshifting, and amino acid mis-incorporation. Error rates in cells are normally considered low,
with 1 mis-incorporation event occurring for every 1,000 to 10,000 codons translated (6,7). Cells
can tolerate or even derive a selective advantage from elevated mistranslation rates as a result of
stress (8-11), chemical treatment (12-14), or mutations in the protein synthesis machinery (15-18).
The conserved sequence and structure of transfer RNAs (tRNAs) are a major determinant of
proteome fidelity. Consequently, single nucleotide substitutions in individual tRNA genes can lead
to proteome-wide mistranslation in bacteria (19,20), yeast (18), and mammalian cells (17,21,22).
The relevance of tRNA mutations to human disease is becoming more evident since the discovery
that cytoplasmic tRNA variants, including those likely to cause errors in translation, are more
common in the human population than previously recognized (23). Sequencing efforts, such as the
1000 Genomes Project and our own work (24), confirm that mistranslating tRNA mutants occur
in individuals as both rare and common variants with some found in 1-5% of the population.
Mutations in protein coding genes that cause mistranslation, such as aminoacyl-tRNA
synthetases, are associated with neurodegeneration in mice (25) and Drosophila (26). Mutant
tRNAs that lead to a loss of tRNA function were linked to neurodegenerative disease and neuronal
phenotypic defects in mice (27,28) and a genetic disorder in humans (29). Mitochondrial tRNA
variants have long been associated with human diseases, including neurodegeneration (30).
MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke‐like episodes) (31)
and MERRF (myoclonus epilepsy associated with ragged red fibers) (32) are two major
1

Work in this chapter was published in: Lant, J.T., Kiri, R., Duennwald, M.L., O’Donoghue, P.
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neurodegenerative diseases caused by mutations in mitochondrial tRNAs. In both cases, the mutant
tRNAs, which occur at different locations in the tRNA body, cannot be properly posttranscriptionally modified at position 34 of the anticodon. Single mitochondrial tRNA mutants
lacking the base 34 taurine modification are less efficient in decoding their cognate codons,
resulting in reduced protein synthesis in the mitochondria. The tRNA Leu variants lacking U34
modification can read UUA but not UUG Leu codons (33).
Cytoplasmic tRNAs that specifically cause amino acid mis-incorporation, however, have not
been assessed for their contribution to neurodegenerative disease. Recently, loss-of-function
cytoplasmic tRNA variants emerged with connections to neurodegeneration (23). The n-Tr20
mutant is a tRNAArgCTC with a C50T substitution in the T-arm of the tRNA (27). The mutation
leads to a processing defect and the mature tRNA is not produced. Although there are five nearly
identical tRNAArgCTC genes in the genome, the affected tRNA gene normally shows high
expression in the cerebellum where the n-Tr20 gene product accounts for 60% of the tRNA ArgCUC
pool (27). In a screen for neurodegeneration in mice, this tRNA mutant was found to be causative
when co-incident with a mutation in the ribosome recycling factor GTPBP2. Together both
mutants act to stall the ribosome and reduce the rate of protein synthesis. Mice with these mutations
displayed multiple neurodegenerative phenotypes, locomotor defects, and died at 8 to 9 weeks
(27). Further studies of this tRNAArg mutant found altered synaptic transmission and increased
susceptibility to seizures in mice (28).
Mistranslation is also associated with proteotoxic stress and neurodegeneration in mice (25)
and patient-derived cell lines (34). Many studies have focused on tRNA synthetase mutants,
particularly those defective in editing mis-charged amino acids. One example involves an editing
defective AlaRS that mis-charges tRNAAla with Ser, causing increased levels of misfolded proteins
in neurons. Mice expressing the mutant AlaRS displayed reduced body weight and a
neurodegenerative phenotype resulting from cell loss and ataxia of Purkinje cells in the cerebellum
(25). Another AlaRS editing-defective mutation caused cardioproteinopathy in mice, characterized
by protein aggregation in cardiomyocytes, cardiac fibrosis and dysfunction (35). AlaRS mutants
are also associated with additional diseases of the nervous system, including Charcot-Marie-Tooth
(CMT) disease (36) and early-onset epileptic encephalopathy (37).
Inspired by these studies, we hypothesized that a tRNA variant that also caused mistranslation
will act to modify the progression of neurodegenerative disease at the molecular level by affecting
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protein homeostasis and protein aggregation. We investigated the disease-modifying potential of
mistranslating tRNA variants in combination with multiple mammalian cellular models of
Huntington’s disease (HD). HD, like many other neurodegenerative diseases (38), is characterized
by the misfolding and aggregation of specific proteins. Protein misfolding typically has the greatest
impact on post-mitotic cells such as those found in the heart, brain, and eye (25,39). Since these
cells cannot readily divide or undergo apoptosis, misfolded proteins and protein aggregates
accumulate over time, leading to dysregulation of the proteome, cytotoxicity, and eventually cell
death (39).
Disorders characterized by protein folding stress or by impaired protein quality control may be
particularly susceptible to the effects of mistranslating tRNAs, since mistranslation increases the
synthesis of misfolded proteins to further burden the cellular protein folding stress responses
(17,21,40). In the case of HD, proteinopathy is triggered by an expanded CAG (Gln) codon repeat
in exon1 of the HTT gene encoding the huntingtin protein. Pathogenicity results primarily from a
region corresponding to the first exon of the HTT gene (mHTTexon1), which can generate a polyQ
expanded Htt protein either by mRNA splicing or proteolysis (41,42). CAG repeats of > 38
glutamine residues are associated with disease risk (43). CAG repeat length thereafter correlates
with age of onset and severity, but the relationship is highly variable (44). Indeed, some patients
with the same CAG repeat length differ by over 20 years in age of onset (44). Further, the severity
of symptoms can differ greatly between individuals with a similar age of onset (45). The
discrepancies imply the existence of genetic modifiers of Huntington’s disease, and several
protein-coding genes have been proposed (44). Searches for genetic modifiers, thus far, have relied
on whole exome sequencing and single nucleotide polymorphism (SNP) arrays which do not
capture tRNA or other non-protein coding RNA gene variants. In addition, whole genome
sequencing approaches lack the depth of coverage, read length, and mapping strategy required to
confidently identify all tRNA variants in a human genome (24). In this study, we demonstrate that
a naturally occurring tRNA variant has significant potential to act as a genetic modifier to
Huntington’s disease and conceivably other forms of neurodegenerative disease.
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3.2 Materials and Methods
3.2.1 Plasmids and strains.
Expression constructs, cloning procedures, and primers (Table S3.1) are described in
supplemental methods. Plasmid DNA for transfection in mammalian cells was purified by MidiPrep (GeneAid, New Taipei City, Taiwan) from 100 ml Escherichia coli DH5α cultures according
to manufacturers’ instructions. For all tRNA genes used in our study, we collected data on the
folding predictions of the wild-type and mutant tRNAs (gtRNAdb (46)), and available expression
data from human cells (gtRNAdb (46), UCSC genome browser (47)). All tRNAs used were
predicted to be expressed and fold into a canonical tRNA structure in human cells (Table 3.1).

3.2.2 Cell culture and transfection.
Experiments were performed in murine Neuro2a Neuroblastoma (N2a; ATCC #CCL-131),
human SH-SY5Y neuroblastoma (SH-SY5Y; ATCC #CRL-226), or rat pheochromocytoma
(PC12; parent cells: ATCC #CRL-1721)-derived cells. PC12-derived cell lines containing
HTTexon1 fused to EGFP with 23Q or 74Q polyQ under doxycycline promoter (48) were a gift
from David Rubinsztein (University of Cambridge, U.K.). All cell lines were grown at 37°C with
humidity and 5% CO2. N2a and SHSY5Y cells were cultured in high glucose Dulbecco’s modified
Eagle medium (DMEM, 4.5 g/L glucose; Gibco by Life Technologies, Carlsbad, CA) containing
penicillin (100 IU/mL), streptomycin (100 µg/ml; P/S; Wisent Bioproducts, Montreal, QC,
Canada), and 10% fetal bovine serum (FBS; Gibco). PC12-derived cell lines were cultured in high
glucose DMEM containing P/S, 10% horse serum (Gibco), 5% FBS (Gibco), 50 µg/ml G418
(Gibco), and 150 µg/ml hygromycin B (Invitrogen, Carlsbad, CA, USA). All transfections were
performed using Lipofectamine 2000 transfection reagent (Invitrogen) with 2 µg/ml plasmid DNA,
following the manufacturer’s instructions.

3.2.3 Small molecules and peptides.
Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132; Sigma-Aldrich 474790, Darmstadt,
Germany) and integrated stress response inhibitor (ISRIB; Sigma-Aldrich SML0843) were
dissolved in DMSO and cells were treated with final concentrations as described.
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3.2.4 Cellular viability and toxicity assays.
Cellular viability was assessed using a CelltitreGlo 2.0 Luminescent Viability Assay
(Promega, Madison, WI) in at least three biological replicates following the manufacturer’s
instructions. Cytotoxicity was assayed with a CytotoxGlo luminescent cytotoxicity assay
(Promega) in at least four biological replicates, following the manufacturer’s instructions. Cells
were assayed 48 hours post-transfection. For assays containing the proteasome inhibitor, cells were
treated with MG132 (0.1 to 10 µM as indicated) or vehicle (DMSO) for 4 hours immediately
before assay.

3.2.5 Western blotting.
Detailed western blotting procedures are described in supplemental methods. The
following primary antibodies were used in this work: α-GFP, Abcam, Cambridge, UK, ab32146;
α-GAPDH, Sigma-Aldrich, Darmstadt, Germany, MAB374m; α-HSP70, Invitrogen, MA3-006; αHSP90, Protein Tech, Rosemont, IL, USA, 13171-1-AP; α-Phospho-eIF2α Ser52, ThermoFisher
Scientific, 44-728G; α-eIF2α, ThermoFisher Scientific, AHO0802; α-eEF2, Cell Signaling
Technology, Danvers, MA, USA, 2332; α-Phospho-eEF2 (Thr56), Cell Signaling Technology,
2331.

3.2.6 Mass spectrometry.
Detailed mass spectrometry protocols are described in the supplemental methods. Briefly,
mCherry protein and wild-type or mistranslating tRNASer were co-expressed in N2a cells and
mCherry protein was purified using RFP-trap agarose bead immunoprecipitation (Chromotek,
Munich, Germany). Immunoprecipitated mCherry was visualized on SDS-PAGE and bands at the
correct molecular weight were excised from the gel for MS/MS following tryptic digest of the
protein samples. Hits representing Ser misincorporation at Phe codons were curated to include
only peptides with a peptide score (-10logP) of > 50.

3.2.7 Fluorescence microscopy.
Detailed fluorescence microscopy methods are described in supplemental methods.
Briefly, Fluorescent microscopy images were captured on an EVOS FL auto fluorescent
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microscope (Thermo Fisher Scientific). GFP (470 ± 22 nm excitation, 510 ± 42 nm emission) and
RFP (531 ± 40 nm excitation, 593 ± 40 nm emission) filter cubes were used to capture green or
red fluorescence. An EVOS onstage incubator was used for live cell experiments and images were
quantitated using ImageJ/Fiji (49,50) (see supplemental methods, supplemental appendix).

3.2.8 Cycloheximide chase protein degradation assays.
N2a cells were transfected for 48 hr before the experiment in 96-well plates with three
biological and six technical replicates. Cells were washed once with Hank’s buffered salt solution
(HBSS; Gibco by Life Technologies), then media was replaced with DMEM (10% FBS, P/S)
containing 50μg/ml cycloheximide (Sigma-Aldrich) and either 10 μM MG132 or equivalent
concentration of DMSO. The plate was immediately transferred to the EVOS FL environment
chamber pre-heated to 37°C with 5% CO2 and humidity. After acclimatizing the plate for 1 hr,
images were captured every 30 min for 12 hr. Fluorescence was quantitated using a semiautomated approach in ImageJ (see supplemental information). Initially, increasing concentrations
of cycloheximide (0, 50, 250, and 500 μg/mL) were also assessed with single fluorescent images
with the same approach after 24 hr incubation (see supplemental information). All concentrations
resulted in a similar reduction in fluorescence after 24 hours, so the lowest concentration (50
μg/ml) was selected for the kinetic assay.

3.2.9 Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE).
N2a cells were transfected as above. In one experiment (Fig. S3.6A), cells were incubated
with DNA and lipofectamine 2000 for 24 hr. In another experiment (Fig. 3.5C,D,E), cells were
incubated for 48 hr with lipofectamine 2000 and DNA, then cells were treated for 4 hr with either
10 μM MG132 dissolved in DMSO or an equal volume of DMSO. Cell lysates were prepared as
above (see Western blotting) and protein concentrations were measured with the BCA assay
following manufacturer’s instructions. SDD-AGE assays were performed similarly to published
approaches (51). Lysate volumes containing 40 μg protein were diluted in 3× loading dye (0.5 M
Tris-HCl, pH 6.8; 1.12 M sucrose; 0.025% bromophenol blue; 3.8% SDS) with sterile milliQ H 2O,
loaded and separated on 1.5% agarose gels containing 0.1% SDS. Proteins were transferred to a
nitrocellulose membrane by capillary electrophoresis overnight using Tris-acetate-EDTA buffer
(40 mM Tris-base, 20 mM acetic acid, 1 mM EDTA) with 0.1% SDS. EGFP-tagged polyQ
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aggregates were visualized by western blotting with α-GFP antibody (see supplemental
information).

3.2.10 Protein aggregation clearance assay.
PC12-derived cells were transfected using lipofectamine 2000 and transfectants expressing
wild-type or mutant tRNAs were identified by red fluorescence from a plasmid-encoded mCherry
protein. 48 hrs post-transfection, mHTTexon1 74Q-EGFP expression was induced with 2 µg/ml
doxycycline (doxycycline hydrochloride; Sigma-Aldrich) as before (48). After 96 hrs, cells were
washed once with doxycycline-free medium and thereafter maintained in doxycycline-free
medium. Images were captured daily in RFP (531 ± 40 nm excitation, 593 ± 40 nm emission) and
GFP (470 ± 22 nm excitation, 510 ± 42 nm emission) settings from the time at induction to 72 hrs
after doxycycline was removed. To determine the fraction of transfected cells containing
aggregates at each time point, the number of transfected cells (red) containing visible aggregates
(green) in each image was counted manually by overlaying fluorescent images in ImageJ.

3.3 Results
3.3.1 Transfer RNA variants used in this study.
Transfer RNA variants can elicit several different types of errors in protein synthesis (23). Here
we focused on tRNA variants that specifically cause amino acid misincorporation. The cognate
aminoacyl-tRNA synthetases (AARS) for Ser, Ala, and to a lesser extent for Leu, do not use the
anticodon as an identity or recognition element (52). Thus, nonsynonymous anticodon variants of
tRNASer, tRNAAla and tRNALeu have potential to cause amino acid misincorporation. Seryl-tRNA
synthetase is especially flexible in recognizing tRNASer with different anticodons (53), since serine
is encoded by six codons with no single nucleotide common to all possible sequences. Indeed,
engineered tRNASer anticodon variants cause mistranslation in mouse and human cells (21), but
naturally occurring variants have not been tested.
By searching the genomic tRNA database (46), we found an uncharacterized tRNA Ser anticodon
mutant (tRNA-Ser-AGA-2-3 G35A) that occurs in 1.8% of the sequenced population (Fig. 3.1A)
(23). The mutant occurs primarily in the tRNASer-AGA-2-3 gene and is also found more rarely in
the identical tRNASer-AGA-2-2 gene (23). In an independent targeted sequencing effort covering
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all human tRNA genes, we identified the same mutant in the tRNASer-AGA-2-3 gene at a minor
allele frequency of 3% in a population of 84 individuals (24). In eukaryotes, tRNA SerAGA is a
substrate for A34-to-I34 editing (54), yielding an IGA anticodon which can decode UCU, UCC, and
to a lesser extent UCA codons (55). Hence, assuming canonical A:U pairing in the second
anticodon:codon position, the tRNA-AGA-2-3 G35A variant has potential to decode UUU (Phe),
UUC (Phe), and UUA (Leu) codons. We also investigated two additional mistranslating tRNA
variants that we previously characterized in yeast (18,56) and mammalian cells (22) for their ability
to direct amino acid mis-incorporation. One variant is caused by mutation of an identity element
such that a different AARS recognizes the tRNA (Fig 3.1B). The resulting Ala-tRNA Pro decodes
Pro (CCA/G/U) codons with Ala (18,22). The second variant (tRNA Ser CGA-2-1 C34T, A36G) is
a human homolog of a tRNASer with a UGG (proline) anticodon that led to mis-incorporation of
Ser at Pro codons (CCA/G/U) in yeast (56). Properties of the tRNA genes and variants are noted
below (Table 3.1), while additional gene and SNP identifiers as well as sequences for each tRNA
gene locus are listed in the supplemental information (Table S3.2).
Table 3.1. tRNA genes and variants
variant
tRNA gene

variants

mistranslation

Ser-AGA-2-3

G35A

Ser at Phe
(UUU/C), Leu

documented

description mistranslation
natural
MAF = 1.8%

tRNA scoref
wt

variant

Expression
ARMg CHIPh

N2A cellsb

89.6

89.6

+

+

yeastc

94.0

94.1

+

+

74.9

70.8

+

+

a

(UUA) codons
Ser-CGA-2-1

C34T,

Ser at Pro codons

synthetic

A36G
Pro-TGG-1-1 C3G, G70T Ala at Pro codons

N2A cells
synthetic

b

yeastd
HEK293e cells

a

Data from 1000 Genomes Project (46,82); bthis study; chomolog of Ser-CGA C34T, A36G

mistranslation documented in yeast (56,83), dhomolog of Pro-TGG-1-1 3G, 70T mistranslation
documented in yeast (18), ePro-TGG-1-1 C3G, G70T mistranslation documented in HEK293 cells
(22), ftRNA gene score calculated using tRNA-Scan SE (Infernal score) (46); gARM = ARM-seq
data suggesting expression (46,84); hCHIP = CHIP-seq hits for at least 3 proteins found in RNA
Polymerase III holoenzyme or initiation complex (RPC155, POLR3G, BRF1, BDP1, GTF3C2,
TBP) (47,85-88).
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Figure 3.1. Mechanisms of tRNA-dependent mistranslation. Anticodon (A) or identity element
(B) mutations in tRNAs can lead to mistranslation. Anticodon mutations in tRNA Ser genes (A) lead
to a mutant tRNA that still accepts serine and now decodes other codons. The tRNA Ser G35A
mutant decodes phenylalanine or leucine (UUN) codons with serine. We also characterized a
tRNASerUGG variant (not shown) that decodes proline codons with serine. Mutations in human
tRNAs can lead to the acquisition of a G3:U70 base pair, which is a critical identity element for
AlaRS (B). The resulting tRNAPro (G3:U70) is an efficient alanine but not proline acceptor that
retains the ability to decode Pro codons.
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3.3.2 tRNASerAAA-dependent amino acid misincorporation.
To confirm that the tRNASerAAA variant causes the expected Ser incorporation at Phe
codons in cells, we immunoprecipitated mCherry protein from cells expressing tRNA SerAGA or
tRNASerAAA and identified multiple peptides corresponding to Ser misincorporation by mass
spectrometry. The mCherry coding sequence contains ten UUC codons that may be mistranslated
by tRNASerAAA. We detected Ser misincorporation at multiple Phe codons in mCherry from cells
expressing tRNASerAAA. In addition, we observed potential mistranslated peptide hits, i.e.,
probability of random hit score (-10logP) ~ 40-60, in both normal (Fig S3.1A) and mistranslating
cells (Fig S3.1C, Tables 3.2,3.3). While these lower scoring hits match the full peptide mass,
following fragmentation, both hits contain significantly more unidentified peaks and lack multiple
y and b ions that cover the site of interest. This is in contrast to the higher scoring hits documenting
mistranslation in cells expressing tRNASerAAA, where the spectra have multiple ions with a much
higher signal to noise ratio confirming misincorporation (Fig S3.1B,D,E, Table 3.2). For an
overview of misincorporation in the mCherry reporter, we summarized all peptide hits with 10logP > 50 for Phe or Ser incorporation at each Phe codon in mCherry (Table 3.3). The spectral
counts indicate a greater level of mis-incorporation of Ser at Phe codons in mistranslating cells (26
Ser / 266 Phe) compared to the background level (6 Ser / 304 Phe) observed in normal cells. Most
of the hits in wild-type cells occur at Phe70 (Fig S3.1A), yet these spectra lack sufficient y and b
ion support to confirm these peptides as evidence that mis-incorporation occurs in normal cells.
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Table 3.2. Selected observed peptides showing Ser mis-incorporation at Phe codons in
mCherry.
Fig.

tRNASer

Phe

AA

S3.1

anticodon

codon

change

mCherry

mCherry

UUC

F70S

panel
A

AGA

Peptide sequence

-10logP

Area

GGPLPFAWDILSPQ(+.98)SMYG

58.75

1.7×109

94.78

3.8×107

48.50

2.3×107

88.19

2.0×107

92.40

2.0×107

SKA
B

AAA

UUC

F70S

GGPLPFAWDILSPQSM(+15.99)
YGSK

C

AAA

UUC

F70S

GGPLPFAWDILSPQ(+.98)SMYG
SKA

D

AAA

UUC

F104S

VM(+15.99)NSEDGGVVTVTQD
SSLQDGEFIYK

E

AAA

UUC

F123S

VM(+15.99)NFEDGGVVTVTQD
SSLQDGESIYK

S indicates Ser misincorporation at Phe codons. Spectra for these peptides are shown in Fig. S3.1.
Table 3.3. Observed spectral counts for Ser or Phe incorporation at Phe codons in
mCherry.
tRNASerAGA

Phe codon
position in

No. Phe peptides

mCherry

Total:

tRNASerAAA

No. Ser

No. Phe peptides

peptides

No. Ser
peptides

32

122

1

86

5

61

18

0

15

1

70

14

4

9

9

92

5

0

5

2

96

0

0

0

0

104

54

1

36

4

123

55

0

36

5

134

36

0

42

0

304

6

229

26

Peptides hits with -10logP score > 50 are shown.
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3.3.3 Reduced protein levels in mistranslating cells.
Previous reports established a translation-inhibition response to mistranslating tRNAs
expressed in mammalian cells (21,40). Through inhibition of mRNA translation initiation or
elongation, general protein synthesis can be downregulated in response to mistranslation or tRNA
dysfunction (21,57). Using fluorescence microscopy, we measured red fluorescence (ex. 542 ± 20
nm, em. 593 ± 40 nm) of N2a cells expressing tRNASerAGA, tRNASerAAA, tRNASerCGA, or
tRNASerUGG and mCherry. We observed a significant reduction in fluorescence of cells expressing
either tRNASer mutant compared to wild-type tRNA (Fig 3.2A,B). The transfections were repeated
with plasmids expressing wild-type tRNASerAGA or the tRNASerAAA variant for western blotting
analysis of GFP (S65F)-mCherry expression (see supplementary methods). Compared to a
GAPDH control, the GFP-mCherry protein levels were reduced > 3.6-fold in mistranslating cells
(Fig. 3.2C). We captured images of HEK239 cells expressing wild-type and mistranslating
tRNAPro G3:U70 with an EGFP reporter as before (22). Analysis of these images confirmed that
tRNAPro G3:U70 does not elicit the translation suppression response (Fig. S3.2A) that we observed
with the anticodon variants of tRNASer.
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Figure 3.2. Fluorescence and expression of mCherry protein in mistranslating cells. N2a cells
were transfected with a plasmid encoding human tRNASerAGA or G35A variant tRNASerAAA; or
tRNASerCGA or the C34G, A36G variant tRNASerUGG and fluorescently dead GFP (S65F or P) fused
to an active mCherry transfection marker. Fluorescence of cells was measured by fluorescence
microscopy (RFP, ex 531 nm, em 593 nm). Each box represents data from 135 cells from three
biological and nine technical replicates (A). Midline represents the median, boxes represent
quartiles, and whiskers represent 1.5× the interquartile range. Representative images were captured
under 20× magnification with phase or RFP settings (B). Cell lysates were harvested and western
blotted for fluorescent protein expression with anti-GFP and anti-GAPDH antibodies as a loading
control (C). Anti-GFP blots were quantitated in three biological replicates by densitometry
normalized to GAPDH. Stars indicate p-values from independent sample t-tests (n.s. = no
significant difference, * = p < 0.05, ** = p < 0.01, *** = p < 0.001) and letters indicate significantly
different groups determined by Tukey’s Honestly Significant Different (HSD) test, where groups
sharing a letter are not significantly different and groups not sharing a letter are significantly
different (α = 0.05).
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3.3.4 tRNA-dependent toxicity in human and mouse cellular models of HD.
To investigate the viability of cells expressing a known mistranslating tRNA combined with an
aggregating polyQ allele, we co-transfected plasmids encoding a wild-type or G3:U70 human
tRNAPro with a non-pathogenic (25Q) or mildly pathogenic (46Q) version of HTTexon1 (58). The
experiments were performed in murine N2a and human SHSY5Y cells. Both are neuroblastomaderived lines that are routinely used as a model for protein misfolding disease, including HD
(48,59). Using a luminescent assay for cell viability (Celltitre Glo 2.0), we observed no significant
loss of viability from the mutant tRNA alone or from the mildly deleterious HTT-allele coexpressed with a wild-type tRNA. Only the combination of HTTexon1 46Q expression in
mistranslating cells resulted in a significant reduction (1.3 ± 0.05-fold in SHSY5Y; 1.2 ± 0.06-fold
in N2a) in cellular viability compared to cells expressing wild-type tRNA and 25Q (Fig 3.3A,B).
The data demonstrate a synthetic toxic interaction between the Ala accepting tRNA Pro G3:U70
mutant and a deleterious HTT allele. We observed the same result in both mouse (Fig 3.3A) and
human cells (Fig 3.3B).
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Figure 3.3. Toxic interactions of tRNA variants with a deleterious polyQ allele or proteosome
inhibition. N2a (A) or SHSY5Y cells (B) were co-transfected with two plasmids encoding human
tRNAProUGG or the G3:U70 variant and HTTexon1 containing 25 (25Q) or 46 (46Q) CAG/CAA
mixed codon repeats encoding polyQ. Cellular viability was measured 24 hr post-transfection with
CellTitreGlo 2.0. Luminescence readings were normalized to the “25Q WT” control. N2a cells
were transfected with a plasmid encoding human tRNA Ser AGA (C) or G35A variant tRNASerAAA
(D) and HTTexon1 containing 23Q fused to EGFP as a transfection marker. Cellular viability was
assayed 48 hr post-transfection with the CellTitreGlo 2.0 assay following 4 hr treatment with
increasing concentrations of MG132 or equal concentration of DMSO. Luminescence readings
were normalized to the DMSO controls. Stars indicate p-values from independent sample t-tests
(n.s. = no significant difference, * = p < 0.05, ** = p < 0.01, *** = p < 0.001); letters indicate
significantly different groups determined by Tukey’s HSD test (α = 0.05). Error bars represent the
mean ± 1 standard deviation of at least three biological replicates.
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3.3.5 Interactions of polyQ HTT alleles with tRNASer mutants.
We cloned the tRNA-Ser-AGA-2-3 wild type and G35A variant and tRNA-Ser-CGA-2-1 wild
type and C34G, A36G double mutant with native genomic context (+/- 300bp) into plasmids
containing mCherry fused to a fluorescence-inactivated GFP variant (see supplemental methods).
In N2a cells, we co-transfected plasmids with tRNASerAAA, tRNASerUGG or the respective WT tRNA
controls along with the 23Q or 46Q HTTexon1 allele. Unlike our studies with tRNA Pro G3:U70,
the tRNASer anticodon variants showed no significant loss of cellular viability on their own or in
combination with the 46Q HTTexon1 (Fig. S3.3A,B).
For the following experiments, we focused our investigations on tRNA SerAGA and the G35A
variant, since the variant occurs naturally in the human population and leads to phenotypic defects,
including inhibited protein synthesis. We cloned the tRNASerAGA and the tRNASerAAA variant genes
into plasmids expressing 23Q or 74Q HTTexon1 allele fused to EGFP. We used a CytotoxGlo
assay to measure cellular toxicity. In this assay, the tRNASerAAA variant was significantly cytotoxic
compared to the wild-type tRNASerAGA, but the mutant tRNA showed no apparent additional toxic
effect in combination with 74Q HTTexon1 (Fig. S3.3C,D).
We hypothesized that inhibition of the proteasome would increase the toxicity of
mistranslating cells because of the accumulation of mistranslated and misfolded proteins. We used
increasing concentrations of MG132 in cells expressing 23Q Httexon1-EGFP and either
tRNASerAGA (Fig 3.3C) or the tRNASerAAA variant (Fig 3.3D) and measured cell viability. We
observed a MG132 concentration-dependent decrease in cell viability only in cells expressing the
mistranslating tRNA variant, demonstrating a synthetic toxic interaction between the naturally
occurring tRNASerAAA mutant and proteasome inhibition. MG132 treatments at the same
concentrations had no effect on the viability of cells expressing wild-type tRNA (Fig. 3.3C).
Anticipating that proteasome inhibition would exacerbate toxicity of both the mistranslating
tRNA and the 74Q allele, we measured the toxicity of cells with or without treatment of MG132.
We again confirmed cytotoxicity resulting from the tRNASerAAA variant in comparison to wildtype tRNA, however, we observed no additional toxicity with 74Q compared to the 23Q HTTallele in mistranslating cells (Fig. S3.3D). Compared to normal conditions (Fig S3.3C), we note
that the addition of MG132 (Fig. S3.3D) resulted in a greater and more significant increase in
cytotoxicity for mistranslating cells compare with wild type cells.
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3.3.6 Kinetics of polyQ aggregate formation in mistranslating cells.
Using live cell fluorescence microscopy, we captured the formation of EGFP-tagged polyQ
aggregates in N2a cells expressing either tRNASerAGA or the tRNASerAAA variant over an 18 hr timecourse. We quantified the fluorescence and number of aggregates in each image series using a
semi-automated approach in ImageJ (Fig. S3.4). Mistranslating cells accumulated fewer 74Q
aggregates and less overall fluorescence signal over the time-course (Fig. 3.4A, S3.5, Data File
S3.1). We normalized the number of aggregates in each image to total fluorescence of the image
to account for the reduced fluorescence in mistranslating cells and variability in the number of
fluorescing cells between images. In cells expressing the wild-type tRNA, the number of
aggregates per unit fluorescence increased over time. In mistranslating cells, the appearance of
aggregates proceeded at a slower rate and plateaued earlier at the 10-hour time point (Fig. 3.4B).
To further validate that the observed reduction in fluorescence was due to expression of the mutant
tRNA, we co-transfected plasmids expressing mCherry and 23Q HTTexon1 allele fused to EGFP,
with the mutant tRNASerAAA encoded on either one plasmid or the other. Regardless of which
plasmid the tRNA was expressed from, 23Q-EGFP fluorescence was significantly and
equivalently reduced compared to cells expressing no additional tRNA, and the effect was
maintained for at least 48 hrs post-transfection (Fig. S3.2B).

Figure 3.4. Formation of polyQ aggregates in mistranslating cells. N2a cells were transfected
with a plasmid encoding human tRNASerAGA or G35A variant tRNASerAAA and HTTexon1
containing 74Q-EGFP. Images were captured beginning 24 hrs post-transfection by fluorescence
microscopy in GFP settings at 10× magnification every 30 min for an 18 hr time course. (A)
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Representative images from the beginning (t = 0 hr) and end (t = 18 hr) of the time course are
shown. (B) The number of aggregates in each image was quantitated in ImageJ (see supplemental
information). The number of aggregates in each image of the series was then normalized to total
fluorescence of the same image (Naggregates/total fluorescence), and initial values were subtracted
(ΔNaggregates/total fluorescence). Error bars represent the mean ± 1 standard deviation of six
biological replicates.

3.3.7 Mistranslating cells accumulate smaller and fewer polyQ aggregates.
To assess the effects of a mistranslating tRNA on insoluble polyQ aggregate formation, we
performed a membrane detergent assay to quantify insoluble EGFP-HTTexon1 polyQ aggregates
in cells expressing either tRNASerAGA or the tRNASerAAA variant. Aggregates were allowed to from
over a 48 hr transfection period, after which cells were treated with Triton X-100 to permeate the
cell membrane. Large, insoluble fluorescent aggregates are retained in the cell, whereas soluble
polyQ or small oligomers defuse into the media (Fig. 3.5A) (60). We used thresholding analysis
to assess the number and size of aggregates in images captured before and after Triton X-100
treatment. All fluorescent foci disappeared from cells expressing the non-aggregating 23Q-EGFP
following Triton X-100 treatment, while the 74Q foci were clearly visible (Fig. 3.5A). Foci
remaining in the mistranslating cells were significantly smaller than cells expressing wild-type
tRNA, with a median area of 257 µm2 compared to 315 µm2 in the wild-type tRNA-expressing
cells (Fig. 3.5B).
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Figure 3.5. Insoluble polyQ aggregate size and levels in mistranslating cells. N2a cells were
transfected with a plasmid encoding human tRNA SerAGA or G35A variant tRNASerAAA and
HTTexon1 containing 23Q or 74Q fused to EGFP. (A) Representative images were captured by
fluorescence microscopy before and after Triton X-100 treatment at 10× magnification. Images
are overlaid from GFP and phase settings. (B) The area of fluorescent bodies remaining after
detergent was measured in ImageJ (see supplemental methods). Midline represents the median,
boxes represent quartiles, and whiskers represent 1.5× the interquartile range. (C) Cell lysates were
harvested from N2a cells transfected with the same plasmids and analyzed by SDD-AGE and
western blotting (α-GFP). Cells were treated for 4 hr with 10 µM MG132 or an equivalent volume
of DMSO. Higher molecular weight smears in the 74Q lanes indicate the presence of aggregated
proteins. The SDD-AGE images were quantified for (D) 23Q and (E) 74Q aggregates by
densitometry (see Fig. S3.6). Intensity of the high molecular weight aggregates was normalized to
total intensity and expressed as a percentage. Error bars represent mean ± 1 standard deviation
from 3 biological replicates. Stars indicate p-values from independent sample t-tests (n.s. = no
significant difference, * = p < 0.05, ** = p < 0.01, *** = p < 0.001). Letters indicate significantly
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different groups determined by Tukey’s HSD test, where groups sharing a letter are not
significantly different and groups not sharing a letter are significantly different (α = 0.05).
We further investigated the effect of the tRNASerAAA variant on aggregate formation using semidenaturing detergent agarose gel electrophoresis (SDD-AGE) (51). SDD-AGE is a semiquantitative method to visualize insoluble protein aggregates as high molecular weight products
after agarose gel electrophoresis and western blotting. We used an α-GFP antibody to detect the
EGFP-tagged polyQ proteins. At 24 hrs post-transfection, we observed less aggregated 74Q
protein in cells expressing the mistranslating tRNA compared to wild type, and no evidence of
aggregated 23Q-EGFP protein in cells expressing either tRNA (Fig. S3.6).
To further promote formation of protein aggregates, we transfected cells for 48 hrs and then
treated them for 4 hr with MG132 or DMSO as a control. With 48 hr transfections, high molecular
weight aggregates were observed even in 23Q-expressing cells (Fig. 3.5C,D). Comparing the wildtype tRNASerAGA and mistranslating tRNASerAAA, we observed different effects on 23Q and 74Q
aggregation behavior. Cells expressing 23Q with the wild-type tRNA showed a small fraction of
aggregated polyQ in the SDD-AGE assay with 13% of the HTT-23Q protein aggregated. In 23Qexpressing cells with the mistranslating tRNA, however, we found a significant increase in the
proportion of aggregated protein (33%) compared to cells expressing the wild-type tRNA (Fig.
3.5C,D). The data suggest that mistranslation of the HTT-23Q allele contributes to an increase in
aggregation of the non-deleterious HTT allele.
Cells expressing either wild type or mutant tRNA both showed aggregation of the 74Q protein,
but mistranslating cells displayed a smaller fraction of high molecular weight 74Q aggregates (Fig.
3.5C,E) in agreement with our Triton-X100 treatments (Fig. 3.5A,B). Proteasome inhibition with
MG132 had no significant effect on aggregation of either 23Q or 74Q in mistranslating cells. We
observed a greater accumulation of 23Q aggregates in MG132-treated cells expressing wild-type
tRNA, which was still significantly less than the level of 23Q aggregates seen in mistranslating
cells (Fig 3.5D). MG132-treated cells expressing the wild type tRNA and 74Q showed an
intermediate level of protein aggregation, which was not significantly different from either
untreated wild-type cells or from cells expressing the mistranslating tRNA (Fig 3.5E). The absence
of any change in protein aggregates in mistranslating cells with or without MG132 treatment
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suggests that the mistranslating tRNA has a dominant effect on Htt protein aggregation that is
independent of proteasome activity.

3.3.8 Heat shock protein levels in mistranslating cells.
Heat shock protein production is a common cellular stress response mounted to mitigate
the toxic effects of misfolded proteins in cells and is known to be activated by mistranslating
tRNAs in yeast (18,56). Increased heat shock protein levels were also observed in mice expressing
editing-defective aminoacyl-tRNA synthetases (25), and mammalian cells expressing
mistranslating tRNAs after extended transfection periods of up to 72 hr (21). In a previous study,
we observed no change in HSP70 or HSP90 levels in HEK293 cells expressing tRNA Pro G3:U70
(22). Here, we measured the level of heat shock response factors HSP70 and HSP90 24 hrs after
transfection in cells expressing tRNASerAAA or wild-type tRNASerAAA. Consistent with our previous
study on tRNAPro G3:U70, we did not observe any evidence of increased HSP levels at 24 hrs (Fig.
S3.7A). We also measured HSP70 levels after more extended transfections periods (24, 48, and 72
hr) and observed no significant differences between wild-type and mistranslating cells (Fig.
S3.7B).

3.3.9 Regulation of translation initiation and elongation in mistranslating
cells.
Previous studies established that certain tRNA anticodon variants expressed in mammalian
cells lead to increased phosphorylation of eIF2α at Ser52 (21,28,40). Phospho-Ser52 in eIF2α
prevents translation initiation of most cellular mRNAs and is a converging point of the integrated
stress response stimulated by numerous cellular stresses. However, p-eIF2α levels vary
substantially depending on the tRNA gene variant expressed (21), and how long cells have been
expressing the tRNA variant (40). We used western blotting to measure p-eIF2α, eIF2α, and GFP
levels from cells expressing all combinations of EGFP-fused Httexon1 23Q and 74Q with wildtype tRNASerAGA or the tRNASerAAA variant. Despite a reduction in the EGFP-fused HTTexon1 in
all mistranslating cells, we did not observe an increase in the level of p-eIF2α in mistranslating
cells, even after longer transfection periods (Fig. S3.8A).
Cells can also down-regulate mRNA translation at the level of elongation. Eukaryotic
elongation factor 2 (eEF2) is involved in ribosome repositioning and movement of tRNA from the
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A-site to P-site during translation (61). Phosphorylation of the eukaryotic elongation factor 2
(eEF2) by eEF2 kinase (eEF2K) at Thr56 reduces translation elongation rates in conditions of
nutrient deprivation or various other forms of cellular stress, including proteasome inhibition with
MG132 (62). We used western blotting to measure p-eEF2 and eEF2 levels from cells expressing
an mCherry transfection marker and tRNASerAGA or the tRNASerAAA variant with or without
treatment with 10 μM MG132 (Fig. S3.8B). MG132 treatment stimulated a significant increase in
p-eEF2 levels in both cell lines (Fig S3.8), but we did not observe any difference in p-eEF2 levels
in the mistranslating cells compared to wild type. In normal cells, MG132 inhibits both protein
degradation (see Fig 3.7C) and protein synthesis, leading to no change in the steady state protein
levels. Despite the clear induction of p-eEF2 in MG132-treated cells, mistranslating cells show a
severely reduced level of protein synthesis in conditions that have high or low p-eEF2 (Fig S3.8C).

3.3.10 Mistranslating cells are resistant to the integrated stress response
inhibitor.
To further probe the integrated stress response in cells expressing tRNA SerAAA, we tested
whether the reduction in protein levels could be reversed with a p-eIF2α antagonist. The integrated
stress response inhibitor, ISRIB, relieves translation suppression caused by eIF2α phosphorylation.
ISRIB promotes the formation of active heterodecameric eIF2B complexes to stimulate eIF2Bdependent translation initiation (63). Cells transfected with plasmids expressing EGFP-fused
HTTexon1 23Q and no tRNA, wild-type tRNASerAGA, or the tRNASerAAA variant were treated with
500 nM ISRIB over an 18 hr time-course. Fluorescent images were captured throughout the time
course, and a cytotoxicity assay was completed at the final timepoint.
Unlike normal cells, mistranslating cells were unable to increase protein synthesis levels in
response to ISRIB. In cells expressing no ectopic tRNA, fluorescence of the EGFP-fused HTTallele increased significantly from the beginning to end of the time course by 25% in DMSO
control and 40% in 500 nM ISRIB. In cells expressing wild-type tRNA SerAGA, fluorescence
increased by 26% in DMSO control and 34% in 500 nM ISRIB. In cells expressing tRNA SerAAA,
ISRIB did not significantly increase protein levels, with only a 6% increase of 23Q-EGFP
production in the DMSO control, and a similar 7% increase in 500 nM ISRIB. Hence, the addition
of ISRIB did not simulate synthesis of the 23Q-EGFP HTTexon1 alleles in mistranslating cells
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(Fig. 3.6A,B). As anticipated, ISRIB also had no effect on the cytotoxicity of the mistranslating
tRNA (Fig. 3.6C).

Figure 3.6. Fluorescence and cytotoxicity of mistranslating cells treated with p-eIF2α
antagonist ISRIB. N2a cells were transfected with a plasmid encoding no tRNA, human
tRNASerAGA or G35A variant tRNASerAAA and HTTexon1 23Q-EGFP. Cells were treated for 18 hr
with 500 nM ISRIB or equivalent concentration of DMSO. (A) Representative images were
capture by fluorescence microscopy in GFP settings after 18 hr ISRIB treatment. (B) Fluorescence
intensity per cell area of six technical and three biological replicates was quantitated in ImageJ
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(see supplemental methods) before and after treatment. Each bar represents mean (± 1 standard
deviation) increase in fluorescence intensity per area as a percentage. (C) Cytotoxicity after
treatment was measured with CytotoxGlo. Luminescence readings were normalized to the “23Q /-” control. Stars indicate p-values from independent sample t-tests (n.s. = no significant difference,
* = p < 0.05, ** = p < 0.01, *** = p < 0.001).

3.3.11 Defective protein turnover and aggregate clearance in mistranslating
cells.
Given the synthetic toxic effect we observed in mistranslating cells treated with MG132, and
previous reports of tRNA anticodon variants promoting increased proteasome activity (40), we
assayed protein turnover in mistranslating cells. Cycloheximide chase assays (64) were performed
on N2a cells expressing no tRNA, wild-type tRNASerAGA, or the tRNASerAAA variant with EGFPfused HttExon1 23Q and 74Q (Fig. 3.7A-D). Cycloheximide concentrations of 50, 250 and 500
μg/ml were effective in inhibiting translation and promoting turnover of the 23Q-EGFP protein in
N2a cells (Fig. S3.9). Treatment with MG132 to inhibit the proteasome was used as a negative
control as described (64). In cells expressing the tRNASerAAA variant (Fig. 3.7B,D), we observed a
significantly lower rate of protein turnover of both the Httexon1 23Q-EGFP and 74Q-EGFP alleles
compared to cells expressing wild-type tRNASerAGA (Fig. 3.7B,C). Compared to cells expressing
no plasmid-borne tRNA, turnover of the aggregating 74Q-EGFP but not 23Q-EGFP was
significantly reduced in mistranslating cells (Fig. 3.7B). In normal cells, MG132 lead to a reduced
rate or protein degradation (Fig. 3.7C), while in mistranslating cells MG132 was not able to further
slow their already defective rate of protein degradation (Fig. 3.7D).
To assess whether 74Q aggregate clearance was reduced in an independent polyQ model, we
used a rat PC12-derived cell line with a stable, genome-integrated HTTexon1 74Q fused to EGFP
under control of a doxycycline inducible promoter (48). We transfected either tRNA SerAGA or the
tRNASerAAA variant on plasmids with an mCherry transfection marker and monitored the
appearance and disappearance of aggregates by induction and removal of doxycycline. Using
mCherry to identify tRNA-transfected cells, we counted the number of transfected cells expressing
either wild-type or mutant tRNAs containing at least one aggregate (Fig. S3.10). The number of
cells containing aggregates was not significantly different during doxycycline treatment, but after
doxycycline was removed, aggregates persisted significantly longer in cells expressing the
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mistranslating tRNA (Fig. 3.7E). Indeed, cells with wild-type tRNA had a significantly reduced
number of polyQ aggregates at 48 and 72 hrs after removal of doxycycline, yet we did not observe
any decrease in polyQ aggregates in the mistranslating cells following removal of doxycycline.
The data suggest that mistranslating cells are defective in clearing protein aggregates that cause
disease.

Figure 3.7. Protein turnover and clearance of polyQ aggregates in mistranslating cells. N2a
cells were transfected with a plasmid encoding human tRNASerAGA or G35A variant
tRNASerAAA and HTTexon1 containing 23Q or 74Q fused to EGFP for 48 hr before cycloheximide
chase assays (A-D). Cells were treated with cycloheximide and/or MG132 and fluorescence was
captured by live cell fluorescence microscopy. (A) Representative images of 23QEGFP/tRNASerAGA and 23Q-EGFP/tRNASerAAA expressing cells at the indicated timepoints.
Fluorescence was quantitated in ImageJ (see supplemental methods). Average rate of protein
decay (B) is shown as a change in fluorescence normalized to initial cell area (C,D) (see
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supplemental information). (E) PC12 cells with genomically integrated HTTexon1 74Q-EGFP
under a doxycycline (Dox)-inducible promoter were transfected with a plasmid encoding human
tRNASerAGA or G35A variant tRNASerAAA and mCherry transfection marker. HTTexon1 expression
was induced with doxycycline 48 hrs post-transfection and cells were imaged daily by fluorescence
microscopy. After 96 hr, Dox was removed and daily imaging was resumed for 72 hr. Aggregate
counting is described in methods (see Fig. S3.10). Error bars represent the mean ± 1 standard
deviation of at least three biological replicates and nine technical replicates each. Stars indicate pvalues from independent sample t-tests (n.s. = no significant difference, * = p < 0.05, ** = p <
0.01, *** = p < 0.001) and letters indicate significantly different groups determined by Tukey’s
HSD test (α = 0.05).

3.4 Discussion
3.4.1 Huntingtin protein aggregation in mistranslating cells.
Our data show that HTT aggregates form readily in mistranslating cells, but at a slower rate
than in wild-type cells. Since cells expressing the 74Q and mistranslating tRNA strongly suppress
protein synthesis, polyQ protein concentrations are less likely to reach the threshold required to
seed aggregates (65). Consistent with the translation suppression response in mistranslating cells,
we observed fewer and smaller aggregates in cells expressing HTTexon1 74Q and the tRNA SerAAA
variant compared to wild-type tRNASer. Further, in N2a cells and in an inducible PC12 cell line of
HTTexon1 74Q, we observed a greater persistence of aggregates in cells expressing tRNA SerAAA
compared to wild-type tRNASer. We also found that mistranslating cells were generally defective
in their ability to degrade proteins. While mistranslating cells synthesize aggregating proteins more
slowly, they are also defective in their ability to degrade HTT-aggregates. In these cellular models
of neurodegenerative disease, the data indicate that natural mistranslating tRNA variants have the
potential to affect the onset, progression, and severity of HD.
The Ser mis-incorporation at Phe codons we observed in cells expressing tRNA SerAAA led to
the accumulation of misfolded proteins. The label-free MS/MS approach we used is admittedly
not ideal for quantifying the mistranslation rate, which will be the subject of future work. The data
suggest an estimate for the rate of Ser mis-incorporation at Phe codons could be ~9% per UUC
codon, which is 90 to 900 times more than the generally accepted translation error rate of 1 mistake
per 1,000 to 10,000 codons (6,7). Even modest levels of mis-incorporation can lead to the
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accumulation of mis-made protein as we found. Although mistranslating cells were slower in
forming HTTexon1 74Q aggregates, we observed the normally non-aggregating 23Q protein form
a significant amount of protein aggregate in mistranslating cells. While 23Q HTTexon1 is less
aggregation prone than 74Q, in vitro studies have demonstrated that 23Q and shorter HTTexon1
polyQ peptides are capable of aggregation (66). In mistranslating cells, we observed 23Q
aggregates at 48 hrs post-transfection. The data suggest that compared to 74Q, higher expression
levels and longer times were needed for the 23Q-EGFP protein to aggregate in mistranslating cells.
We also observed increased 23Q aggregation in cells treated with the proteasome inhibition. Our
observations on HTT protein aggregation suggest mistranslating cells are compromised in their
ability to both synthesize and degrade protein aggregates.

3.4.2 Huntingtin protein aggregation and defects in protein quality control.
Our work is the first to explore the interaction between mistranslation and HTT polyQ
aggregation. Our studies, focused on mistranslation resulting from a tRNA mutant, suggest that
other routes to amino acid mis-incorporation, e.g., editing-defective AARS variants, can also
exacerbate polyQ aggregation and HD. Interactions between other factors regulating protein
homeostasis and polyQ aggregation represent a continuing theme in yeast and mammalian cell
models of polyQ aggregation and toxicity.
For example, work in yeast shows that molecular chaperones (67,68) and protein degradation
(69) are critical systems to combat polyQ aggregation. In Drosophila S2 cells expressing long
138Q, but not shorter polyQ alleles, protein synthesis is downregulated via the translation regulator
Orb2 (70). Studies using N2a cells, as we used, examined production and aggregate formation of
HTT alleles with 18Q, 64Q or 150Q. Aggregates were monitored over a 48 hr period, and in
agreement with our study, no toxicity from the 64Q or even the 150Q HTT allele was observed
(71). In HeLa cells, the same authors used a reporter for nuclear retention of ribosomal protein S2,
which signifies inhibition of ribosome biogenesis. Cells expressing a 97Q allele showed a 3-fold
increase in nuclear localization of ribosomal protein S2, demonstrating defective ribosome
biogenesis in cells expressing an aggregating HTT allele (71). The authors did not directly measure
the rate of protein synthesis, but their data suggest dysregulation of protein synthesis in cells
expressing long polyQ alleles. Our data suggest that tRNA variants which compromise protein
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homeostasis may exacerbate the dysregulation of protein synthesis caused by deleterious and
longer polyQ alleles.

3.4.3 Compromised proteostasis in cells expressing mistranslating tRNAs.
We found that cells expressing the naturally occurring tRNASerAAA variant were characterized
by several phenotypic defects. Using mass spectrometry, we confirmed amino acid misincorporation of Ser at multiple Phe codons. Mistranslating cells were characterized by increased
cytotoxicity, general inhibition of protein synthesis, sensitivity to proteosome inhibition, and
resistance to the neuroprotective stress response inhibitor ISRIB. Together the data demonstrate
that tRNASerAAA expression leads to a loss of protein homoeostasis.
Despite a mistranslation rate of ~2-3% Ala incorporation at Pro codons, tRNA Pro G3:U70 is
not toxic when expressed alone (22). Here we found that toxicity of tRNA Pro G3:U70 is evident in
combination with a mildly deleterious 46Q HTTexon1 allele. The data suggest that some
mistranslating tRNA variants can exacerbate polyQ toxicity in a model of neurodegenerative
disease. Conversely, the naturally occurring tRNASerAAA variant was toxic alone, but did not show
additional toxicity with aggregating HTT protein. The differences in toxicity may depend on how
cells respond to different types of mistranslation. We observed a consistent reduction in protein
synthesis in cells expressing the tRNASerAAA or tRNASerUGG variants, but not in cells expressing
tRNAPro G3:U70. Furthermore, cells mis-incorporating Ser at Phe codons showed a stronger
repression of translation than cells mistranslating Pro codons with Ser. The severely inhibited
protein synthesis observed in cells with tRNASerAAA may indeed protect the cell from the toxicity
of the aggerating Htt allele and amino acid mis-incorporation.
A recent study in yeast demonstrated that tRNA variants that result in different types of amino
acid change can elicit distinct cellular responses (72). A tRNA Ser mutant that mistranslates Arg
and a yeast homolog of the same tRNAPro G3:U70 variant we tested were found to mistranslate at
similar levels. However, in RNA sequencing experiments, each tRNA-expressing strain elicited
distinct changes in the transcriptome. For example, down-regulation of genes involved in cell
cycle, DNA replication, transcription, and response to stress was observed in cells mistranslating
Pro codons with Ala but not in cells mis-incorporating Ser at Arg codons (72).
Phenotypic differences observed from expressing different tRNA variants may also depend on
the compatibility of the tRNA in question with a given gain-of-function mutation. For example,
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nucleotides in and adjacent to the anticodon sequence are often conserved within tRNA isoacceptor
groups (46), and can be modified to ensure optimal fidelity and efficiency in recognizing certain
codon sets. This is true for wild-type tRNAPhe, wherein modified guanine bases in position 34 (73)
of the anticodon and the anticodon-adjacent position 37 (74) are used to efficiently and accurately
decode UUU and UUC codons. Conversely, the tRNASerAAA variant we investigated has adenine
at 34 and 37, so it is possible that the strong reduction in protein synthesis we observed is due in
part to suboptimal codon:anticodon recognition kinetics in the tRNA variant compared to tRNA Phe.
In a previous study of tRNASer anticodon variants expressed in HEK293 cells with an EGFP
marker, similar to our observations, translation inhibition was recorded for different tRNA Ser
anticodon variants (21). For some tRNASer variants, translation suppression was attributed to an
integrated stress response involving phosphorylation of eIF2α at Ser52 (21). Phosphorylation of
eIF2α at Ser52 is one mechanism to down-regulate translation initiation. Although tRNA Ser with a
Phe anticodon (tRNASerAAA) was not tested before, a mutant that decoded Ile codons with Ser
showed a strong correlation between increased eIF2α phosphorylation and depressed protein
synthesis (21). Like our observations, mutant tRNAs that decoded His and Lys codons with Ser
showed a more muted or little response in p-eIF2α despite each tRNA mutant causing repression
of growth and protein synthesis (21). Another study assayed eIF2α phosphorylation in stably
transfected HEK293 cells expressing tRNASer with Ala- and Leu-decoding anticodon mutations
(40). In this case, eIF2α phosphorylation was never observed in cells expressing the Ala anticodon
variant and only observed in cells expressing tRNASer with a Leu anticodon after aging cells for
30 passages. Compared to normal cells, we did not observe a significant increase in eIF2α
phosphorylation in cells expressing the tRNASerAAA variant. The observation was corroborated by
our experiments with the inhibitor ISRIB. Treatment of cells expressing wild-type tRNA with
ISRIB increased protein synthesis, while treatment of cells expressing tRNA SerAAA with ISRIB did
not increase protein production. Thus, the mistranslating cells were resistant to ISRIB. A previous
study demonstrated that ISRIB fails to antagonize excessively high levels of p-eIF2α induced by
arsenite treatment (75). Although eIF2a is phosphorylated in our mistranslating cells, their lack of
response to ISRIB suggests mistranslating cells are defective in translation regulation.
Finally, we found that cells expressing the tRNASerAAA variant were sensitive to treatment with
the proteasome inhibitor MG132. The synthetic phenotype suggests that mistranslating cells rely
critically on protein turnover and activity of the proteasome. We also found that protein turnover
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rates were reduced in cells expressing tRNASerAAA, consistent with an increased burden on the
proteasome caused by amino acid misincorporation. In conditions of nutrient deprivation and
various forms of cellular stress (62), cells can also down-regulate elongation through inhibitory
phosphorylation of eEF2 (76), which catalyzes ribosomal translocation and repositioning of tRNA
from the A-site to P-site of the ribosome (77). While mistranslating cells responded to proteasome
inhibition (MG132) by phosphorylated eEF2 similarly to normal cells, expression of tRNA SerAAA
showed a dominant effect on repressing protein synthesis, regardless of stress conditions tested or
eEF2 phosphorylation status. Stressors, including MG132, may also alter the activity of the mutant
tRNA or the tRNome more broadly, as transcription (78) and modification (79) of tRNAs are
regulated in response to stress. Investigating the interaction between mistranslating tRNAs and
impact of tRNA processing on protein quality control will form the basis of future investigations.

3.5 Conclusion
Humans encode over 600 tRNA genes. Human cells and tissues are estimated to express between
200 and 400 different tRNA genes (23). While some of these genes may be redundant in function,
others are critical for maintaining protein homeostasis. Despite a vast background of tRNA genes,
even a single tRNA mutant has the potential to cause amino acid mis-incorporation thus exacerbate
protein misfolding diseases at the molecular level. We found that a tRNA SerAAA gene that occurs
in 1.8% of the population indeed directs Ser mis-incorporation at Phe codons and leads to increased
cytotoxicity and increased need for protein degradation in mammalian cells. Notably,
mistranslating cells exhibit severely inhibited protein synthesis, leading to reduced but effective
formation of protein aggregates in cellular models of HD. The mistranslating cells were also
defective in clearing huntingtin aggregates and were resistant to the neuroprotective compound
ISRIB. Because this compound shows promise as a treatment for neurodegeneration (80), our
studies suggest that an active mistranslating tRNA in a patient’s genetic background may
contribute to drug resistance. Taken together, our data show that naturally occurring tRNA
mistranslators have significant potential to disrupt protein homeostasis and act as modifiers of
neurodegenerative disease.
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3.6 Data availability
Custom imageJ macros are available in the Supplementary Information. For western blots, full size
images are included as a supplementary data file. The mass spectrometry data have been deposited
to

the

ProteomeXchange

Consortium

via

the

PRIDE

(81)

repository

with

the

identifier PXD027837 (doi 10.6019/PXD027837).
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3.8 Supplemental information
3.8.1 Supplemental Methods
Plasmids and strains.
Plasmid manipulations were performed with Escherichia coli DH5α cells (Invitrogen).
Multiple vectors for HTTexon1 expression were used. The polyQ regions were encoded by mixed
CAG/CAA codon repeats. For the pcDNA3.1-derived HTTexon1 (MATLEKLMKAFESLKSF[polyQ]-P11-QLPQPP) expression plasmids, we subcloned the HTTexon1 fragment into
pCDNA3.1 from a plasmid that as a kind gift of Leslie Thompson (UC Irvine) (1). The pEGFPderived HTTexon1 (MKAFESLKSF-[polyQ]-P11-QLPQPP) expression plasmids were purchased
from Addgene (WT-Pan #99638, pEGFP-Q23 #40261, pEGFP-Q74 #40262). tRNA Pro WT and
G3:U70 variants were expressed from a U6 promoter with polythymidine terminator as previously
described (2). Human tRNASer genes (Ser-AGA-2-3, Ser-CGA-2-1) were PCR amplified from
HEK293 genomic DNA with ~300 bp flanking sequence. Anticodon variants were introduced in
PCR fragments using overlap extension PCR. tRNA expression cassettes inserted at the PciI (New
England Biolabs (NEB), Ipswich, MA, USA) restriction site in pWTPAN, pEGFP-Q23, or
pEGFP-Q74-derived plasmids. In pWTPAN constructs, which contain mCherry linked to EGFP,
the EGFP was reverted to GFP by site-directed mutagenesis: L64F(TTC), T65S(TCT). Previously,
we successfully used a EGFP D129P mistranslation sensitive reporter to observe mis-incorporation
resulting from the tRNAPro G3:U70 variant, that rescued fluorescence by incorporation of Ala at
residue 129 (2). S65 in GFP was mutated to Phe (TTT) or Pro (CCA) with the intent of generating
similar reporters sensitive to mistranslation of UUU or CCA codons with serine. We found
wildtype GFP fluorescence (compared to EGFP) was insufficient to detect mistranslation by
fluorescence restoration from these tRNASer variants tested. These constructs were used to track
transfection efficiency of tRNA expression cassettes and measure protein synthesis rates according
to the mCherry fluorescence or by Western blotting. Plasmid DNA for transfection in mammalian
cells was purified by Midi-Prep (GeneAid) from 100 ml E. coli DH5α cultures grown at 37°C for
16 hrs to an OD600 > 1.0. DNA concentrations were measured using a Nanodrop 2000C
(ThermoFisher Scientific).
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Western blotting.
Cells were lifted in phosphate buffered saline (1  PBS pH 7.4; Corning Cellgro, Corning,
NY, USA) supplemented with 1 mM EDTA, harvested by pipetting, and centrifuged in 1.5 ml
microcentrifuge tubes at 900  g for 3 min at 4°C. Supernatant was removed and cells washed with
ice cold PBS (Corning Cellgro) and centrifuged again. Supernatant was removed and cells were
suspended in 50 μl of ice-cold lysis buffer: 50 mM Tris-HCl (pH 7.4), 1% Triton X-100, 150 mM
NaCl, 0.1% sodium dodecyl sulfate (SDS), and 1 mM phenylmethylsulfonyl fluoride. The resuspended cells were incubated on ice for 5 min then centrifuged at 4C, 20,000 × g for 10 minutes.
Supernatant was collected and used immediately or flash-frozen and stored at -80°C. Protein
concentrations were measured in duplicate using the bicinchoninic acid (BCA) assay
(ThermoFisher Scientific) and diluted to equimolar protein concentrations before SDSpolyacrylamide gel electrophoresis (SDS-PAGE). Lysates were separated on SDS-PAGE (10%
acrylamide) with protein standards (BioRad, Hercules, CA, USA) for size determination. After
SDS-PAGE, proteins were transferred to polyvinylidene fluoride membranes using a Trans-Blot
Turbo Transfer System (max 25 V, 2.5 A constant for 7 min; BioRad). Membranes were incubated
for 1 hr in blocking solution (3% bovine serum albumin (BSA), 0.1% Tween 20, 1% PBS) before
adding primary antibodies at a 1:5000 (α-GFP, Abcam, ab32146; α-GAPDH, Sigma-Aldrich,
MAB374m, α-HSP70, Invitrogen, MA3-006; α-HSP90, Protein Tech, Rosemont, IL, USA, 131711-AP) or 1:1000 (α-Phospho-eIF2a Ser52, ThermoFisher Scientific, 44-728G; α-eIF2a,
ThermoFisher Scientific, AHO0802). Membranes were incubated with primary antibody in
blocking solution overnight at 4°C, washed 3  10 min in washing solution (1% BSA, 0.1% Tween
20, 1% PBS), then incubated with anti-mouse (Thermo Fisher Scientific, MA1-21315) or antirabbit (Sigma, GENA9340) horse radish peroxidase-linked secondary antibodies for 2 hr at room
temperature (~22°C) with a 1:2000 final dilution. Membranes were then washed with 1  PBS
with 0.1% Tween 20 for 3  10 min, followed by one wash for 10 minutes in 1  PBS. Proteins
were visualized using Clarity Western enhanced chemiluminescence (ECL) Substrates (Bio-Rad)
following the manufacturer’s instructions and imaged with a ChemiDoc XRS+ System (Bio-Rad).
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Mass Spectrometry.
mCherry protein was immunoprecipitated from N2a cells expressing wildtype tRNA SerAGA
or mistranslating tRNASerAAA after 48 hr transfection. Three 10 cm plates of transfected cells were
harvested for each plasmid and lysed in ice-cold lysis buffer (see Western Blotting). mCherry
protein was immunoprecipitated using RFP-trap agarose affinity resin (Chromotek, Munich,
Germany) following the manufacturer’s instructions. In the final step, mCherry protein was eluted
by boiling the affinity beads in SDS loading dye at 95°C for 5 min. Beads were pelleted in a
quickspin mini centrifuge, and supernatants were loaded on a 12% SDS-PAGE gel. Gels were
stained with Coomassie blue to visualize the mCherry protein.
Bands corresponding to mCherry protein were picked from the SDS-PAGE gel using an Ettan
Robotic Spot-Picker and submitted for proteolytic digestion (Trypsin) and peptide extraction at
the Functional Proteomics Facility at the University of Western Ontario, Canada. Gel plugs were
de-stained with 50 mM ammonium bicarbonate and 50% acetonitrile solution, dehydrated in 100%
acetonitrile solution, then reduced with 10 mM DTT at 40°C. Alkylation was performed with 55
mM iodoacetamide at 40°C. Gel plugs were then washed once with 100% acetonitrile, once with
50 mM ammonium bicarbonate and 50% acetonitrile, then twice with 100% acetonitrile. Gelbound proteins were digested overnight with 4 ng/μl trypsin in 50 mM ammonium bicarbonate at
40°C. Trypsinized proteins were extracted from gel plugs with 2% formic acid and 2% acetonitrile.
The dried sample was reconstituted in 40 μl for sample WT, and in 25 μl or sample VAR, of 0.1%
Formic acid in water and 1 μl was injected onto an ACQUITY MClass UPLC system using an
ACQUITY UPLC MClass Symmetry C18 trap column (Waters Corporation, Milford, MA), at a
flow rate of 5 μl/min for 6 minutes using 99% buffer A (0.1% formic acid) and 1% buffer B
(Acetonitrile + 0.1% formic acid). After trapping the peptides were eluted onto the analytical
column for separation, using a 90 min run time. Flow was established at 300 nl/min for the
ACQUITY UPLC MClass Peptide BEH C18 Column 15K psi, 130A, 1.7 μm x 25mm which was
held at 35°C. The gradient initial condition was 1% buffer B. Buffer B then increased to 7.0% over
1 min, then to 23% over 44 min, then to 35% over 15 min, then to 98% over 5 min, then held at
98% for 5 min, before washing and re-equilibration steps. The LC system was directly connected
to a NanoFlex (Thermo Electron Corp., Waltham, MA) nanospray ionization source with a source
voltage of 2.3 KV and was interfaced to a QExactive Plus mass spectrometer (Thermo Electron
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Corp., Waltham, MA). The mass spectrometer was controlled by Xcalibur software (Thermo, v.
2.8.1) and operated in the data-dependent mode using an FT/FT/HCD Top 12 scheme. The MS
scan recorded the mass-to-charge ratios (m/z) of ions over the range of 375–1500 with a resolution
of 70,000 at m/z 400, positive ion, profile, full MS mode using a lock mass (445.120025 m/z). The
12 most abundant multiply charged ions were automatically selected for subsequent high energy
collisional induced dissociation in the HCD cell, (FT/HCD) with an isolation width of 2.00 Da,
and a 0.5 Da offset, centroid mode, 17500 resolution in the orbitrap, with charge state filtering
allowing only ions of +2, to +6 charged states. Normalized Collision energy was 25, and precursor
ions were then excluded from further HCD for 15s.
Raw data files were loaded, processed, and searched using Peaks X+ (Bioinformatics Solutions
Inc.), against a custom database, consisting of a group of common contaminants and possible
proteoforms of mCherry resulting from Phe-to-Ser, and Leu-to-Ser possible substitutions. An FDR
of 0.1% and at least 1 unique peptide were used. A maximum of 3 missed cleavages (MC) were
allowed for searching tryptic peptides. Fixed modification of carbamidomethylation (CAM)
Cysteine, and variable modifications of deamidation (N/Q), oxidation (M, H, W), sulphone (M),
and iodination (YH) with a parent mass error tolerance of 10.0 ppm and fragment mass error
tolerance of 0.02 Da were used, allowing non-specific cleavage at one end of peptide. Hits
representing Phe-to-Ser misincorporation were curated to include only peptides with area-underthe-curve values ≥ 1x107 and with y and b ion spectra capturing the misincorporation event.
Example peptides demonstrating mis-incorporation (Table 3.2, Fig. S3.1) as well as a complete
list (Table 3.3) are included.

Fluorescence microscopy.
ImageJ macros are included in the appendix of this file with detailed analysis, descriptions,
and line-by-line commentary. Fluorescent microscopy images were captured on an EVOS FL auto
fluorescent microscope (Thermo Fisher Scientific). GFP (470 ± 22 nm excitation, 510 ± 42 nm
emission) and RFP (531 ± 40 nm excitation, 593 ± 40 nm emission) filter cubes were used to
capture green or red fluorescence. In our initial experiments (Fig. 3.2A), fluorescence was
quantitated on the EVOS software by drawing ellipses within fluorescing cells as described
previously (2). For subsequent fluorescence analyses, we used semi-automated ImageJ macros to
annotate cells and measure intensity within regions of interest (ROI; see appendix). For
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experiments with ISRIB, 500nM ISRIB dissolved in DMSO or an equivalent volume of DMSO
was added to cells after 24 hrs transfection. Images were captured immediately after adding ISRIB
and again after 18 hr incubation. For fluorescence-based aggregation experiments, aggregates of
EGFP-fused polyQ proteins were visible after 24-48 hrs, and all images of aggregates were
captured at least 24 hrs post-transfection unless otherwise stated. To quantify insoluble protein
aggregate size, an established membrane detergent assay with Triton X-100 was performed (3).
Initial images were captured 48 hrs post-transfection, cells were incubated for 40 min in media
containing 0.25% Triton X-100, and images were captured again from the same location using the
EVOS microscope. The size of the insoluble aggregates was quantified using ImageJ thresholding
analysis (see appendix) similarly to published approaches (4). Scale bars were used to determine
the conversion factor of pixels to µm2. For live cell imaging, cells were incubated at 37°C with
humidity and 5% CO2 in the EVOS FL auto-fluorescent microscope environment chamber. Images
were captured every 30 minutes for an 18 hr time-course, starting 24 hrs post-transfection.
Fluorescence and number of aggregates were quantified using a semi-automated approach in
ImageJ (see appendix) based on established approaches to quantitate protein aggregation (4).

3.8.2 Supplemental Tables
Table S3.1. Oligonucleotide sequences
Description

Nucleotide sequence

tRNA-Ser-AGA-2-3 genomic PCR (Fwd)

CCTGGAAGTCCGAACACC

tRNA-Ser-AGA-2-3 genomic PCR (Rev)

GTGAACACAAAGATGAGAGACACC

tRNA-Ser-AGA-2-3 nested PCR with PciI

CAGACTACATGTGTTGGCCATGACTCCCC

cloning site (Fwd)
tRNA-Ser-AGA-2-3 nested PCR with PciI

CAGACTACATGTGCAATTCCGTGAGGGAAATTCG

cloning site (Rev)
tRNA-Ser-AGA-2-3 G35A mutagenesis

GCGATGGACTAAAAATCCATTGGGGTCTCCCC

(Fwd)
tRNA-Ser-AGA-2-3 G35A mutagenesis

CCAATGGATTTTTAGTCCATCGCCTTAACCACTC

(Rev)
tRNA-Ser-CGA-2-1 nested PCR with PciI
cloning site (Fwd)

CAGACTACATGTACATGCACAGCAGCGTTC
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tRNA-Ser-CGA-2-1 nested PCR with PciI

CAGACTACATGTTTGCCGTTAGAATCTGTCGC

cloning site (Rev)
tRNA-Ser-CGA-2-1 C34T, A36G

CGTTGGACTTGGAATCCAATGGGGTCTCCCC

mutagenesis (Fwd)
tRNA-Ser-CGA-2-1 C34T, A36G

CCATTGGATTCCAAGTCCAACGCCTTAACCAC

mutagenesis (Rev)
Replace EGFP in WT-PAN with GFP

CAGACTGAATTCGCCACCATGGTGAGCAAG

mutant with EcoRI (Fwd)
Replace EGFP in WT-PAN with GFP

CAGACTGGATCCGACTTGTACAGCTCGTCCATG

mutant with BamHI (Fwd)
GFP S65F(UUU) mutagenesis (Fwd)

GACCACCTTCTTTTACGGCGTGCAGTGCTTC

GFP S65F(UUU) mutagenesis (Rev)

GCCGTAAAAGAAGGTGGTCACGAGGGTGG

GFP S65P(CCA) mutagenesis (Fwd)

GACCACCTTCCCATACGGCGTGCAGTGCTTC

GFP S65P(CCA) mutagenesis (Rev)

GCCGTATGGGAAGGTGGTCACGAGGGTGG

Table S3.2. tRNA gene sequences and identifiers
tRNA genea

genomic sequenceb

locus

Ser-AGA-2-3 GTAGTCGTGGCCGAGTGGTTAAGGCGAT chr6:27463593
GGACTAGAAATCCATTGGGGTCTCCCCG

variants

dbSNP IDc

G35A

rs14743933

-27463674

7

CGCAGGTTCGAATCCTGCCGACTACG
Ser-CGA-2-1 GCTGTGATGGCCGAGTGGTTAAGGCGTT chr6:27177628
GGACTCGAAATCCAATGGGGTCTCCCCG

-27177709

C34T,

n.a.d

A36G

CGCAGGTTCAAATCCTGCTCACAGCG
Pro-TGG-1-1 GGCTCGTTGGTCTAGTGGTATGATTCTCG chr14:2110116 C3G, G70T

n.a.d

CTTTGGGTGCGAGAGGtCCCGGGTTCAAA 5-21101236
TCCCGGACGAGCCC
a

GtRNAdb gene symbol from high confidence tRNA gene set (Human Feb. 2009 GRCh37/hg19)
(5). bNone of the listed tRNA genes contain introns compared to the predicted mature tRNA
sequence (5). cdbSNP is the NCBI database of genetic variation (build 155; released Apr. 9, 2021)
(6). dSynthetic variants, no associated SNP ID.
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3.8.3 Supplemental Figures

A
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Figure S3.1. Detailed y and b ion spectra of observed Ser mistranslation at Phe codons.
MS/MS spectra of high abundance peptides (area > 1×107) described in Table 2 are shown. Stars
indicate Phe (UUC) codons that were mistranslated as Ser. One low scoring peptide hit (-10logP
= 58.8) was observed from cells expressing (A) tRNASerAGA and a (C) similar low scoring hit (10logP = 48) was found in mistranslating cells. (B, D, E) Multiple high-quality hits (-10logP > 88)
demonstrated Ser mis-incorporation at three different Phe codons in mCherry in cells expressing
tRNASerAAA.
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Figure S3.2. HEK293 cells expressing tRNAPro G3:U70 and cis/trans-plasmid expression tests
of N2a cells expressing tRNASerAAA. (A) HEK293 cells were transfected with a plasmid encoding
human tRNAPro or the tRNAPro G3:U70 variant and wild-type EGFP as previously described (2).
Fluorescence of cells was measured by fluorescence microscopy in GFP settings. Significant
differences (independent sample t-test) of biological means are marked (n.s. = no significant
difference). (B) N2a cells were co-transfected with two plasmids: one encoding 23Q-EGFP (p23Q)
and another encoding mCherry (pMCh). The tRNASerAAA variant was either not included (-) or
cloned into the p23Q or the pMCh plasmid as indicated. Cellular fluorescence was captured by
fluorescence microscopy in GFP and RFP settings at 24 hr and 48 hr timepoints. Fluorescence per
unit area was quantitated in ImageJ. Error bars represent the mean ± 1 standard deviation of three
biological replicates; stars indicate statistically significant differences according to independent
sample t-tests (n.s. = no significant difference, * = p < 0.05, ** = p < 0.01).
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Figure S3.3. Viability of cells mistranslating Phe or Pro codons with Ser and expressing
HTTexon1 variants. (A, B) N2a cells were co-transfected with two plasmids encoding HTTexon1
25Q or 46Q and (A) tRNASerAGA or G35A variant tRNASerAAA or (B) tRNASerCGA or C34G, A36G
variant tRNASerUGG. Cellular viability was assayed 24 hr post-transfection with the CellTitreGlo
2.0 assay. Luminescence readings were normalized to the (A) 25Q/AGA or (B) 25Q/CGA
controls. (C, D) N2a cells were transfected with a plasmid encoding human tRNA SerAGA or G35A
variant tRNASerAAA and HTTexon1 containing 23Q- or 74Q-EGFP. (C) Cytotoxicity was assayed
48 hr post-transfection with the CytotoxGlo assay. (D) The experiment was repeated with a 4-hour
treatment of 10µM MG132 before assay. Luminescence readings were normalized to the (C)
23Q/no tRNA control or to the (D) 23Q/AGA control. Stars represent p-values from (A,B)
ANOVA or (C,D) pairwise independent sample t-tests (n.s. = no significant difference, * = p <
0.05, ** = p < 0.01, *** = p < 0.001); letters represent significantly different groups from Tukey’s
honestly significant difference tests (α = 0.05). Each bar represents the mean ± 1 standard deviation
of four (A,B) or five (C,D) biological replicates.
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Figure S3.4. Quantitation of aggregate fluorescence and area in ImageJ. Images represent
steps in ImageJ macros used to quantitate fluorescent aggregates in live cell data shown in Fig.
3.4. See supplemental methods and appendix for details and ImageJ macros.
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Figure S3.5. Live cell imaging raw fluorescence and number of aggregates (N aggregates). Raw
data from live cell imaging experiment shown in Fig. 3.4B. The data represent replicates showing
the relationship between ΔFluorescence and ΔNaggregates, where each point is a single 30 min
timepoint in one field of view. Images were captured for 18 hr as described in Fig. 3.4 (see also
Fig. S3.4 and supplementary information appendix).
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Figure S3.6. Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE). N2a cells
were transfected with a plasmid encoding human tRNA SerAGA or G35A variant tRNASerAAA and
HTTexon1 containing 23Q- or 74Q-EGFP. Cell lysates were harvested and analyzed by SDDAGE and western blotting (αGFP) after 24 hr (A) or 48 hr (B) transfection. Higher molecular
weight smears in the 74Q lanes indicate the presence of aggregated proteins. Cells in (B) were
treated for 4 hr in DMSO or 10 µM MG132 prior to lysis. Blue boxes (C) were used for
densitometry quantitation shown in Fig. 3.5D.

109

Figure S3.7. Heat shock protein levels in mistranslating cells. N2a cells were transfected with
a plasmid encoding human tRNASerAGA or G35A variant tRNASerAAA and dead GFP(S65F)mCherry transfection marker. (A) After 24 hr transfections, cell lysates were harvested and western
blotted for HSP90, HSP70, and GAPDH loading control. (B) The same transfections were repeated
with longer transfection periods and western blotted for HSP70 and GAPDH. Significant
differences (independent sample t-test) of three biological replicates are marked with stars (n.s. =
no significant difference, * = p < 0.05). Error bars represent ± 1 standard deviation.
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Figure S3.8. Regulation of translation initiation and elongation in mistranslating cells. (A)
N2a cells were transfected with a plasmid encoding human tRNA SerAGA or G35A variant
tRNASerAAA and HTTexon1 containing 23 (23Q) CAG/CAA mixed codon repeats encoding polyQ
fused to EGFP as a transfection marker. Cells were imaged by fluorescence microscopy in GFP
settings (A, right panel), harvested, lysed, and western blotted with anti-p-eIF2α (pSer52), antieIF2α, anti-GFP, and anti-GAPDH antibodies after 24, 48, or 72 hr transfection. (B) N2a cells
were transfected with a plasmid encoding human tRNA SerAGA or G35A variant tRNASerAAA and
mCherry for 48 hr, treated with MG132 or DMSO for 4 hr, and western blotted with anti-eEF2,
anti-p-eEF2 (pThr56). (C) N2a cells were transfected as in (A) and fluorescence was measured
after 4 hr treatment with DMSO or MG132. Stars indicate p-values from independent sample ttests (n.s. = no significant difference, * = p < 0.05, ** = p < 0.01) and letters indicate significantly
different groups determined by Tukey’s HSD test (α = 0.05).
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Figure S3.9. Cycloheximide concentration testing. N2a cells were transfected with a plasmid
encoding human tRNASerAGA or G35A variant tRNASerAAA and HTTexon1 containing 23Q- or
74Q-EGFP for 48 hr. Cells were washed and treated with indicated concentrations of
cycloheximide for 24 hr before capturing images by fluorescence microscopy in GFP settings.
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Figure S3.10. Aggregate counting in PC12 cells transfected with mCherry-tRNA plasmids.
Mistranslating tRNASerAAA and wildtype tRNASerAGA were co-expressed with mCherry on plasmids
to identify transfected cells. (A) Red channel images were used to generate region of interest
markers in ImageJ using (B) threshold and analyze particles functions, then overlayed on (C,D)
green channel images to identify cells containing the ectopically expressed tRNA variant and
EGFP-tagged polyQ aggregates.
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3.8.4 Supporting Data File
Data File S1. Single cell kinetics of polyQ formation in wild type and mistranslating cells.
Image series from live cell fluorescence experiments described in Fig. 3.4 were imported to ImageJ
and background fluorescence was subtracted using the rolling circle function. Image series were
converted to surface plots using the analyze; surface plot function and saved as .gif files. Peaks
represent fluorescent objects in a single field of view. Peak heights represent brightness intensity
on a 0-255 scale where zero is black and 255 is maximum pixel intensity.

3.8.5 Supplemental Appendix: ImageJ macros
ImageJ macros and analyses
The following text describes Fiji/ImageJ (7,8) macros used in the manuscript. ImageJ
version 1.53c was run on a Windows 10 (64-bit) operating system. Lines beginning with // are
commentary describing the line below. See Fig. S3.4 for step-by-step example images showing
Macros 3.1.1-3.1.2. Other macros use a similar thresholding approach.
Macros 3.1.1 and 3.1.2: Live cell fluorescence and aggregate count. Live cell image analysis
(Fig. 3.4) was done with two split macros on the same image sequences. See Fig. S3.4 for images
demonstrating the method. Data sets obtained from ImageJ macros were processed and analyzed
in Microsoft Excel. Each image (Fig. 3.4) represented a single time point in one field of view. For
each treatment (WT or mutant tRNA), two fields of view were used on three biological replicates,
totaling six technical replicates. For fluorescence analysis, image numbers paired to ROIs were
copied from the ImageJ ROI manager along with integrated density values from the results window
(Macro 3.1.1 and Macro 3.1.2). Using Microsoft Excel, total fluorescence contained within ROIs
was calculated for each image (cellular fluorescence).
For aggregate analysis, image numbers paired to ROIs were copied from the ImageJ ROI
manager along with area values from the results window (Macro 3.1.2). Using Microsoft Excel,
we calculated the sum of area covered by pixels over our aggregation threshold (brightness and
size) for each image. We then calculated the average aggregate size across all images. The sum of
area covered by aggregates in each image was divided by average aggregate size to estimate the
number of aggregates in each image. This approach corrects for clustered objects that cannot be
separated by the watershed function. Similar approaches have been used by others to count
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fluorescent polyQ protein aggregates in cells (4). For each image sequence (technical replicate),
the estimated number of aggregates was plotted against fluorescence (Fig. S3.5). Initial values
were subtracted from all data points in each series to exclude fluorescence and aggregates present
before the beginning of the time course. Number of aggregates was normalized to image
fluorescence for each image series and plotted against time (Fig. 3.4). Error bars represent one
standard deviation of the mean for each time point.
Macro 3.1.1.
This macro is to select area containing fluorescing cells from a series of fluorescent cell images,
create region of interest (ROI) annotations, and measure fluorescence (integrated density).
//Import image sequence. Replace “file” with desired image series location. “number” is the
number of images in the series and “increment” is used to exclude unwanted images in the file
folder.
run("Image Sequence...", "open=[file] number=37 increment=2 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//Set threshold to exclude pixels below chosen cutoff (6 in this case). Fine-tune according to your
image brightness and use same cutoff for all images in one experiment.
setThreshold(6, 255);
//Next two lines convert image to black features (above threshold) on white background (below
threshold)
setOption("BlackBackground", false);
run("Convert to Mask", "method=Default background=Dark");
//Remove noise with despeckle function
run("Despeckle", "stack");
//Create annotations covering area above threshold. Excludes objects under size cutoff of 20
pixels. Size cutoff should be adjusted depending on the magnification of the image and the size
of objects you wish to exclude (noise).
run("Analyze Particles...", "size=20-Infinity display clear summarize add stack");
//Clear results. This macro is only to create ROIs so results meaningless at this point.
run("Clear Results");
//Import unmodified image sequence again. Should be identical to line 1
run("Image Sequence...", "open=[file] number=37 increment=2 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//Set measurements to record integrated density to 3 decimals.
run("Set Measurements...", "integrated redirect=None decimal=3");
//The next three lines overlay the ROIs generated from thresholding steps on the original image
sequence, calculate the intensity within the ROIs, and display the results in the “Results”
window.

115

roiManager("Show None");
roiManager("Show All");
roiManager("Measure");
Macro 3.1.2.
This macro is to select area containing fluorescing protein aggregates from a series of fluorescent
cell images, create region of interest (ROI) annotations, and measure area. The threshold should
be fine-tuned to capture only subcellular objects (protein aggregates) and avoid whole fluorescent
cells.
//import image sequence. Should be identical to line 1 in Macro 3.1.1
run("Image Sequence...", "open=[file] number=37 increment=2 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//Set threshold to exclude pixels below chosen cutoff (180 in this case). Fine-tune according to
your image brightness and use same cutoff for all images in one experiment.
setThreshold(180, 255);
//Next two lines convert image to black features (above threshold) on white background (below
threshold)
setOption("BlackBackground", false);
run("Convert to Mask", "method=Default background=Dark");
//Watershed function separates closely adjacent objects with a line. This is important when
measuring area of objects.
run("Watershed");
//Creates annotations covering area above threshold. Excludes objects under size cutoff of 20
pixels. Size cutoff should be adjusted depending on the magnification of the image and the size
of objects you wish to exclude (noise).
run("Analyze Particles...", "size=20-Infinity display clear summarize add stack");
//Clear results outputting from analyze particles function
run("Clear Results");
//next two lines measure the area of objects above the intensity and size cutoffs and display the
results in the “Results” window.
run("Set Measurements...", "area redirect=None decimal=3");
roiManager("Measure");

Macro 3.2.1: Aggregate size and count. The output of this analysis includes the count and size
of objects in fluorescent cell images (Fig. 3.5B). Nine images were captured across three biological
replicates from each transfected plasmid. Images were captured before and after Triton X-100
treatment. Post-treatment images were used for size analysis. Scale bars was measured in ImageJ
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to calculate the conversion factor of pixels to µm2. The area values of fluorescent objects (postTriton X-100) outputted from ImageJ were converted from pixels to µm2 and all data were plotted
as boxplots using R. Outliers exceeding 1.5X the interquartile range of the entire dataset were
omitted from plots and statistical analysis. Outlier removal excludes clustered objects that are not
properly separated by the watershed function. Statistical differences were calculated with an
independent sample t-test based on means of biological replicates.
//open image. Replace “file” with desired image location.
open("file");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50");
//Set threshold to exclude pixels below chosen cutoff (100 in this case). Fine-tune according to
your image brightness and use same cutoff for all images in one experiment.
setThreshold(100, 255);
//Next two lines convert image to black features (above threshold) on white background (below
threshold)
setOption("BlackBackground", false);
run("Convert to Mask");
//Remove noise with despeckle function
run("Despeckle");
//Watershed function separates closely adjacent objects with a line.
run("Watershed");
//Set measurements to record object area
run("Set Measurements...", "area redirect=None decimal=3");
//Record measurements and display results summary
run("Analyze Particles...", "display clear summarize add");

Macro 3.3.1: % increase fluorescence/area. The “mean” measurement parameter on ImageJ is
equal to the integrated density divided by area (pixels) within a region of interest (ROI). ROI
annotations were used to select only the area in images covered by fluorescing cells. Mean
(fluorescence/area) was measured rather than integrated density to accommodate differences in
cell sizes or cell clusters which could not be resolved by the watershed function. Two images were
captured from each of three biological replicates, totaling six technical replicates. Images from
before (i) and after (f) an 18 hr time course were used in analysis. “% increase fluorescence/area”
(Fig. 3.6B) was calculated by the following formula:
% 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒

𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒
= 100 ×
𝑎𝑟𝑒𝑎

𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒
−
𝑎𝑟𝑒𝑎
𝑎𝑟𝑒𝑎
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Statistical differences were calculated with an independent sample t-test based on means of
biological replicates.
//open image. Replace “file” with desired image location.
open("file");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50");
//Set threshold to exclude pixels below chosen cutoff (6 in this case). Fine-tune according to your
image brightness and use same cutoff for all images in one experiment.
setThreshold(6, 255);
//Next two lines convert image to black features (above threshold) on white background (below
threshold)
setOption("BlackBackground", false);
run("Convert to Mask");
//Remove noise with despeckle function
run("Despeckle");
//Watershed function separates closely adjacent objects with a line.
run("Watershed");
//Analyze particles to generate ROI annotations. Excludes objects under size cutoff of 20 pixels.
Size cutoff should be adjusted depending on the magnification of the image and the size of
objects you wish to exclude (noise).
run("Analyze Particles...", "size=20-Infinity display clear summarize add");
//Clear results
run("Clear Results");
//Reopen the same file from step 1
open("file");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50");
//Overlay ROI markers on reopened image
roiManager("Show None");
roiManager("Show All");
//Set measurements to mean and measure
run("Set Measurements...", "mean redirect=None decimal=3");
roiManager("Measure");
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Macro 3.4.1: Fluorescence/initial cell area. This macro is to select area containing fluorescing
cells from a series of fluorescent cell images, create region of interest (ROI) annotations, and
measure fluorescence (integrated density) and area of the ROIs. This was used to quantitate
decreasing fluorescence in cycloheximide chase assays (Fig 3.7). A modified analysis was used in
this case because cycloheximide-treated cells shrink in size over time. Hence, we found that
normalizing fluorescence/area on a per-image basis was ineffective. Therefore, we instead
normalized the total fluorescence in each image sequence to the area of fluorescing cells in the
first image of the same sequence. We then subtracted the initial values of fluorescence/area for
each sequence and calculated the average slope of each data sequence to produce the “Delta
Fluorescence/Initial Cell Area” and “Average Slope” plots shown in Fig. 3.7. Six image sequences
were captured across three biological replicates for each combination of transfected plasmid and
treatment condition.
//Import image sequence. Replace “file” with desired image series location. “number” is the
number of images in the series and “increment” is used to exclude unwanted images in the file
folder.
run("Image Sequence...", "open=[file] number=49 starting=2 increment=3 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//Set threshold to exclude pixels below chosen cutoff (6 in this case). Fine-tune according to your
image brightness and use same cutoff for all images in one experiment.
setThreshold(10, 255);
//Next two lines convert image to black features (above threshold) on white background (below
threshold)
setOption("BlackBackground", false);
run("Convert to Mask", "method=Default background=Dark");
//Remove noise with despeckle function
run("Despeckle", "stack");
//Watershed function separates closely adjacent objects with a line.
run("Watershed", "stack");
//Analyze particles to generate ROI annotations. Excludes objects under size cutoff of 100 pixels.
Size cutoff should be adjusted depending on the magnification of the image and the size of
objects you wish to exclude (noise).
run("Analyze Particles...", "size=100-Infinity display clear summarize add stack");
//Clear results
run("Clear Results");
//Reopen the same file from step 1
run("Image Sequence...", "open=[file] number=49 starting=2 increment=3 sort");
//Overlay ROI markers on reopened image
roiManager("Show None");
roiManager("Show All");
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//Set measurements to area and integrated density, then measure
run("Set Measurements...", "area integrated redirect=None decimal=3");
roiManager("Measure");
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Chapter 4
4. Kinetics of amyotrophic lateral sclerosis-associated protein
aggregation in mistranslating cells1
4.1 Introduction
Transfer RNAs (tRNAs) play an essential role in the translation of messenger RNA (mRNA)
into protein. High-fidelity protein synthesis or the accurate translation of the genetic code was
considered an essential feature of cells and organisms. Although errors in protein synthesis
normally occur rarely with estimates suggesting that every 1 in 1,000 to 10,000 codons is misread
(1), diverse cells can survive or tolerate significantly elevated levels of mistranslation of 1-10%
per codon (2-4). Mistranslation can result from mutations in tRNAs (5) or the aminoacyl-tRNA
synthetases (6) that are responsible for ligating each tRNA with its cognate amino acid (7). In
addition, mutations to the ribosome (8), ribosomal proteins ((9)), and other (10) components of the
protein quality control machinery can also increase rates of error in protein synthesis.
Mistranslation due to tRNA variants can result from a mutation in the anticodon or in identity
element nucleotides (11) that each AARS uses to recognize its cognate tRNA. Anti-codon
mutations have great potential to cause loss of tRNA function, yet for certain tRNAs, the cognate
AARS does not recognize the anticodon nucleotides. Thus, mutations to the anticodon in alanine
(Ala), serine (Ser), and in part leucine (Leu) tRNAs have significant potential to cause amino acid
mis-incorporation at different codons in cells. In a distinct mechanism, mutations to tRNA identity
elements that inhibit AARS activity may cause loss-of-function (12), while mutations that enable
a tRNA to acquire new identity can lead to mis-aminoacylation of tRNAs and mistranslation
(3,13). For example, the G3:U70 base pair is the major recognition element for alanyl-tRNA
synthetase (AlaRS) (14). Certain variants in the human population (5) create alanine identity
elements in other tRNAs that direct alanine mis-incorporation in yeast (13) and cells (3).
There are over 600 tRNA genes in the human genome. In comparison to the reference genome,
individuals carry many single nucleotide (15,16) and even multi-site variants in their tRNA genes
(17). In a study of 84 individuals, unprecedented variation in tRNAs was uncovered, indicating
individuals harbor 60-70 tRNA variants, including mistranslating tRNAs that occur as both rare
or more common variants in the population (17). One such mistranslating tRNA is a G35A variant
1.

Work in this chapter is preparation for publication. Authorship: Jeremy T. Lant, Farah Hasan,
Julia Briggs, and Patrick O’Donoghue.
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in the tRNA-Ser-AGA-2-3 gene (tRNASerAGA). The resulting tRNASerAAA mutant contains a G-toA substitution in the second position of the anticodon. Because seryl-tRNA synthetase (SerRS)
does not recognize the anticodon of tRNASer (18), the mutant tRNA causes mis-incorporation of
serine at phenylalanine codons in mammalian cells (19).
The tRNASerAAA variants, which are found in 2-3% of the population (5,17), have the potential
to exacerbate human diseases, including neurodegeneration (19). We recently characterized the
impact of tRNASerAAA on cytotoxicity, protein synthesis, and in genetic interactions with nonaggregating and aggregating huntingtin alleles. Mistranslating cells expressing the tRNA Ser G35A
variant were slow but effective in forming disease-causing huntingtin aggregates, but
mistranslating cells were completely deficient in degrading and clearing the same aggregates. The
results suggested that natural tRNA variants compromise translation fidelity, which may increase
the severity of Huntington’s disease caused by protein aggregation. We hypothesized that other
neurodegenerative diseases may also be exacerbated by the presence of a mistranslating tRNA in
a patient’s genetic background. To establish the general potential for mistranslating tRNA variants
to modify neurogenerative disease, we characterized tRNA-dependent mistranslation in a wellestablished cellular models of Amyotrophic Lateral Sclerosis (ALS)
Protein misfolding and aggregation is characteristic of many neurodegenerative diseases,
however, the impact of mistranslation on the molecular pathology of neurodegenerative diseases
is unknown aside from the Huntington’s Disease model noted above. ALS is a neurodegenerative
disease caused by the aggregation of proteins in neurons, leading to muscle wasting, weakness,
and eventual death (20). The aggregation of nuclear RNA binding proteins, notably the fused in
sarcoma (FUS) protein, is commonly associated with ALS (21). FUS is a DNA and RNA binding
protein that is important for transcription and mRNA processing in neurons (22). There are 19
known FUS mutations that are linked to the development of ALS, and FUS mutations are found
>4% of patients who present with ALS (23-26). Most FUS mutations are present in the nuclear
localization domain at the C-terminus of the protein, which prevents translocation of FUS into the
nucleus where it normally regulates transcription and RNA splicing (27,28) through interactions
with RNA polymerase II, transcription factor TFIID, and directly with RNA (29,30). FUS also
plays important roles in regulating DNA replication kinetics (31).
FUS variants associated with disease mis-localize to the cytoplasm and form insoluble protein
aggregates. Disease pathology results from both loss of nuclear function as well as gain of toxic
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function in the cytosol (32). The Arg521Cys (R521C) mutation occurs in the C-terminal noncanonical nuclear localization signal (NLS) domain of the FUS protein and leads to decreased
trafficking of FUS into the nucleus, increased cytoplasmic FUS concentrations (33), and greater
insoluble protein aggregate formation (34). Individuals carrying mutations like R521C tend to
develop early onset ALS, with 60% of cases occurring before 40 years of age (28).
Here we tested our hypothesis that compromised translation fidelity will alter FUS aggregation
kinetics in neuroblastoma cells and exacerbate FUS toxicity. Using established cellular model of
ALS (35,36), we found that mistranslating cells readily formed FUS protein aggregates but at a
slower rate compared to cells expressing wild-type tRNA. We observed a synthetic toxic
interaction between the FUS R521C mutant and tRNA-dependent mistranslation in mammalian
cells. The data further establishes the ability of naturally occurring tRNA mistranslators to impact
cell fitness and protein aggregation in a cellular model of neurodegeneration.

4.2 Material and Methods
4.2.1 Plasmids and strains
Plasmid manipulations were performed in Escherichia coli DH5α cells (Invitrogen Canada,
Burlington, ON). tRNAPro WT and G3:U70 variants were expressed from a U6 promoter with
polythymidine terminator as previously described (3). Human tRNA Ser genes (Ser-AGA-2-3) were
PCR amplified from human embryonic kidney (HEK) 293T genomic DNA with ± 300 bp flanking
sequence. Anticodon variants were introduced in PCR fragments using overlap extension PCR, as
previously described (19). The tRNA expression cassettes were inserted at the PciI (New England
Biolabs, Ipswich, MA, USA) restriction site in pWTPAN-derived plasmids or at the NruI site in
pcDNA3.1-derived plasmids.
Fusions of the FUS gene with fluorescent proteins were created by PCR amplifying the fulllength FUS gene (encoding residues 1-526) from a pCDNA3.1 plasmid containing the human FUS
gene isoform 1 (a kind gift of Dr. Michael Strong) with a primer-encoded flexible linker sequence
(amino acid sequence GGGSGG). EGFP fusions were created by inserting the FUS-linker
sequence into NheI and HindIII restriction sites in our previously described pcDNA3.1-EGFP
plasmid (3). FUS-mCherry fusion constructs were also created by inserting the FUS-linker PCR
product into the NheI and SpeI sites of WT-PAN (37). WT-PAN contains an EGFP-mCherry
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fusion protein, and our approach replaced the EGFP segment with the FUS gene and linker
sequence.
The R521C variant of the FUS-mCherry protein was created by round-the-horn PCR
mutagenesis using primers, including the mutant nucleotide C1561T. Plasmids containing
mCherry were created by digesting and cross-ligating the isoschizomeric NheI and SpeI sites in
WT-PAN to remove the EGFP gene. Plasmid DNA for transfection in mammalian cells was
purified by Midi-Prep (GeneAid, New Taipei City, Taiwan) from 100 ml E. coli DH5α cultures
grown at 37 °C for 16 hrs to an A600 > 1.0. DNA concentrations were measured using a Nanodrop
2000C (ThermoFisher Scientific, Waltham, MA).

4.2.2 Cell culture and transfections
Experiments were performed in murine Neuro2a Neuroblastoma (N2a) cells (ATCC
#CCL-131) or HEK 293T cells (ATCC #CRL-3216). All cell lines were grown at 37 °C with
humidity and 5% CO2. Cells were cultured in high glucose Dulbecco’s modified Eagle medium
(DMEM with 4.5 g/L glucose, Gibco by Life Technologies, Carlsbad, CA) containing penicillin
(100 IU/mL, Wisent Bioproducts, Montreal, QC, Canada), streptomycin (100 µg/mL, Wisent
Bioproducts), and 10% fetal bovine serum (FBS, Gibco). All transfections were performed using
Lipofectamine 3000 transfection reagent (Invitrogen) with 2 µg/mL plasmid DNA, following the
manufacturer’s instructions.

4.2.3 Cytotoxicity assay
Cytotoxicity was determined using a dye-exclusion assay with SYTOX Blue Dead Cell
Stain (Invitrogen). No tRNA, wild-type tRNASerAGA, or the tRNASerAAA variant was co-expressed
in N2a cells with mCherry, FUS-mCherry or R521C FUS-mCherry in N = 5 biological replicates.
After 48 hrs, cells were washed once with Hank’s buffered salt solution (HBSS) and the media
was replaced with DMEM containing 1 μM SYTOX Blue Dead Cell Stain. SYTOX Blue
fluorescence intensity was measured with a Synergy H1 plate reader with a monochromatic filter
set to 444 nm excitation and 480 nm emission. Images were captured using an EVOS FL auto
fluorescent microscope using an RFP filter cube (531 ± 40 nm excitation, 593 ± 40 nm emission)
to measure mCherry fluorescence and CFP filter cube (445 ± 45 nm excitation, 510 ± 42 nm
emission) to measure SYTOX Blue fluorescence. To establish the total number of cells, 0.25% v/v
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Triton X-100 was added to each well and the cells were incubated at 37 C for 40 min to completely
permeate cell membranes and allow SYTOX Blue staining. Images were captured again from the
same location using the EVOS microscope and SYTOX Blue fluorescence was measured again
with the Synergy H1 after Triton X-100 treatment. Cell death levels were calculated as the ratio
SYTOX blue fluorescence before and after Triton X-100 treatment.

4.2.4 Fluorescence microscopy
Green and red fluorescent images were captured on an EVOS FL auto fluorescent
microscope using GFP (470 ± 22nm excitation, 510 ± 42nm emission) and RFP (531 ± 40 nm
excitation, 593 ± 40 nm emission) filter cubes. Aggregates of FUS begin to form at 24 hrs posttransfection, and all images of cells were taken between 24- and 72-hours post-transfection. For
live cell imaging, cells were incubated in the EVOS environment chamber at 37 °C and 5% CO 2
with humidity. Images were captured every 30 min, beginning 24 hrs after the start of transfection
for time courses of 18 to 44 hrs as indicated. Before beginning the time course, culture plates were
placed in the environment chamber for 1 hr to acclimate before fine-tuning fields of view.
Fluorescence per cell and number of aggregates per cell were quantitated using a semi-automated
approach in ImageJ (see supplemental information). To further investigate aggregate solubility, an
established membrane detergent assay with Triton X-100 was performed (38). Initial images were
captured 72 hrs post-transfection, cells were then incubated for 40 min in DMEM containing
0.25% Triton X-100, and images were captured again from the same location using the EVOS
microscope, as before (19). We determined the number of aggregates remaining post-triton X-100
with a semi-automated approach in ImageJ (see supplemental information).

4.2.5 Cell harvesting and western blotting
At 48 or 72 hrs post-transfection, as indicated, cells grown in 6-well plates were lifted in
phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na 2HPO4, 1.8 mM KH2PO4,
pH 7.4) with 10 mM EDTA for 10 min at 37 °C, collected in sterile 1.5 mL microcentrifuge tubes,
and pelleted by centrifugation at 300 × g for 3 min at 4 °C. The supernatant was aspirated, and cell
pellets were stored at -80 C. Cell pellets were resuspended in 90 L of mammalian cell lysis
buffer containing 50 mM Na2HPO4, 1 mM Na4P2O7, 20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1
mM Triton X-100, 1 mM dithiothrieitol, 0.3 mM phenylmethylsulfonyl fluoride, and 1 tablet/10
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ml complete mini EDTA-free Protease Inhibitor Cocktail (Roche, Mississauga, ON), incubated for
5 min on ice, and centrifuged at 21,000  g for 10 min at 4C. Supernatants were collected in 1.5
mL microcentrifuge tubes and kept on ice or stored at -20°C for up to one week. Protein
concentrations in the lysates were determined with a Pierce bicinchoninic acid (BCA) protein assay
kit (ThermoFisher Scientific). Lysates were diluted to equal concentrations with sterile milliQ H 2O
and 3  sodium dodecyl sulfate (SDS) loading dye (0.5 M Tris-HCl, pH 6.8; 1.12 M sucrose;
0.025% w/v bromophenol blue; 3.8% w/v SDS). Lysate corresponding to 12 μg total soluble
protein was separated by SDS-polyacrylamide gel electrophoresis (10% acrylamide) with protein
standards (BioRad, Hercules, CA, USA) for size determination. Proteins were transferred to
methanol-activated polyvinylidene fluoride membranes using a Trans-Blot Turbo Transfer System
(25 V, 1.3 A for 14 min; BioRad). Blocking and washing solutions were prepared in tris-buffered
saline (TBS; 50 mM Tris-HCl, pH 7.5, 150 mM NaCl). Membranes were incubated for 1 hr in
blocking solution (3% bovine serum albumin (BSA), 0.1% Tween 20, 1X TBS) before adding
primary antibodies at a 1:1000 (α-mCherry, abcam, ab213511) or 1:5000 (α-GAPDH, SigmaAldrich, MAB374m) dilution in blocking solution. Membranes were incubated with primary
antibody in blocking solution overnight at 4 °C, washed 3  10 min in washing solution (1% BSA,
0.1% Tween 20, 1X TBS), then incubated with anti-mouse (Thermo Fisher Scientific, MA121315) or anti-rabbit (Sigma, GENA9340) horse radish peroxidase-linked secondary antibodies
for 2 hr at room temperature with a 1:2000 final dilution. Membranes were washed with 1  TBS
with 0.1% Tween 20 for 3  10 min, followed by one wash for 10 minutes in 1  TBS. Proteins
were visualized using Clarity Western enhanced chemiluminescence (ECL) Substrates (Bio-Rad)
following the manufacturer’s instructions and imaged with a ChemiDoc MP System (Bio-Rad).

4.2.6 Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE)
Cell lysates were prepared, and protein concentrations were measured 72 hrs posttransfection as described above. A 1.5% agarose gel and Tris-acetate EDTA (TAE) running buffer
containing 40 mM Tris-acetate, 1 mM EDTA, and 0.1% w/v SDS were prepared according to
established protocols (39). Lysate samples containing 20 μg of protein were diluted in 3  loading
dye (0.5 M Tris-HCl, pH 6.8, 1.12 M sucrose; 0.025% w/v bromophenol blue; 3.8% w/v SDS)
with sterile milliQ H2O. Lysates were separated on the agarose-SDS gel for at least 3 hours at 20V.
Proteins were transferred to a PVDF membrane by capillary gel transfer overnight using TAE with
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0.1% SDS as a buffer. mCherry-tagged FUS aggregates were visualized by western blotting with
an α-mCherry antibody.

4.2.7 Statistical analysis
Statistical analyses used in each figure are referenced in the figure legends. All statistical
analysis was done in Microsoft Excel (2019). Independent sample t-tests were done by pairwise
comparison of groups of biological means. Tukey-Kramer multiple comparison tests were
computed by first completing an ANOVA single-factor (one-way) test on all groups of biological
means from the experiment. Critical q values were found in studentized range tables (α = 0.05).
Standard error to determine Tukey’s significance threshold was calculated for each pairwise
comparison when necessary to account for groups of unequal sample size (eg. some microscopy
images were poor quality and excluded).

4.3 Results
4.3.1 FUS protein synthesis in mistranslating cells
To monitor the synthesis and aggregation of FUS proteins in mistranslating cells, we
cloned wild-type and R521C FUS as fluorescently tagged fusion proteins (Fig. S4.1A) that were
expressed from plasmids containing wild-type tRNA genes or variant alleles that cause
mistranslation (3,19). We chose to C-terminally-tag FUS proteins with mCherry, since this
approach was already established as an appropriate model of FUS protein aggregation associated
with ALS (35,36,40,41). Since FUS aggregation is caused by mis-localization of the FUS protein
to the cytoplasm, and FUS utilizes a C-terminal nuclear localization signal, C-terminal fluorescent
protein fusions both promote aggregation of FUS and provide a means to visualize FUS
aggregation in live cells (42). Since the R521C variant is a common mutation in patients with ALS
(23-26), we anticipated that it would be more prone to aggregate and that cells expressing the FUS
variant would provide an appropriate model of disease pathology at the cellular level.
To validate expression and aggregation of the FUS-mCherry protein from our constructs,
we initially transfected all plasmids in HEK293T cells. Thus, we established transiently transfected
cell lines expressing all combinations of wild-type FUS-mCherry or FUS(R521C)-mCherry and
wild-type tRNA-Ser-AGA-2-3 (tRNASerAGA) or G35A variant (tRNASerAAA) (Fig. S4.1B,C). In
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HEK293T cells we observed production of the FUS-mCherry variants in normal and
mistranslating cells within 24 hrs transfection and clear evidence of subcellular aggregate
formation (Fig. S4.1B,C). The data suggested that both FUS and FUS R521C variants were
produced and that less protein production was observed in cells also expressing the mistranslating
tRNA, in agreement with our previous observations (19).

Figure 4.1. Kinetics of FUS protein synthesis in wild-type and mistranslating cells. N2a cells
were transfected with a plasmid encoding no tRNA, human tRNA SerAGA or G35A variant
tRNASerAAA and mCherry, human FUS-mCherry fusion or R521C variant FUS-mCherry fusion
protein. Images of fluorescing cells were captured by live cell fluorescence microscopy (RFP, ex
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531 nm, em 593 nm) beginning 24 h after transfection for a 43.5 h timelapse. Representative
images at the start and end of the timelapse are shown (A). Fluorescence per cell was quantitated
with a custom Fiji/ImageJ macro (see supplemental information) in at least three biological
replicates (B,C). Letters indicate significantly different groups determined by Tukey-Kramer tests
based on the means across all timepoints, where groups sharing a letter are not significantly
different and groups not sharing a letter are significantly different (α = 0.05).
To further investigate the synthesis of FUS proteins in normal and mistranslating cells, we
employed murine Neuro2A neuroblastoma (N2a) cells that are more accurate models of diseasecausing protein aggregation in neuronal cells. In addition to FUS alleles and tRNA variants, we
transfected N2a cells with plasmids including mCherry without a FUS allele, as well as plasmids
that contained no additional tRNA (Fig. 4.1A). Beginning 25 hr post-transfection, we captured the
fluorescence of the mCherry or FUS-mCherry proteins per cell over a 43.5-hr time-course.
Strikingly, we observed a significant 2.28 ± 0.24 fold increase in FUS-mCherry and 2.05 ± 0.06
fold increase in FUS(R521C)-mCherry fluorescence of cells expressing the wild-type tRNA SerAGA
compared to no tRNA (Fig 4.1B,C,S4.2A,B). In cells expressing the variant tRNA SerAAA, we
observed fewer living cells with visible FUS-mCherry fluorescence, but surprisingly fluorescence
per cell was not reduced significantly compared to cells expressing no tRNA (Fig. 4.1B,C,
S4.2A,B).
We found in all cases that FUS-mCherry fluorescence was substantially lower than
fluorescence from mCherry alone (Fig. 4.1A). For this reason, quantitative FUS-mCherry and
mCherry images could not be obtained at the same exposure settings. To establish effects of the
tRNAs on mCherry alone, we transfected the mCherry with no tRNA, tRNA SerAGA, and
tRNASerAAA variant separately in N2a cells for 24 hr (Fig. S4.2C). In cells expressing mCherry
alone, tRNASerAGA caused a significant 1.31 ± 0.05-fold increase in fluorescence compared to no
tRNA, and the tRNASerAAA caused a significant 1.28 ± 0.03-fold reduction in fluorescence
compared to no tRNA. Thus, only in cells expressing the FUS-mCherry or FUS(R521C)-mCherry
did we not observe a significant reduction in fluorescence when tRNA SerAAA was expressed
compared to no tRNA.
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4.3.2 Toxicity of FUS alleles in mistranslating cells
To assess the cytotoxic effects of the tRNA and FUS-mCherry models, we used a dye
exclusion assay with Sytox Blue stain to label and count dead cells before and after treatment with
a strong membrane detergent (Triton X-100). At 70 hrs post-transfection and following the
observation of FUS-mCherry production (Fig. 4.2), the cells were stained with Sytox Blue, and
images and fluorescence were captured by fluorescence microscopy and with a microplate reader.
Cellular and nuclear membranes were then permeabilized with detergent to establish total cell
number and Sytox Blue fluorescence in each well (Fig. 4.2, S4.3). We then calculated the ratio of
Sytox blue fluorescence before and after cell permeation to measure the fraction of dead cells in
each cell line. In comparing cells expressing the wild-type tRNA, we recorded a significant
increase in cell death in cells also expressing the FUS R521C allele compared to cells expressing
the wild-type FUS protein or to cells that did not express a FUS allele (Fig. 4.2). While
mistranslation resulting from tRNASerAAA alone did not significantly increase cell death, we found
significantly more cell death in mistranslating cells that also expressed the FUS R521C allele. This
is the first report of synthetic toxicity between mistranslation caused by a natural tRNA variant
and cell death induced by an ALS-associated FUS allele.

Figure 4.2. Synthetic toxicity of mistranslation and FUS R521C aggregation. N2a cells were
transfected with a plasmid encoding no tRNA, human tRNASerAGA or G35A variant tRNASerAAA
and mCherry, human FUS-mCherry fusion or R521C variant FUS-mCherry fusion protein. After
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72hr, cytotoxicity was assayed with a dye exclusion assay using Sytox blue nucleic acid stain.
Sytox blue fluorescence was measured in a plate reader (ex 444 nm, em 488 nm) before and after
treatment with a cell membrane detergent (Triton X-100) and relative cell death was calculated as
the Sytox blue fluorescence ratio before and after detergent. Biological means were normalized to
the mean of the wildtype tRNA, mCherry (no FUS) control (A). Error bars represent the mean ± 1
standard deviation of five biological replicates. Letters indicate significantly different groups
determined by Tukey’s Honestly Significant Difference (HSD) test, where groups sharing a letter
are not significantly different and groups not sharing a letter are significantly different (α = 0.05).
Representative images were captured by fluorescence microscopy (CFP; ex 445 nm, em 510 nm)
(B; Fig. S4.3).

4.3.3 Aggregation kinetics of FUS in normal and mistranslating cells
Previously, we developed a semi-automated approach based on published methods to
quantitate the appearance of fluorescing aggregates of huntingtin poly-glutamine (polyQ) proteins
(19). The method employs a dual thresholding strategy, where total cell area is established with a
lower intensity threshold that captures all cellular fluorescence, and aggregated protein area is
established with a higher intensity threshold which only captures fluorescence emanating from the
bright puncta caused by subcellular protein aggregates. Aggregated protein area is then normalized
to total cellular fluorescence for a quantitative comparison of the proportion of aggregated protein
in live cells. Using this same approach, we first assayed aggregation kinetics of FUS-EGFP fusion
protein co-expressed with a synthetic variant of tRNAPro (G3:U70) which we previously
established causes proline to alanine mistranslation in mammalian cells (3). Consistent with our
finding on this tRNA and models of huntingtin poly-glutamine proteins (19), we did not observe
any significant effects of the tRNAPro G3:U70 variant on FUS-EGFP aggregation (Fig. S4.4).
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Figure 4.3. Kinetics of FUS protein aggregation in wild-type and mistranslating cells. N2a
cells were transfected with a plasmid encoding no tRNA, human tRNA SerAGA or G35A variant
tRNASerAAA and mCherry, human FUS-mCherry fusion or R521C variant FUS-mCherry fusion
protein. Images of fluorescing cells were captured by live cell fluorescence microscopy (RFP, ex
531 nm, em 593 nm) beginning 24 h after transfection for a 43.5 h timelapse. Fluorescent cell area
representing cells and aggregates was determined using a custom Fiji/ImageJ macro and cell and
aggregate counts were determined based on correcting object sizes to the median sizes of cells and
aggregates (see supplemental information). Representative images of the fluorescing cells and
black and white mask images showing aggregate area with blue outlined cell area determined by
the macro are shown (A, C). The number of aggregates per cell was plotted against time (B, D).
Error bars represent the mean ± 1 standard deviation of at least four biological replicates. Letters
indicate significantly different groups determined by Tukey-Kramer tests based on biological
means at the final timepoint, where groups sharing a letter are not significantly different and groups
not sharing a letter are significantly different (α = 0.05).
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To assess aggregation kinetics of our FUS-mCherry and FUS(R521C)-mCherry proteins
in the presence of the naturally occurring tRNASerAAA variant, we improved on our aggregation
analysis by adding a median size adjustment step, where cellular area and aggregate area were
normalized to their respective median area values across the entire experiment (Fig. 4.3 A,C, see
supplemental information). This allowed us to establish aggregation kinetics on a per-cell rather
than per-image basis. Using this approach we measured the number of aggregates per cell over a
43.5 hr time-course (starting 25hr post-transfection) in N2a cells transfected with plasmids
encoding FUS-mCherry or FUS(R521C)-mCherry and no tRNA, tRNA SerAGA, or tRNASerAAA.
In cells expressing wild-type tRNASerAGA the number of FUS-mCherry aggregates per cell was
5.35 ± 0.76-fold increased (p = 0.0004) at the start of the timecourse and 4.59 ± 0.26-fold increased
(p = 1.9x10-6) at the end of the timecourse compared to cells expressing no additional tRNA (Fig.
4A,B, S4.5A). In cells expressing the variant tRNASerAAA, the number of aggregates per cell did
not differ significantly at the beginning of the timecourse (p = 0.72) compared to cells expressing
no additional tRNA (Fig. 4.3A,B, S4.5A). However, in the final ~5.5 hours of the timecourse, the
number of aggregates per cell began increasing rapidly in cells expressing tRNA SerAAA and FUSmCherry, to a point where the number of aggregates per cell was 1.97 ± 0.16-fold increased (p =
0.0055) compared to cells expressing no additional tRNA at the end of the timecourse (Fig. 4.3A,B,
S5A). While aggregation was still reduced in mistranslating cells compared to cells expressing
tRNASerAGA (2.38 ± 0.21-fold, p = 5.4x10-5), this suggests that the tRNASerAAA variant may promote
rapid protein aggregate formation after cells acclimate to the effects of mistranslation.
In cells expressing wild-type tRNASerAGA, effects on FUS(R521C)-mCherry aggregation were
similar to what we observed for FUS-mCherry, with an initial 4.12 ± 0.29-fold increase (p =
1.1x10-5) in the number of aggregates per cell and 4.59 ± 0.26-fold increased (p = 1.8x10 -5)
aggregates per cell at the end of the timecourse compared to cells expressing no tRNA (Fig.
4.3C,D, S4.5B). In cells expressing the variant tRNASerAAA and FUS(R521C)-mCherry, the
increase in cell death (Fig. 4.2) contributed to fewer visibly fluorescing cells. This made
aggregation kinetics difficult to quantitate, as dying cells released fluorescent protein into the
medium and caused sudden drops in aggregate-per-cell counts (Fig. 4.3D). However, towards the
end of the timecourse the variance in aggregates per cell in the tRNA SerAAA expressing cell
population stabilized somewhat and we calculated a significant 2.38 ± 0.89-fold increase (p =
0.0172) in aggregates per cell compared to cells expressing no additional tRNA.
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In sum, cells with the additional wild-type tRNASer produced FUS and FUS(R521C) more
efficiently than cells lacking an additional tRNA, suggesting the added tRNA may provide a more
tractable model to study FUS aggregates. Cells with the variant tRNA SerAAA also promote FUS
aggregation compared to cells expressing no tRNA, but the effect is more variable and can be
repressed in early stages of tRNA expression. Hence, the tRNASerAAA variant caused a
discoordination between tRNA expression and protein synthesis, which altered the aggregation
kinetics of FUS.

4.3.4 Measuring insoluble FUS aggregates in mistranslating cells
To further assess the effects of mistranslation on FUS aggregation, we attempted a
membrane detergent assay (38), which we have used previously to establish the size of huntingtin
poly-glutamine aggregates in mistranslating cells compared to wild type . The assay involves mild
permeation of cells with Triton X-100, such that diffuse fluorescence dissipates into the medium
while insoluble aggregates remain in cells. However, in agreement with our difficulties in
quantitating FUS(R521C) in dying cells, we found that FUS aggregates were unstable in
permeated cells, and in most cases we could not reliably determine significant differences in the
number of aggregates remaining in cells after Triton X-100 treatment (Fig. S4.6).
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Figure 4.4. FUS protein and aggregate production in wild-type and mistranslating cells. N2a
cells were transfected with a plasmid encoding human tRNA SerAGA or G35A variant tRNASerAAA
and mCherry, human FUS-mCherry fusion or R521C variant FUS-mCherry fusion protein. Cell
lysates were separated on SDS-PAGE (A) or SDD-AGE (B) gels and Western blotted using αRFP antibody. Percentage aggregated protein in SDD-AGE blots was determined by densitometry
(C). Error bars represent the mean ± 1 standard deviation of three biological replicates. Stars
indicate P-values from independent sample t-tests (** P < 0.01, *** P < 0.001).
As an alternative assay of insoluble aggregate abundance, we assayed the levels of FUSmCherry protein in cells expressing tRNASerAGA or tRNASerAAA by western blotting and semidenaturing detergent agarose gel electrophoresis (SDD-AGE; (39)). SDD-AGE is a semiquantitative approach which utilizes partial denaturation of aggregated proteins and separation by
agarose gel electrophoresis. This is followed by western blotting to visual the presence of
aggregated proteins from cell lysates as high molecular weight smears. N2a cells were transfected
with plasmids encoding mCherry, FUS-mCherry, FUS(R521C)-mCherry, and tRNA SerAGA or
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tRNASerAAA. After 72 hr to allow for protein expression, cells were harvested and lysed, and lysates
were run on SDS-PAGE or SDD-AGE gels, then western blotted with antibodies against mCherry.
The western blots from SDS-PAGE gels revealed discrete bands in all samples corresponding to
the molecular weight of the mCherry or FUS-mCherry proteins (Fig. 4.4A). The western blots
from SDD-AGE gels revealed a lower band and higher molecular weight smear corresponding to
aggregated FUS-mCherry or FUS(R521C)-mCherry protein (Fig. 4.4B). We quantitated the
fraction of aggregated protein in each by normalizing the intensity of the aggregate smear to the
total band intensity in the lane (Fig. 4.4C). We observed a significant 2.2 ± 0.1-fold reduction in
the amount of aggregated FUS-mCherry and 1.5 ± 0.1-fold reduction in the amount of aggregated
FUS(R521C)-mCherry in mistranslating cells compared to cells expressing wild-type tRNA SerAGA.
Hence, in agreement with our live cell fluorescence experiment, the variant tRNA SerAAA causes a
significant reduction in the aggregation of FUS proteins compared to cells expressing wild-type
tRNA.

4.4 Discussion
4.4.1 Protein synthesis de-regulation in ALS models and mistranslating cells
Studies in N2a cells (43), HEK293T cells (44) and mice (45) have demonstrated a downregulation of mRNA translation in cells expressing mutant human FUS proteins, including the
R521C variant tested in this study. Proposed mechanisms overlap but vary, from disruptions to
non-sense mediated decay pathways (43), to cellular signaling to inhibit protein synthesis via the
mTOR (44) or integrated stress response pathways (45). FUS mutations can also indirectly affect
protein synthesis by causing complex dysregulation of transcription (46) and RNA metabolism
(47). Likewise, we and others have shown that amino acid mis-incorporation resulting from
mutations in tRNA genes (19,48-50) and aminoacyl-tRNA synthetases (51) can cause downregulation of protein synthesis.
Our work is the first to explore interactions of tRNAs and naturally occurring variants with
the ALS-associated FUS protein. First, we found that expression of a wild-type tRNA Ser gene
increased protein synthesis in cells expressing FUS or FUS(R521C). Transfer RNA gene
supplementation is a common approach to increase protein synthesis in E. coli (52), and tRNA
upregulation has been shown to promote protein synthesis in human cancer cells (53). Hence, our
observation that tRNASerAGA expression promoted protein synthesis was not surprising. Alas, the
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finding has interesting implications for the potential use of tRNAs in therapy. For example, a recent
study demonstrated that tRNA overexpression can rescue peripheral neuropathy in animal and
cellular models of Charcot-Marie Tooth disease caused by mutations in glycine-tRNA synthetase
(54). In that case, overexpression of tRNAGly was proposed to promote substrate turnover on a
mutated GlyRS which fails to release Gly-tRNAGly after aminoacylation. Other studies have shown
that tRNA expression, however, can more generally enhance cell metabolic activity and
proliferation (55,56). While this effect has mainly been viewed as an aberrant gain-of-function in
cancer cells (53), it could be used to advantage in cells where protein synthesis is chronically
repressed. Indeed, genetic screens in yeast have found that in addition to a multitude of RNA
metabolism and transcription-associated factors, some translation initiation factors can suppress
toxicity of mutant FUS, and one of these suppressors (eIF4A1) was validated in HEK293T cells
(57).
In cells expressing the variant tRNASerAAA, which causes Phe to Ser amino acid misincorporation (19), we found a significant reduction in the synthesis of mCherry protein, but not
in the synthesis of FUS-mCherry or FUS(R521C)-mCherry compared to cells with no additional
tRNASer. Hence, expression of FUS-mCherry and FUS(R521C)-mCherry had a dominant effect in
reducing protein synthesis in cells, which was not further influenced by expression of the
mistranslating tRNA variant. However, given that the tRNA variant causes a reduction in protein
synthesis alone, it could contribute to the challenge of “rebooting” protein synthesis in patients
with ALS. Indeed, in our study on poly-glutamine models of Huntington’s disease (58), we found
that the same tRNA variant expressed in N2a cells caused resistance to the integrated stress
response inhibitor (ISRIB), which was designed to stimulate protein synthesis in the cells of
neurodegenerative disease patients (59,60).

4.4.2 Influence of tRNAs on FUS aggregation
Compared to our previous work on polyglutamine protein aggregates, lower stability of FUS
aggregates and increased death in cells expressing the mutant FUS(R521C) caused higher
variability in our quantitation of aggregation kinetics. For example, we found that both FUS and
FUS(R521C) aggregates dissipated rapidly in dying cells and in membrane detergent assays
developed for poly-glutamine aggregate quantitation (38). By contrast, we found this assay to be
a highly effective method for quantitating the size and abundance of poly-glutamine aggregates in
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cells (19). The differences in aggregate solubility we observed may be due to differences in the
physical properties of FUS aggregates compared to polyglutamine aggregates. Indeed, others have
shown that FUS aggregates initially coalesce into liquid-like droplets before maturing into more
solid forms (35). Hence, higher solubility of FUS aggregates compared to poly-glutamine
aggregates may contribute to their rapid dissolution in membrane-permeated cells. Nonetheless,
we found that both wild-type and mutant tRNA expression had modifying effects on FUS
aggregation.
Similarly to our previous work on Huntington’s disease models, aggregation of FUS-mCherry
was reduced in cells expressing the variant tRNA compared to wild-type. However, in this work
we followed aggregation kinetics over a longer time-course, finding that aggregates began to form
rapidly in mistranslating cells after a long ~63 hour lag of FUS-mCherry expression. Ours and
other works on cellular responses to protein folding stress provide clues to why this occurred.
Firstly, mistranslation places an increased burden on protein degradation and the unfolded protein
response, by constantly generating misfolded proteins (19,48,61) (49). Secondly, cellular stress
responses associated with amino acid mis-incorporation cannot be maintained indefinitely. Indeed,
chronic activation of the unfolded protein response can result in the toxic accumulation of reactive
oxygen species (62) and apoptosis (63). For this reason, cells may mitigate or silence unfolded
protein responses in chronically mistranslating cells. Indeed, others have observed this effect in
cells expressing ribosomal mutations that cause mistranslation (64). Thus, increased mistranslation
caused by natural variants in human tRNAs likely exacerbates the already existing paradox of
beneficial and detrimental activation of protein folding stress responses in cells expressing mutant
FUS.
This phenomenon was particularly evident in our experiments on aggregates of the
FUS(R521C)-mCherry protein in mistranslating cells. Co-expression of the tRNA SerAAA variant
and FUS(R521C) had a potent synthetic toxic effect, and FUS(R521C)-mCherry aggregation
kinetics were highly variable compared to cells expressing no tRNA or wild type. Despite the
variability, we found that FUS(R521C)-mCherry aggregation was significantly increased in the
latter time-points of our assay compared to cells expressing no tRNA. Expression of the wild-type
tRNA also promoted FUS-mCherry and FUS(R521C)-mCherry aggregation, but this was expected
given that the wild-type tRNA increased expression of the FUS proteins compared to no tRNA.
By contrast, the mistranslating tRNA increased aggregation of FUS-mCherry and FUS(R521C)-
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mCherry proteins without significantly changing expression. Taken together, our aggregation and
cytotoxicity data suggest a highly deleterious interaction between the tRNA and FUS variants.
These results provide further support to our hypothesis that naturally occurring tRNA
variants, while tolerable alone, can exacerbate human diseases including neurodegenerative
disease (5). While mutations in numerous other mRNA translation-associated factors such as
aminoacyl-tRNA synthetases, elongation factors, tRNA modifying enzymes, and more have been
linked to neurodegenerative disease (reviewed in (65)), research on tRNA variants in
neurodegenerative disease is limited but growing. Including our own work on cellular models of
Huntington’s disease (19), others researchers identified links between a loss-of-function tRNA
mutation and neurodegenerative phenotypes in mice (50), which we reviewed in chapter 1. Briefly,
the variant causes ribosome stalling in mice also carrying a mutation in the ribosomal recycling
factor GTPBP2 (50). The same group recently expanded on this work, demonstrating that mice
harboring the tRNAArgUCU C50T mutation had defects in synaptic transmission in neuronal cells,
and increased seizure susceptibility (66). They also used partial CRISPR genetic knockouts in
mouse forebrains to demonstrate that deletion of another tRNA gene, tRNA-Ile-TAT-2-3,
stimulated an integrated stress response (66). As with our previous work on Huntington’s disease
models, we hope that the growing list of associations between tRNA variants and
neurodegenerative disease will motivate the greater inclusion of tRNA genes in sequencing studies
of patients with neurodegenerative disease.
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4.6 Supplemental information
4.6.1 Supporting Tables
Table S4.1 Oligonucleotide sequences
Description
FUS cloning in pcDNA3.1 NheI/HindIII
sites (Fwd)
FUS cloning in pcDNA3.1 NheI/HindIII
sites (Rev with linker sequence)
FUS R521C round-the-horn mutagenesis
(Fwd)
FUS R521C round-the-horn mutagenesis
(Rev)
FUS cloning in WT-Pan NheI/SpeI sites
(Fwd)
FUS cloning in WT-Pan NheI/SpeI sites
(Rev with linker sequence)

Nucleotide sequence
CAGACTGCTAGCATGGCCTCAAACGATTATACCC
CAGACTAAGCTTGCCTCCAGACCCTCCGCCATAC
GGCCTCTCCCTGC
TGCAGGGAGAGGCCGT
ATCCTGTCTGTGCTCACCC
CAGACTGCTAGCATGGCCTCAAACGATTATACCC
CAGACTACTAGTGAGCCTCCAGACCCTCCGCCAT
ACGGCCTCTCCCTGC

4.6.2 Supporting figures

Figure S4.1. FUS-mCherry construct and fluorescence in HEK 293T cells. (A) The human
FUS gene was fused to the mCherry coding sequence via a flexible linker sequence. Numbers
indicate amino acid positions in the fusion protein. (B,C) Representative images of HEK 293T
cells 24 hrs post-transfection with a plasmid co-expressing a human tRNA SerAGA or G35A variant
(tRNASerAAA) and human FUS-mCherry (WT) or R521C variant FUS-mCherry were captured by
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fluorescence microscopy (RFP, ex. 531 nm, em. 593 nm). (B) Cropped and enlarged images of the
tRNASerAGA transfections with arrows showing subcellular aggregates. (C) Full-size images
overlaid with bright field images of the cells.

Figure S4.2. FUS-mCherry fluorescence timecourse statistical analysis and mCherry control
transfections. (A,B) Tukey-Kramer multiple comparisons test results from initial (A) and final
(B) timepoints of FUS-mCherry and FUS(R521C)-mCherry fluorescence timecourse experiments
(see Fig. 4.1). Letters indicate significantly different groups based on at least three biological
means at the indicated timepoints, where groups sharing a letter are not significantly different and
groups not sharing a letter are significantly different (α = 0.05). (C) N2a cells were transfected
with a plasmid encoding no tRNA, human tRNASerAGA or G35A variant tRNASerAAA and mCherry.
Images of fluorescing cells were captured by fluorescence microscopy (RFP, ex 531 nm, em 593
nm) after 24 hr transfection. Fluorescent images were also overlain with brightfield images of
cells. Fluorescence per cell was quantitated with a custom Fiji/ImageJ macro (see appendix) in
five biological replicates. Letters represent Tukey-Kramer multiple comparison test results as
described above.
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Figure S4.3. Cell death assay for N2a cells co-expressing tRNA Ser variants with mCherry or
FUS-mCherry variants. N2a cells were transfected with a plasmid encoding no tRNA, human
tRNASerAGA or G35A variant tRNASerAAA, and mCherry, human FUS-mCherry, or the FUS R521CmCherry protein. After 72-hr post-transfection, cytotoxicity was assayed with a dye exclusion
assay using Sytox blue nucleic acid stain. The images are representative of images from the five
biological replicates included in Fig. 4.2A. The images were captured by fluorescence microscopy
(CFP ex. 445 nm, em. 510 nm).
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Figure S4.4. FUS aggregate formation in cells expressing wild-type and G3:U70 tRNAPro
variants. N2a cells were transfected with a plasmid encoding human FUS-EGFP fusion protein
and wild-type human tRNAPro or a G3:U70 variant that decodes proline codons with alanine (3).
(A) Representative images were captured by fluorescence microscopy (GFP; ex 470 nm, em 510
nm) (bottom) and overlaid with bright field images of the cells (top). (B) Starting 24 hrs postransfection, the change in number of aggregates over total cell fluorescence was quantified over
an 18-hr live cell imaging time-course with a custom Fiji/ImageJ macro (see appendix) as
previously described (19).
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Figure S4.5. FUS-mCherry aggregation timecourse statistical analysis. (A,B) Tukey-Kramer
multiple comparisons test results from initial (25 hr) and final (68.5 hr) timepoints of FUSmCherry (A) and FUS(R521C)-mCherry (B) aggregation timecourse experiments (see Fig. 4.3).
Letters indicate significantly different groups based on at least three biological means at the
indicated timepoints, where groups sharing a letter are not significantly different and groups not
sharing a letter are significantly different (α = 0.05). An independent sample t-test comparing the
no tRNA and tRNASerAGA transfections in (B) 25 hr panel is also shown (**** = p < 0.0001).
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Figure S4.6. Insoluble FUS aggregate levels in wild-type and mistranslating cells. N2a cells
were transfected with a plasmid encoding no tRNA, human tRNA SerAGA or G35A variant
tRNASerAAA and human FUS-mCherry or FUS R521C-mCherry. After 72 hrs post-transfection,
membrane detergent assays were performed using Triton X-100 to permeate cell membranes and
reveal insoluble aggregates. Representative images are shown from a series of images captured by
fluorescence microscopy (bottom) (RFP; ex 531 nm, em 593 nm) and overlaid with brightfield
images (top) both (A) before and (B) after treatment with Triton-X100. The number of aggregates
remaining per cell after membrane permeation was quantified using a custom Fiji/ImageJ macro
(see Supplemental appendix). Error bars represent the mean ± 1 standard deviation of N = 5
biological replicates. Stars indicate statistically significant differences determined by pairwise
independent sample t-tests (n.s. = no significant difference, * p < 0.05).
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4.6.3. Appendix: Fiji/ImageJ macros
ImageJ (version 1.53f51 (67); Java version 1.8.0_172 (64-bit)) scripts to measure the
fluorescence and analyze images of transfected cells. All macros were run on 16-bit, singlechannel images.
Fiji/ImageJ macros used in Figure 4.1 – Mean fluorescence per cell plots. Fluorescence in
regions of interest (ROI; fluorescing cells) was measured with the following Macro in Fiji/ImageJ.
Since some ROIs capture multiple cells in clusters, ROI areas were weighted in Microsoft Excel
by dividing the area of each ROI by median ROI size (i.e., median cell size) for the entire
experiment. Hence, all fluorescence measurements underlying the means were weighted to the
same fixed area, which approximates median cell size. Standard deviations were calculated based
on the means of at least N = 3 biological replicates at each timepoint.
//Import image sequence. Replace “folder name” with desired image series location. “number” is
the number of images in the series and “increment” is used to exclude unwanted images in the file
folder.
run("Image Sequence...", "open=[“folder name”] number=88 starting=5 increment=3 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//Set threshold to exclude pixels below chosen cutoff (6 in this case). Fine-tune according to your
image brightness and use same cutoff for all images in one experiment.
setThreshold(6, 255);
//Next two lines convert image to black features (above threshold) on white background (below
threshold)
setOption("BlackBackground", false);
run("Convert to Mask", "method=Default background=Dark");
//Remove noise with despeckle function.
run("Despeckle", "stack");
//Create annotations covering area above threshold. Excludes objects of area under chosen size
cut-off (20 pixels in this case). Size cut-off should be adjusted depending on the magnification of
the image and the size of objects you wish to exclude (noise).
run("Analyze Particles...", "size=20-Infinity display clear summarize add stack");
//Clear results. Steps so far to are to create region of interest annotations (ROIs), results will be
collected in following steps.
run("Clear Results");
//Import unmodified image sequence again. Should be identical to line 1
run("Image Sequence...", "open=[“folder name”] number=88 starting=5 increment=3 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
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//Set measurements to record area, mean, integrated density to 3 decimal places.
run("Set Measurements...", "area mean integrated redirect=None decimal=3");
//The next three lines overlay the ROIs on the fluorescent cell image sequence, calculate the
intensity within the ROIs, and display the results in the “Results” window.
roiManager("Show None");
roiManager("Show All");
roiManager("Measure");
Fiji/ImageJ macros used in Figure 4.3 – Number of aggregates per cell plots. The same ROIs
(outlining whole cell area) used in Figure 4.1 fluorescence analysis were used for cell size
determination. To determine the size of aggregates, black and white mask images were produced
at a higher intensity threshold to select for the brightest foci emanated from protein aggregates.
Then the whole cell ROIs were overlaid on the aggregate mask image and “area” and “area
fraction” were measured. Aggregate area per ROI was calculated in Microsoft Excel as the product
of (Area ∙ Area Fraction). Since some ROIs capture multiple cells or aggregates in clusters, cell
and aggregate areas were weighted in Microsoft Excel by dividing the area of each ROI by median
cell or aggregate size calculated over the entire experiment. Standard deviation was calculated
based on the means of at least N = 3 biological replicates at each timepoint.
//Import image sequence. Replace “folder name” with desired image series location. “number” is
the number of images in the series and “increment” is used to exclude unwanted images in the file
folder.
run("Image Sequence...", "open=[“folder name”] number=88 starting=5 increment=3 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//Set threshold to exclude pixels below chosen cutoff (6 in this case). Fine-tune according to your
image brightness and use same cutoff for all images in one experiment. In this step, threshold
should be adjusted to capture whole cell area.
setThreshold(6, 255);
//Next two lines convert image to black features (above threshold) on white background (below
threshold).
setOption("BlackBackground", false);
run("Convert to Mask", "method=Default background=Dark");
//Remove noise with despeckle function.
run("Despeckle", "stack");
//Separate closely adjacent objects with watershed function.
run("Watershed", "stack");
//Create annotations covering area above threshold. Excludes objects of area under chosen size
cut-off (100 pixels in this case). Size cut-off should be adjusted depending on the magnification
of the image and the size of objects you wish to exclude (noise).
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run("Analyze Particles...", "size=100-Infinity display clear summarize add stack");
//Clear results. Steps so far to are to create region of interest annotations (ROIs), results will be
collected in following steps.
run("Clear Results");
//Import unmodified image sequence again. Should be identical to line 1
run("Image Sequence...", "open=[“folder name”] number=88 starting=5 increment=3 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//Set threshold to exclude pixels below chosen cutoff (100 in this case). Fine-tune according to
your image brightness and use same cutoff for all images in one experiment. In this step, threshold
should be adjusted to capture protein aggregate area only.
setThreshold(100, 255);
//Convert image to black features (above threshold) on white background (below threshold).
run("Convert to Mask", "method=Default background=Dark");
//The next two lines overlay the ROIs from whole cell threshold on the mask image produced from
the aggregate threshold.
roiManager("Show None");
roiManager("Show All");
//Set measurements to record area and area fraction to 3 decimal places. Area will output the whole
cell ROI areas, area fraction will output the fraction of that area containing an aggregate object
from the aggregate mask image. Aggregate area can then be calculated as the product of area x
area fraction.
run("Set Measurements...", "area area_fraction redirect=None decimal=3");
//Measure.
roiManager("Measure");
Fiji/ImageJ macros used in Figure S4.4 – Number of aggregates per total fluorescence. Figure
S4.4 was analyzed with a previously described ImageJ macro (19). A lower threshold was used to
generate ROIs capturing all fluorescence in each image (A, cellular fluorescence) and measure the
total fluorescence in each image in the series. A higher threshold was used to generate ROIs
capturing only aggregated FUS-EGFP protein (B, aggregate area). Total fluorescence and
aggregate area were calculated per image in Microsoft Excel using the SUMIF() function. For each
image, total aggregate area was normalized to total transfected cell fluorescence and initial values
were subtracted from all datapoints in the series to obtain “Δ N aggregates / total fluorescence”.
Standard deviation was calculated based on the means of at least three biological replicates at each
timepoint.
A) Cellular fluorescence
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//Import image sequence. Replace “folder name” with desired image series location. “number” is
the number of images in the series and “increment” is used to exclude unwanted images in the file
folder.
run("Image Sequence...", "open=[“folder name”] number=37 starting=2 increment=3 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//Set threshold to exclude pixels below chosen cutoff (6 in this case). Fine-tune according to your
image brightness and use same cutoff for all images in one experiment. In this step, threshold
should be adjusted to capture whole cell area.
setThreshold(6, 255);
//Next two lines convert image to black features (above threshold) on white background (below
threshold).
setOption("BlackBackground", false);
run("Convert to Mask", "method=Default background=Dark");
//Remove noise with despeckle function.
run("Despeckle", "stack");
//Create annotations covering area above threshold. Excludes objects of area under chosen size
cut-off (20 pixels in this case). Size cut-off should be adjusted depending on the magnification of
the image and the size of objects you wish to exclude (noise).
run("Analyze Particles...", "size=20-Infinity display clear summarize add stack");
//Clear results. Steps so far to are to create region of interest annotations (ROIs), results will be
collected in following steps.
run("Clear Results");
//Import unmodified image sequence again. Should be identical to line 1
run("Image Sequence...", "open=[“folder name”] number=37 starting=2 increment=3 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//The next two lines overlay the ROIs from the thresholded on the non-thresholded image.
roiManager("Show None");
roiManager("Show All");
//Set measurements to record integrated density to 3 decimal places, then measure.
run("Set Measurements...", "integrated redirect=None decimal=3");
roiManager("Measure");
B) Aggregate area
//Import image sequence. Replace “folder name” with desired image series location. “number” is
the number of images in the series and “increment” is used to exclude unwanted images in the file
folder.
run("Image Sequence...", "open=[“folder name”] number=37 starting=2 increment=3 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//Set threshold to exclude pixels below chosen cutoff (120 in this case). Fine-tune according to
your image brightness and use same cutoff for all images in one experiment. In this step, threshold
should be adjusted to capture aggregated protein area.
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setThreshold(120, 255);
//Next two lines convert image to black features (above threshold) on white background (below
threshold).
setOption("BlackBackground", false);
run("Convert to Mask", "method=Default background=Dark");
//Create annotations covering area above threshold. Excludes objects of area under chosen size
cut-off (5 pixels in this case). Size cut-off should be adjusted depending on the magnification of
the image and the size of objects you wish to exclude (noise).
run("Analyze Particles...", "size=5-Infinity display clear summarize add stack");
//Set measurements to record area to 3 decimal places, then measure.
run("Set Measurements...", "area redirect=None decimal=3");
roiManager("Measure");

4.7.2.4 Fiji/ImageJ macros used in Figure S4.6 – Number of insoluble aggregates per cell.
Images from before and after Triton X-100 treatment were cropped at the edges to account for
plate shifting during Triton X-100 addition (3.53% y-shift, 3.85% x-shift in this case). This was
done by overlaying images and determining the percentage overhang on each image, then
converting the percentage to a 1280 x 960 pixel frame size used in Fiji. This analysis consists of
two macros, the first was used to determine cell count before Triton X-100 (A, Cell size pre-Triton
X-100) and the second was used to determine insoluble aggregate count after Triton X-100
treatment (B, aggregate size post-Triton X-100). As before, cell and aggregate counts were
determined by normalizing ROI areas to median ROI area from all images at the same threshold.
Standard deviation was calculated based on the means of at least N = 3 biological replicates at
each timepoint. Significant differences were calculated using independent sample t-tests.
A) Cell size pre-Triton X-100.
//Open image. Replace “file name” with desired image directory.
open("file name");
//Next two lines crop the image to account for plate shifting during Triton X-100 treatment.
run("Specify...", "width=1178 height=926 x=102 y=0");
run("Crop");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50");
//Set threshold to exclude pixels below chosen cutoff (10 in this case). Fine-tune according to your
image brightness and use same cutoff for all images in one experiment.
setThreshold(10, 255);
//Convert to black on white mask image
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run("Convert to Mask");
//Remove noise with despeckle function.
run("Despeckle");
//Separate closely adjacent objects with watershed function.
run("Watershed");
//Set measurements to area to three decimal places.
run("Set Measurements...", "area redirect=None decimal=3");
//Create annotations covering area above threshold. Excludes objects of area under chosen size
cut-off (100 pixels in this case). Size cut-off should be adjusted depending on the magnification
of the image and the size of objects you wish to exclude (noise).
run("Analyze Particles...", "size=100-Infinity display clear summarize add");
B) Aggregate size post-Triton X-100.
//Open image. Replace “file name” with desired image directory.
open("file name");
//Next two lines crop the image to account for plate shifting during Triton X-100 treatment.
run("Specify...", "width=1178 height=926 x=0 y=34");
run("Crop");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50");
//Set threshold to exclude pixels below chosen cutoff (10 in this case). Fine-tune according to your
image brightness and use same cutoff for all images in one experiment.
setThreshold(50, 255);
//Convert to black on white mask image
run("Convert to Mask");
//Create annotations covering area above threshold.
run("Analyze Particles...", "size=0-Infinity display clear summarize add");
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Chapter 5
5. Local DNA sequence context alters the phenotypic potency of
identical human tRNA variants1
5.1 Introduction
Recent studies, including our own work, have demonstrated that transfer RNA (tRNA)
variants are more common in the human population than previously thought (1). At the same time,
we and others have highlighted the strong potential for tRNA variants to act as disease modifiers
(2-4). Indeed, specific tRNA variants cause neurodegenerative phenotypes in mice (5,6) and
exacerbate disease in cellular models of cancer (7) and Huntington’s disease (8). We anticipate the
list will continue to grow, since conceivably many tRNA variants have the potential to modify the
development of any human disease. Presently, tRNA genes are not included in the majority of
whole exome and genome-wide association studies, so the extent to which tRNA variants associate
with disease is not yet known. Thus, very few cause-and-effect relationships have been established
between human tRNA variants and disease in real patients (2,9).
Accurately aminoacylated tRNAs and high-fidelity decoding on the ribosome are needed
for the faithful production of all proteins in cells. Indeed, tRNAs are essential to ensure the accurate
translation of the genetic code into an amino acid sequence. Dysfunctional tRNAs can cause amino
acid mis-incorporation, ribosome stalling, or increased reading frame-shifting (2). Further, some
tRNAs act outside of their canonical roles in mRNA translation as tRNA-derived fragments (tRFs,
tiRNAs), which perform an expanding array of functions in regulating cellular processes (10,11),
including protein synthesis (12), stress responses (13), cell proliferation (14), and more. Because
proper tRNA activity is important to virtually all cellular functions, tRNA dysfunction has
significant potential to modify or exacerbate disease.
Predicting whether a human tRNA variant is deleterious represents a significant challenge.
The human genome encodes over 600 tRNA genes and tRNA-like pseudogenes (15). To
discriminate real tRNA genes from pseudogenes, tRNAscan-SE was developed, a scoring
algorithm that computes the likelihood of tRNA genes being functional (16,17). tRNAscan-SE
scores are an assessment of tRNA gene quality which factors in secondary structure predictions
1

Work in this chapter is in preparation for publication. Authorship: Jeremy T. Lant, Farah Hasan,
Andrew Seto, Julia Briggs, Patrick O’Donoghue
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and conservation of internal promoter sequences found in tRNA genes (A and B box) (16).
tRNAscan-SE scores above 50 are considered likely to be functional tRNAs, or “high confidence.”
Based on tRNAscan-SE scores, the human genome encodes 416 high confidence tRNA genes (15),
and recent estimates predict that over 300 human tRNA genes are actively transcribed in cells (18).
Adding to this complexity, healthy individuals commonly harbor ~60-70 tRNA sequence variants
in their genome compared to the human reference genome (1). Surprisingly, many of these variants
are found in tRNA genes that are known to be expressed and functional in human cells (18,19).
Given that many of these variants are found in healthy individuals, the majority of sequenced
human tRNA variants are likely benign or have miniscule effects on cellular fitness. The excessive
number of tRNA genes and variants in humans, however, provides significant potential for
polygenic effects, and we and others have shown that natural tRNA variants can exacerbate or
modify human diseases in cellular (5,7,8) and animal (5,6) models.
Significant methodological challenges have also impeded research on tRNAs. One major
challenge is the repetitive nature of tRNA genes. Specific iso-decoder tRNAs are found in up to
11 identical copies throughout the human genome (15). Many tRNA families also possess
subgroupings which differ by only 1 or 2 nucleotides, making it difficult or impossible to determine
which genomic locus a given tRNA was transcribed from using RNA sequencing data. To address
this problem, recent efforts developed improved bioinformatic approaches to predict the activity
of specific tRNA gene loci based on local sequence context flanking the tRNA gene (18). Even
when tRNA gene sequences are identical, the flanking sequence around tRNA genes is often highly
divergent (20), and 5’ and 3’ flanking sequences have long been known to influence eukaryotic
tRNA transcription levels (21-23). Transfer RNA genes are somewhat unique in that they harbor
internal promoter sequences, referred to as the A and B box, which are sufficient for basal
recruitment of the RNA polymerase III transcription initiation complex (24). However, mutational
studies on tRNA flanking sequences revealed that local sequence context can alter tRNA gene
activity by influencing transcription initiation, termination, and pre-tRNA processing (21,22,2528). While new sequence-based predictions help to evaluate the likelihood of certain tRNA genes
being active, validating the relevance of individual tRNA genes experimentally remains
challenging. Inspired by previous work that utilized tRNA anticodon variants to probe elements of
the unfolded protein stress response in mammalian cells (29), we hypothesized that anticodon
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variants could also be a useful tool in assessing the activity of identical tRNA genes found at
distinct genomic loci.
In recent work, we characterized a non-synonymous anticodon variant in the human tRNASer-AGA-2-3 gene which causes mis-incorporation of Serine (Ser) at Phenylalanine (Phe) codons
(8). Astoundingly, this variant is found in ~1.8% of the sequenced human population (30-32). The
tRNA-Ser-AGA-2-3 gene is one of six identical copies in the human genome, with another five
tRNA-Ser genes (AGA-1, AGA-3-1, AGA-4-1, TGA-2-1, TGA-3-1) differing by only 1-2
nucleotides (15). Interestingly, in other copies of the tRNA-Ser-AGA-2-n genes, the mistranslating
G35A variant is either extremely rare (minor allele frequency > 0.002%) or has never been
observed (32). All six copies of the tRNA-Ser-AGA-2-n genes are thought to be expressed in
human cells based on bioinformatic predictions (18), Chromatin immunoprecipitation (CHIP)sequencing (33,34), DnaseI hypersensitivity sequencing (34,35), and RNA sequencing data (19).
Using the tRNASerAGA isodecoders as a proof-of-principle, we developed new assays to investigate
the relative importance of identical tRNA genes using a well characterized variant as a genetic
probe.

5.2 Materials and Methods
5.2.1 tRNA gene alignments.
tRNA gene sequences were obtained from the human GRCh37/hg19 reference genome
using tRNA gene coordinates from the genomic tRNA database (15,36) with added flanking
sequence representing regions captured by our genomic PCR primers (Table 5.1, S5.1).
Alignments were generated using T-Coffee (37) with ClustalW output format via the EMBL-EBI
tools server (38). Results were visualized in Jalview (2.11.14) (39) and colored by sequence
identity.

5.2.2 Plasmids and strains.
Plasmid manipulations were performed with Escherichia coli DH5α cells (Invitrogen). All
plasmids were derived from WT-Pan (Addgene plasmid #99638; (40)). WT-Pan encodes an
EGFP-mCherry fusion protein. To generate mCherry-only plasmids (hereafter referred to as pPan-
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Cherry), the EGFP sequence was removed by digestion and ligation of the isoschizomeric
SpeI/NheI sites flanking EGFP. Human tRNASer genes were PCR amplified from human
embryonic kidney (HEK) 293T genomic DNA with ± minimum 300 bp flanking sequence (see
Table 5.1, S5.1). This was accomplished with a nested PCR strategy, where larger sequence
regions (± minimum 400 bp flanking sequence) are first captured with genome-unique primers
designed using primer BLAST (41). Inserts for cloning are then re-amplified from the genomic
PCR template with primers capturing desired flanking sequence lengths with restriction sites
included in 5’ tails of the nested PCR primers. Primer sequences are provided (Table S5.1) and
human reference genome coordinates of the cloned loci are in Table 5.1. Anticodon variants were
introduced in PCR fragments using overlap extension PCR, as described (42). The tRNA
expression cassettes were inserted at the PciI (New England Biolabs, Ipswich, MA, USA) site of
pPan-Cherry.

MS-READ

(43)

peptide-encoding

inserts

(peptide

sequence

MSKGPGKVPGAGVPGXGVPGVGKGGGT; X = L (encoded by TTA or TTG) or F (encoded
by TTC or TTT)) were ordered as complimentary DNA oligonucleotides with BamHI/EcoRI
compatible overhang sequences. Oligonucleotides were phosphorylated in vitro using T4
polynucleotide kinase (NEB), then annealed by denaturation for 5 min at 95 °C and gradual cooling
to room temperature. The MS-READ peptide encoding sequences were then inserted into
BamHI/EcoRI sites in WT-Pan, replacing the EGFP sequence. Importantly, WT-Pan harbors a
secondary kozak sequence in the linker sequence immediately upstream of the mCherry coding
sequence, which allowed us to remove EGFP and its upstream kozak sequence without
compromising mCherry expression. Plasmid DNA for transfection in mammalian cells was
purified by Midi-Prep (GeneAid) from 100 mL E. coli DH5α cultures grown at 37 °C for 16 hrs
to an A600 > 1.0. DNA concentrations were measured using a Nanodrop 2000C (ThermoFisher
Scientific).

5.2.3 Cell culture and transfection.
Experiments were performed in human embryonic kidney 293T (HEK 293T; American
Type Culture Collection (ATCC) #CRL-3216), human K-562 chronic myelogenous leukemia
(ATCC #CCL-243), or murine Neuro2a Neuroblastoma (N2a; ATCC #CCL-131) cells. HEK 293T
cells were a generous gift from Dr. Ilka Heinemann (University of Western Ontario), K-562 cells
were a generous gift from Dr. James Koropatnick and René Figueredo (University of Western

159

Ontario), and N2a cells were purchased from ATCC. All cell lines were grown at 37 °C with
humidity and 5 % CO2 and cultured in high glucose Dulbecco’s modified Eagle medium (DMEM,
4.5 g/L glucose; Gibco by Life Technologies, Carlsbad, CA) containing penicillin (100 IU/mL),
streptomycin (100 µg/mL; P/S; Wisent Bioproducts, Montreal, QC, Canada), and 10% fetal bovine
serum (FBS; Gibco). Plasmid transfections were performed using Lipofectamine 3000 transfection
reagent (Invitrogen) with 2 µg/mL DNA (HEK 293T, N2a cells) or Lipofectamine LTX reagent
with PLUS reagent (ThermoFisher Scientific) using 1 µg/mL DNA (K562), following the
manufacturer’s instructions.

5.2.4 Small molecules and peptides.
Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132; Sigma-Aldrich 474790, Darmstadt,
Germany) was dissolved in DMSO and cells were treated with 10 µM final concentration in all
experiments indicated.

5.2.5 Fluorescence microscopy.
Fluorescent microscopy images were captured on an EVOS FL auto fluorescent
microscope (Thermo Fisher Scientific). RFP (531 ± 40 nm excitation, 593 ± 40 nm emission) filter
cubes were used to capture red fluorescence. For fluorescence analyses, we used semi-automated
Fiji/ImageJ (44) macros to annotate cells and measure intensity within regions of interest (ROI),
as previously described (8). Fiji/ImageJ macros are included in the supplemental appendix of this
chapter with detailed analysis, descriptions, and line-by-line commentary. For live cell imaging
(see cell migration assay), cells were incubated at 37 °C with humidity and 5% CO 2 in the EVOS
FL auto-fluorescent microscope environment chamber.

5.2.6 tRNA sequencing.
N2a cells were transfected for 48 hrs in biological triplicate on 10 cm plates with plasmids
encoding tRNA-Ser-AGA-2-3 or tRNA-Ser-AAA-2-3 variant and mCherry as a transfection
marker (Fig. S5.2). We estimated transfection efficiency by manually counting the number of
visibly fluorescing cells in images from each transfection. Based on this count, we estimated 5060% of cells were expressing the transfected plasmids. Cells were harvested by resuspension in
TRIzol Reagent (ThermoFisher Scientific), then stored in liquid nitrogen for 1 week before
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sending to Arraystar Inc (Rockville, MD, USA) for tRNA sequencing. Samples were sent in an
insulated container with dry ice to prevent defrosting during shipment. Detailed descriptions of
sample preparation and sequencing methods used by Arraystar Inc. are provided in supplemental
information.

5.2.7 Cell harvesting and western blotting.
At 48 hr post-transfection, cells grown in 6-well plates were lifted in phosphate buffered
saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) with 10
mM EDTA for 10 min at 37 °C, collected in sterile 1.5 mL microcentrifuge tubes, and pelleted by
centrifugation at 300 × g for 3 min at 4 °C. The supernatant was aspirated, and cell pellets were
resuspended in 90 L of mammalian cell lysis buffer containing 50 mM Na 2HPO4, 1 mM Na4P2O7,
20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1 mM Triton X-100, 1 mM dithiothrieitol, 0.3 mM
phenylmethylsulfonyl fluoride, and 1 tablet/10 mL complete mini EDTA-free Protease Inhibitor
Cocktail (Roche, Mississauga, ON), incubated for 5 min on ice, and centrifuged at 21,000  g for
10 min at 4 C. Supernatants were collected in 1.5 mL microcentrifuge tubes and kept on ice for
immediate use, or samples were stored at -20°C for up to one week. Protein concentrations in the
lysates were determined with a Pierce bicinchoninic acid (BCA) protein assay kit (ThermoFisher
Scientific). Lysates were diluted to equal concentrations with sterile milliQ H 2O and 3  sodium
dodecyl sulfate (SDS) loading dye (0.5 M Tris-HCl, pH 6.8; 1.12 M sucrose; 0.025% w/v
bromophenol blue; 3.8% w/v SDS). Lysate corresponding to 12 μg total soluble protein was
separated by SDS-polyacrylamide gel electrophoresis (10% acrylamide) with protein standards
(BioRad, Hercules, CA, USA) for size determination. Proteins were transferred to methanolactivated polyvinylidene fluoride membranes using a Trans-Blot Turbo Transfer System (25 V,
1.3 A for 14 min; BioRad). Blocking and washing solutions were prepared in tris-buffered saline
(TBS; 50 mM Tris-HCl, pH 7.5, 150 mM NaCl). Membranes were incubated for 1 hr in blocking
solution (3% bovine serum albumin (BSA), 0.1% Tween 20, 1X TBS) before adding primary
antibodies at a 1:1000 (α-mCherry, abcam, ab213511) or 1:5000 (α-GAPDH, Sigma-Aldrich,
MAB374m) dilution in blocking solution. Membranes were incubated with primary antibody in
blocking solution overnight at 4 °C, washed 3  10 min in washing solution (1% BSA, 0.1% Tween
20, 1 TBS), then incubated with anti-mouse (Thermo Fisher Scientific, MA1-21315) or antirabbit (Sigma, GENA9340) horse radish peroxidase-linked secondary antibodies for 2 hr at room
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temperature with a 1:2000 final dilution. Membranes were washed with 1  TBS with 0.1% Tween
20 for 3  10 min, followed by one wash for 10 minutes in 1  TBS. Proteins were visualized using
Clarity Western enhanced chemiluminescence (ECL) Substrates (Bio-Rad) following the
manufacturer’s instructions and imaged with a ChemiDoc MP System (Bio-Rad).

5.2.8 RFP-trap immunoprecipitation.
HEK 293T cells were transfected for 48 hrs in biological triplicate on 10 cm plates with
plasmids encoding tRNA-Ser-AGA-2-5 or tRNA-Ser-AAA-2-5 variant and MS-READ-mCherry
proteins with TTA, TTC, TTG, or TTT encoded at the test position in the MS-READ peptide (see
Results section 5.3.5). Cells were lifted in phosphate buffered saline (1  PBS pH 7.4; Corning
Cellgro, Corning, NY, USA) supplemented with 1 mM EDTA, harvested by pipetting, and
centrifuged in 1.5 mL microcentrifuge tubes at 300  g for 3 min at 4 °C. Supernatant was removed
and cells washed with ice cold PBS (Corning Cellgro) and centrifuged again. The remainder of the
protocol, including buffer recipes, was completed according to the RFP-trap agarose
manufacturer’s instructions (Chromotek). For the elution step, the protein-conjugated RFP-trap
beads were boiled in 2 SDS-sample buffer (Laemmli) buffer for 5 min at 95°C to elute. To ensure
our protein yields were maximally concentrated, we suspended the beads in 40 µl Laemmli buffer
rather than the recommended 80 µL. The beads were then sedimented by centrifugation at 2,500
 g for 2 min at 4 °C, and 30 µL supernatant was loaded on 10% SDS-PAGE gels for gel
purification and sample analysis.
SDS-PAGE gels were run at 100-120 V until band fronts reached ~2/3 length of the gel.
Gels were stained with Coomassie blue in 10% methanol and 10% acetic acid solution overnight,
then de-stained for > 2 hrs in 10% methanol and 10% acetic acid. Bands corresponding to the
purified ~29.7 kDa MS-READ-mCherry proteins were picked from the gels using an Ettan Robotic
Spot-Picker and submitted for proteolytic digestion (Trypsin) and peptide extraction at the
Functional Proteomics Facility at the University of Western Ontario, Canada. Peptide extraction
and trypsinization were performed as described (8). LC-MS/MS was performed at the Biological
Mass Spectrometry Laboratory at the University of Western Ontario, Canada, as previously
described (8).
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Raw data files were loaded, processed, and searched using Peaks X+ (Bioinformatics
Solutions Inc.) against a custom database consisting of a group of common contaminants and
possible proteoforms of MS-READ-mCherry resulting from Phe-to-Ser, and Leu-to-Ser possible
substitutions. An FDR of 0.1% and at least 1 unique peptide were used. Spectral count and areaunder-the-curve values from liquid chromatogram represent only the exact MS-READ encoded or
mistranslated peptides, with no missed cleavages or amino acid modifications. Area-under-thecurve values from mistranslated peptides were normalized to the encoded peptide from the same
sample to estimate misincorporation levels (Fig. 5.4D) and account for differences in mCherry
yield obtained from the different sample conditions.

5.2.9 Cytotoxicity assays.
Cytotoxicity was measured with CytotoxGlo luminescent cytotoxicity assays (Promega) in
at least three biological replicates, following the manufacturer’s instructions. Cells were assayed
24 hr or 48 hours post-transfection, as indicated. We also assayed cell death in HEK 293T cells
independently using dye exclusion assays with the SYTOX Blue dead cell stain, as described in
Chapter 4 (section 4.3.2). For assays involving proteasome inhibition, cells were treated with 10
µM MG132 or vehicle (DMSO) for 4 hours immediately before assay.

5.2.10 Cell migration assay.
HEK 293T cells were grown to ~80% confluence in a 96-well plate, then deprived of serum
by 24 hr incubation in high glucose DMEM containing 1% FBS. Four hours prior to the start of
the assay, cells were transfected with plasmids encoding tRNAs and mCherry transfection marker.
After 4 hr transfection, the media was replaced with high glucose DMEM containing 20% FBS
and either 10 µM MG132 or DMSO control. The FBS deprivation and spike-in was done to
promote de novo protein synthesis in the presence of the expressed tRNAs, and MG132 treatment
was used to exacerbate phenotypes of mistranslating tRNAs. Immediately after changing the
media, wounds were created in the ~90% confluent cell monolayers by scoring each well with a
sterile 10 µl micropipette tip. Live cell fluorescent microscopy time courses were started 1 hr after
wound creation, allowing time for plate acclimation and field-of-view focusing in the EVOS
environment chamber. Hence, the assay started 5 hrs post-transfection and 1 hr after adding the
high serum media with DMSO or 10 µM MG132. Images were captured every 30 minutes over a
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15 hr timecourse. Migration of fluorescing cells was quantitated with the Fiji plugin TrackMate
(45) similarly to published approaches (46,47). Briefly, cell migration velocity was approximated
as an average of speed measurements for each 30 min capture interval, excluding tracks of duration
less than three frames (1.5 hr). Detailed descriptions of TrackMate analysis are included in the
supplemental appendix.

5.3 Results
5.3.1 tRNA gene alignments and variant frequencies.
The tRNA variant used in this study is a G35A mutation found in the tRNA-Ser-AGA-2-3
gene in ~1.8% of the sequenced human population (1,30,31). The G35A variant creates an AAA
anticodon which causes misincorporation of Ser at Phe codons (UUC and presumably UUU) (8).
We previously found that the variant caused a strong reduction in protein synthesis in cells and
altered the kinetics of protein aggregation in models of Huntington’s disease (8) and ALS (see
chapter 4). The human tRNA-Ser-AGA-2-3 gene is one of six identical copies encoded in the
human genome, referred to collectively hereafter as tRNA-Ser-AGA-2-n genes. We gathered
minor allele frequencies for the G35A variant at all tRNA-Ser-AGA-2-n loci found in the single
nucleotide polymorphism database (dbSNP) (32). According to minor allele frequencies from the
largest data source, GnomAD (31), the AGA-2-3 gene is the most frequent site of the G35A variant
(Table 5.1). In other tRNA-Ser-AGA-2-n genes, the G35A variant is either extremely rare (allele
frequency < 0.002%) or has never been observed (Table 5.1).
Transfer RNA genes typically have low sequence conservation immediately flanking the
tRNA gene sequence, as noted (20). To assess local flanking sequence contributions on tRNA
variant activity, we designed primers to PCR amplify all tRNA-Ser-AGA-2-n genes with ~300 bp
flanking sequence from HEK 293T genomic DNA (Table S5.1). We used the regions captured by
our primers to generate sequence alignments (Fig. S5.1). As expected, sequence conservation was
low surrounding the tRNA genes (Fig. S5.1). The only feature which appeared to be conserved
outside of the tRNA gene sequence was a T-rich sequence found 5-11 bp downstream of the tRNA
genes, which is required for transcription termination (26).

164

Table 5.1. tRNA-Ser-AGA-2-n gene loci and variant frequencies.
tRNA gene

gene

+upstreamb

+downstreamb

Cloned loci

length

coordinatesc

coordinates

G35A
MAF
(%)d

Ser-AGA-2-1a

chr6:26327817-

n.a.

n.a.

n.a.

n.a.

0

320

336

chr6:27446271-

737

0.0007

709

1.7662

737

0.0014

730

0

n.a.

0

26327898 (+)
Ser-AGA-2-2

chr6:2744659127446672 (+)

Ser-AGA-2-3

chr6:27463593-

27447008 (+)
320

308

27463674 (+)
Ser-AGA-2-4

chr6:27470818-

27463982 (+)
320

336

27470899 (+)
Ser-AGA-2-5

chr8:96281885chr17:8129928-

chr6:2747049827471235 (+)

323

326

96281966 (-)
Ser-AGA-2-6a

chr6:27463273-

chr8:9628156296282292 (-)

n.a.

n.a.

n.a.

8130009 (-)
a

Not included in experimental work in this study. b+upstream and +downstream represent added
5’ and 3’ sequence lengths respective to the tRNA gene sequence (primer sequences provided in
Table S5.1; tRNA gene coordinates from GtRNAdb (15,36)). cCloned loci coordinates represent
human reference genome GRCh37/hg19 coordinates for complete sequence cloned in our
expression plasmids (see Materials and Methods) dMinor allele frequency of G35A variant from
GnomAD (31) accessed from dbSNP (32) (build 155 released April 9, 2021).

5.3.2 Single nucleotide variants allow detection of tRNA expression by
tRNAseq.
Introduction of a single nucleotide variant in a tRNA gene provides a unique sequence
feature which we hypothesized could be used to detect expression amidst otherwise identical
tRNAs. To test this hypothesis, we conducted tRNA-sequencing of N2a cells expressing the tRNASer-AGA-2-3 or tRNA-Ser-AAA-2-3 genes. We selected N2a cells in this case as we reliably
obtain high transfection efficiency, readily detect cytotoxicity from tRNA SerAAA, and validated Phe
to Ser misincorporation in N2a cells expressing the tRNA-Ser-AAA-2-3 variant using mass
spectrometry (8).
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In addition to having strong tertiary structures (48), tRNAs are among the most densely
modified RNAs in cells (49). Hence, custom tRNA sequencing approaches were developed to
overcome poor cDNA conversion efficiency by reverse transcriptase enzymes on tRNA genes
(50). Cells were sent for a modified version of Hydro-tRNAseq (50) coupled with enzymatic tRNA
modification-stripping, similarly to published approaches (19). Sample preparation and
sequencing was completed by Arraystar Inc. (Rockville, MD, USA).
Transfer RNA sequencing results can be interpreted by two different read counting
strategies, including unique read counts or multi-map-corrected read counts. Unique counts only
consider reads which map to a single tRNA sequence, making them preferable for estimating the
expression of a specific variant. Multi-map-corrected read counts include reads which map to
multiple tRNA gene sequences, considering each unique read as a count of 1 and each multimapped read as 1/n, where n is the number of tRNA sequences which contain the identical
sequence. Since tRNAs contain highly repetitive sequence elements and hydro-tRNA sequencing
is limited to short 18-40 nt reads, multi-map corrected read counting is essential to estimate
expression of most endogenous tRNAs. Indeed, in this case only 8 - 16 % of over five million
reads were uniquely mapped from our samples (Table S5.3).
According to the unique read counts, tRNASerAAA expression was significantly higher in
cells expressing tRNASerAAA compared to cells expressing tRNASerAGA, as expected given that the
tRNASerAAA sequence is not found endogenously in mouse cells (31.48-fold, p = 0.0023; Fig. 5.1).
We note that in one of the samples from cells expressing tRNASerAAA, we did not detect the
tRNASerAAA sequence (additional samples are in preparation to generate more biological replicates
of the sequencing data.). However, in this sample only 237 reads were uniquely mapped to tRNASer sequences in total, compared to 1358 and 2088 in the other samples (Table 5.2). Hence the
lack of tRNA-Ser-AAA detection in that sample was likely a false negative due to low read counts.
Regardless, tRNASerAAA expression was clearly detected in mistranslating cells only. Hence, a
single nucleotide variant in a single tRNA gene can be confidently detected by tRNA sequencing.
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Figure 5.1. tRNA and tRNA variant expression in N2a cells revealed by tRNAseq. N2a cells
were transfected with a plasmid encoding wild-type human tRNA SerAGA or tRNASerAAA G35A
variants (expressed from human tRNA-Ser-AGA-2-3 gene flanking sequence context) and
mCherry (see Materials and Methods). tRNA-sequencing results from the transfected cells are
depicted as volcano plots, where x-asymptotes denote a ± 1.5-fold change and y-asymptote denotes
a p-value of 0.05 based on exact tests by negative binomial distribution. Values were calculated
based on unique (A) or multi-map-corrected (B) read counts. Significantly differentially expressed
genes are highlighted in red and labeled.
Importantly, our results suggest that tRNASerAAA was expressed but not over-expressed in
our cells transfected with the tRNASerAAA plasmid. In the samples where tRNASerAAA expression
was detected, we observed 19 and 29 unique read counts (Table 5.2). By comparison, we observed
hundreds of unique counts for comparable tRNASer isodecoder and isoacceptor sequences (Table
5.2) For example, in the same samples where we observed 19 and 29 unique read counts for
tRNASerAAA, we observed 142 and 290 unique read counts for a comparable tRNA SerGCT sequence
(tRNA-Ser-GCT-3), which differs from three identical copies of the tRNA SerGCT genes (tRNA-SerGCT-4-1, 4-2, 4-3) by only a single nucleotide. While our data is only roughly quantitative from
transiently transfected cells, accounting for transfection efficiency estimates of 50-60% implies
that tRNASerAAA was not expressed more highly than endogenous tRNA-Ser genes.
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Table 5.2. tRNAseq unique read counts for all tRNA-Ser isodecoders.
Sample-replicatea
Isodecoder
AGA-1
AGA-2
AGA-3
AAA-1
AAA-2
AAA-3
tRNA-Ser-AAA
0
1
0
19
0
29
tRNA-Ser-AGA-2
1
2
1
0
0
1
tRNA-Ser-AGA-3
2
2
15
2
0
5
tRNA-Ser-CGA-1
28
162
110
143
15
214
tRNA-Ser-CGA-2
61
1223
716
504
63
807
tRNA-Ser-CGA-3
2
5
4
3
4
5
tRNA-Ser-GCT-1
11
282
149
112
13
146
tRNA-Ser-GCT-2
4
36
64
18
1
27
tRNA-Ser-GCT-3
71
213
354
142
31
290
tRNA-Ser-GCT-4
2
0
2
0
0
2
tRNA-Ser-GCT-5
2
2
2
3
1
4
tRNA-Ser-GGA-1
5
10
12
9
7
7
tRNA-Ser-TGA-1
144
684
448
397
102
542
tRNA-Ser-TGA-2
2
3
6
6
0
9
Total:
335
2625
1883
1358
237
2088
% AAA-2b:
0
0.04
0
1.4
0
1.4
a
Samples are labelled according to the anticodon of expressed tRNA and biological replicate
number. bPercentage of unique tRNASer mapped reads corresponding to the expressed tRNASerAAA
variant.
Table 5.3. tRNAseq multi-map-corrected read counts for all tRNA-Ser isodecoders.

Isodecoder
tRNA-Ser-AAA
tRNA-Ser-AGA-1
tRNA-Ser-AGA-2
tRNA-Ser-AGA-3
tRNA-Ser-CGA-1
tRNA-Ser-CGA-2
tRNA-Ser-CGA-3
tRNA-Ser-GCT-1
tRNA-Ser-GCT-2
tRNA-Ser-GCT-3
tRNA-Ser-GCT-4
tRNA-Ser-GCT-5
tRNA-Ser-GGA-1
tRNA-Ser-TGA-1
tRNA-Ser-TGA-2
Total:

AGA-1
299
328
306
4
63
63
13
52
73
136
86
9
24
146
328
1631

AGA-2
1131
1196
1134
16
195
1224
18
380
966
1201
1029
48
65
692
1185
7432

Sample-replicatea
AGA-3
AAA-1
1030
701
1138
727
1067
682
30
4
144
168
725
510
26
12
297
175
534
395
882
538
576
424
75
30
68
44
467
407
1151
751
6429
4867

AAA-2
221
228
220
1
23
63
12
41
73
107
80
5
21
103
226
1127

AAA-3
912
950
895
8
256
823
21
269
524
817
575
67
46
552
970
6763
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a

Samples are labelled according to the anticodon of expressed tRNA and biological replicate
number. bPercentage of multi-map-corrected tRNA-Ser reads corresponding to the tRNA-SerAGA-2 sequence.
Since the human tRNA-Ser-AGA-2-3 sequence is identical to six endogenous mouse
tRNASer genes, the plasmid based tRNASerAGA could not be detected by unique read counts. Indeed,
we observed at most 2 uniquely mapped reads corresponding to the tRNA-Ser-AGA-2 sequence
(representing all tRNA-Ser-AGA-2-n genes), in a sample where 266,903 uniquely mapped reads
were obtained in total (Table S5.3). Otherwise, the unique read count-based quantitation suggested
a significant change in expression of only one other tRNA when comparing the tRNA-Ser-AAA
and tRNA-Ser-AGA samples, tRNA-Asn-GTT-2 (3.61-fold, p = 0.027, Fig. 6A).
Based on the multi-map-corrected counts, we detected a significant up-regulation of
another single tRNA, tRNA-Pro-TGG-4 (3.04-fold, p = 0.0067, Fig. 5.1B). Our ability to interpret
expression of the tRNA-Ser-AAA and tRNA-Ser-AGA-2 sequences was limited when considering
multi-map-corrected reads (Table 5.3). The expressed human tRNA-Ser-AGA-2-3 gene is
identical to six endogenous mouse tRNA genes, so the expressed and endogenous tRNA-SerAGA-2-n sequences are reported together as “tRNA-Ser-AGA-2”. The tRNA-Ser-AAA sequence
expressed in the “AAA” samples differs by a single nucleotide, and another three endogenous
mouse tRNA-Ser genes (AGA-1-1, TGA-2-1, TGA-2-2) differ by only 1-2 nucleotides (15).
Hence, the majority of reads for the tRNA-Ser-AAA, tRNA-Ser-AGA-1, tRNA-Ser-AGA-2, and
tRNA-Ser-TGA-2 sequences would be counted as a conglomerate in the multi-map-corrected read
calculation. For these reason we could not logically infer changes in expression of tRNA SerAGA or
tRNASerAAA in our samples groups based on the multi-map corrected read counts.
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5.3.3 tRNA gene expression predictions.
While identical tRNA copies cannot be distinguished once transcribed, clues to the
expression of individual loci can be gathered from DNA sequence-based predictive scores (18) as
well as chromatin immunoprecipitation (CHIP) sequencing and DNase hypersensitivity
sequencing data available on the UCSC genome browser (34,51).
Recently, a landmark publication assessed a variety of DNA sequence-based predictive
factors in evaluating the likelihood of individual tRNA genes being active (18). The authors
detailed numerous sequence features which correlate with a higher or lower likelihood of tRNA
gene activity. Among the features assessed, CpG density and CpG island scores upstream of the
tRNA gene were most strongly predictive of tRNA gene activity (18). To visualize predictions on
the tRNA-Ser-AGA-2-n loci, we plotted CpG island scores against CpG density from the human
dataset (high confidence tRNA genes only; available at gtRNAdb.ucsc.edu/tRAP/) as scatter plots
and highlighted all tRNA genes containing the AGA anticodon. In general, all of the tRNA-SerAGA-2-n genes had moderate CpG island and CpG density scores compared to the other high
confidence human tRNA genes. Among the tRNA-Ser-AGA-2-n loci, the 2-3, 2-4, 2-5, and 2-6
loci scored slightly higher than the 2-1 and 2-2 loci (Fig. 5.2A). Compared to the other three
tRNA-Ser-AGA genes (AGA-1-1, -3-1, and -4-1) all of the -2-n genes had generally higher CpG
density and CpG island scores, except for the -2-1 loci, which scored lower than -4-1 in CpG
density.
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Figure 5.2 tRNA gene expression activity predictions from publicly available datasets. CpG
island and CpG density scores reported by Thornlow et al. (18) for all high confidence human
tRNA genes were plotted as scatter plots (A). All tRNA-Ser genes with AGA anticodon were
highlighted with red squares and labeled with standard tRNA gene numbers from GtRNAdb
(15,36). DnaseI hypersensitivity sequencing (35) scores for all AGA anticodon tRNA-Ser genes
with ± 350 bp flanking sequence were gathered from ENCODE human K562 cell data (34)
(accessed through the UCSC genome browser (51)), and descriptive statistics were plotted (B).
Error bars represent one standard deviation of the mean score in each sequence window. A cartoon
depicting RNA polymerase III transcription initiation complex members with associated CHIPsequencing data is shown (C). Cartoon is based on a review by R.J. White (24). CHIP-sequencing
peak maxima from ENCODE human K562 cell data (34) (accessed through the UCSC genome
browser (51)) were tabulated for all tRNA-Ser genes with AGA anticodon and plotted (D). For
each transcription initiation complex protein, peak maxima were weighted to the mean of all
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tRNA-Ser-AGA genes shown, such that a value of 1 represents the mean peak maximum value for
each protein across all high confidence human tRNA-Ser-AGA genes (D).
We also tabulated other predictive scores reported by Thornlow et al. (18) for all AGA
anticodon tRNA-Ser genes (Table 5.4). tRNAscan-SE scores are an assessment of tRNA gene
quality which factors in secondary structure predictions and conservation of internal promoter
sequences found in tRNA genes (A and B box) (16). Since all of the tRNA-Ser-AGA-2-n genes
have identical sequence, their tRNAscan-SE scores are identical, with a score of 89.6. tRNAscanSE scores above 50 are considered likely to be functional tRNAs, so this score suggests that the
tRNA-Ser-AGA-2-n sequence is functional when expressed. The other scores are all predictive
factors associated with likelihood of tRNA genes being active (18). PhyloP scores are a metric of
evolutionary conservation of sequences among mammalian phylogenies (52). High PhyloP scores
in tRNA gene sequences correlate with higher likelihood of gene activity (18). Interestingly, low
PhyloP scores in the 5’ flanking sequence adjacent to tRNA genes also correlate with higher
likelihood of tRNA gene activity (18), since tRNA genes are subject to high rates of transcriptionassociated mutagenesis (20). Other predictive factors reported by Thornlow et al included distance
to TTTT transcription termination sites and number of tRNA gene copies with the same anticodon
sequence (18). Distance to TTTT transcription termination sites correlated negatively with
likelihood of expression. The number of tRNA gene copies with the same anticodon correlated
with a higher likelihood of the tRNA gene being active, but lower likelihood of the tRNA gene
beingly highly expressed. These factors and the CpG density and island scores all contributed to
the calculated probability score.
Comparing the other predictive scores for all tRNA-Ser-AGA genes (Table 5.4), the tRNASer-AGA-2-n genes were all predicted to have higher likelihood of activity (>97%) compared to
the tRNA-Ser-AGA-1-1, 3-1, and 4-1 genes (83.6 – 93.5%), and compared to the mean score of
all high confidence human tRNA-Ser genes (93.9%). Hence, all of the tRNA-Ser-AGA-2-n loci
are likely active tRNA genes in humans. Comparing within the tRNA-Ser-AGA-2-n group, we
could not determine any clear indication of which gene might be more active than another. For
example, the tRNA-Ser-AGA-2-5 locus scored higher than all other tRNA-Ser-AGA genes in CpG
density across the tRNA locus (Fig. 5.2A) and PhyloP score within the tRNA gene sequence (Table
5.4), but also had the longest distance to transcription termination site among the tRNA-Ser-AGA-
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2-n loci, and highest PhyloP score in the 5’ flanking region, which inversely correlates with
likelihood of tRNA gene activity (Table 5.4).
Table 5.4. Extended tRNA gene activity prediction scores.
Total Number
of tRNA Genes
With Identical
Anticodon

tRNAscanSE General
Bit Score

Average
PhyloP
Score in
tRNA Gene
Sequencea

Distance To
Nearest TTTT
Transcription
Termination
Sequence

Average
PhyloP
Score in 5'
Flanking
Regiona

Probability
of active
tRNA
genea,b

AGA-1-1

9

90.3

0.850

100

-3.575

0.850

AGA-2-1

9

89.6

0.984

8

-2.709

0.986

AGA-2-2

9

89.6

0.796

5

-3.311

0.984

AGA-2-3

9

89.6

0.649

6

-3.587

0.985

AGA-2-4

9

89.6

0.588

9

-2.552

0.984

AGA-2-5

9

89.6

1.488

11

-0.774

0.973

AGA-2-6

9

89.6

1.418

5

-4.848

0.988

AGA-3-1

9

87.2

0.838

123

-3.564

0.935

AGA-4-1

9

78.8

0.666

7

-1.330

0.836

7.08

88.772

0.950

17.88

-2.397

0.939

tRNA-Ser
Gene
Name
(suffix)

All human
tRNASer meanc
a

Values were rounded to fit the table. bAll tRNA-Ser-AGA genes shown were predicted active in
H. sapiens. cMean values for all high confidence human tRNA-Ser genes characterized by
Thornlow B.P. et al (18).
As a secondary estimate of tRNA gene expression activity, we tabulated DNase
hypersensitivity sequencing and CHIP-sequencing data from encyclopedia of DNA elements
(ENCODE) (34) datasets available on the UCSC genome browser (51) First, we downloaded
tracks from DNaseI sequencing data ((35) K562, University of Washington) using custom
windows representing each tRNA gene sequence ± 350 bp of flanking sequence (Fig. 5.2B, S5.3BE). DNase I hypersensitivity sequencing uses partial digestion of chromatin with an endonuclease
(DNase I) followed by sequencing to map areas of open and closed chromatin in the genome, since
areas of open chromatin are more susceptible to endonucleolytic cleavage (53). Areas of open
chromatin also tend to be more transcriptionally active, meaning a high DNase sequencing score
is suggestive of higher expression at a given genomic locus. However, since different DNA
sequences are more readily detected in sequencing than others, and some sequences may be more
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amenable to DNase I activity than others, we report these data as merely a qualitative indicator of
tRNA gene expression activity. Based on data collected from human K562 cells, DNase I
sequencing peaks (Fig. S5.3) and descriptive statistics (Fig. 5.2B) suggested that expression
activity of the tRNA-Ser-AGA-2-n loci would occur roughly in order of 2-5 > 2-3 ~ 2-1 > 2-4 ~
2-2 > 2-6. We also found that most of the tRNA-Ser-AGA-2-n loci had generally higher DNase I
sequencing scores compared to the tRNA-Ser-AGA-1-1, 3-1, and 4-1 loci, with the exception of
tRNA-Ser-AGA-2-6, which had among the lowest scores.
CHIP-sequencing data can also be used to estimate tRNA gene expression activity. CHIPsequencing uses antibodies against DNA binding proteins to immunoprecipitate and sequence
chromatin fragments, giving a semi-quantitative readout of the relative binding propensity of
individual proteins based on read counts for the associated DNA sequence (54). By comparing
relative CHIP-sequencing scores from components of the RNA polymerase III transcription
initiation complex (24) on tRNA genes, qualitative inferences of tRNA gene expression activity
can be made. The basal transcription initiation machinery for tRNAs consists of three protein
complexes, the TFIIIB and TFIIIC complexes which bind to internal promoter sequences found
within the tRNA sequence (A and B box), and the RNA polymerase III complex (24). We searched
for CHIP-sequencing data from the encyclopedia of DNA elements (ENCODE) (34) accessed
through the UCSCS genome browser (51). The largest available datasets were gathered from K562
cells, so we limited our search to K562, and excluded any datasets where cells were treated or
stimulated, e.g., with growth factors or small molecules. We found high quality CHIP-sequencing
peaks for two proteins in the RNA polymerase III complex (gene names POLR3A, POLR3G),
three proteins in the TFIIIB complex (gene names TBP, BDP1, BRF1), and one protein in the
TFIIIC complex (gene name GTF3C2) (Fig. 5.2C; Table S5.4).
To compare the relative CHIP-sequencing scores for each transcription factor, we gathered
the peak maximum value found within each tRNA sequence for all human tRNA-Ser genes with
AGA anticodon. We then normalized the individual score at each tRNA gene locus to the mean
score of all the tRNA-Ser-AGA genes, such that a score of one represents the mean value for a
given transcription factor (Fig. 5.2D). Based on this analysis, we found the overall highest binding
activity for RNA polymerase III transcription initiation complex proteins occurred on the tRNASer-AGA-2-5 locus. We also observed elevated scores on the tRNA-Ser-AGA-2-1, 2-2, and 2-3

174

loci for certain factors, and generally lower binding activity on the AGA-1-1, -2-4, 2-6, and -3-1
loci. Hence, the CHIP-sequencing data suggest that expression activity of the tRNA-Ser-AGA-2n loci would occur roughly in order of 2-5 > 2-3 ~ 2-1 ~ 2-2 > 2-4 ~ 2-6 in human K562 cells.
Another observation we made based on the CHIP-sequencing data was that the tRNA-SerAGA-2-1 and 2-6 genes both had closely neighboring tRNA genes, such that peaks from
transcription factors binding to the nearby genes overlapped in the ± 350 bp windows capturing
the genomic loci (Fig. S3). For this reason, we decided to limit the remainder of our study to the
tRNA-Ser-AGA-2-2, 2-3 ,2-4, and 2-5 loci, which could be more easily isolated with their flanking
sequences.

5.3.4 Mistranslating tRNAs reduce protein synthesis to varying degrees
depending on local sequence context.
To test the effects of local sequence context on identical tRNA variants expressed in
mammalian cells, we PCR amplified a subset of the tRNA-Ser-AGA-2-n loci (2-2, -2-3, -2-4, and
-2-5) with local sequence context (± 300 bp; see Table 5.1) from HEK 293T cell genomic DNA
and cloned the tRNA alleles into plasmids that co-express an mCherry transfection marker. In each
gene, we created constructs with the corresponding G35A variant, which is naturally found in the
tRNA-Ser-AGA-2-3 and 2-2 loci (see Table 5.1).
In previous work, we observed a strong reduction in protein synthesis in cells expressing
the tRNA-Ser-AGA-2-3 G35A variant (8), and others have observed this effect from expressing
different synthetic anticodon variants of tRNASer (29,55). We transfected all plasmids expressing
wild-type or G35A tRNA genes and mCherry into K562 (Fig. 5.3A,D), HEK 293T (Fig. 5.3B,E),
and N2a cells (Fig. 5.3C,F) and measured mCherry fluorescence per cell using fluorescence
microscopy and a custom analysis macro in Fiji/ImageJ (see supplemental information). We also
used western blotting against mCherry (α-RFP) from HEK 293T cell lysates to confirm that
observed changes in fluorescence were associated with changes in mCherry protein expression
(Fig. 5.3G).
In K562 cells, mCherry fluorescence was reduced in cells expressing the variant compared
to wild-type tRNASer from all sequence contexts except the Ser-AGA-2-4 gene. We observed the
strongest reductions in cellular fluorescence when the variant was expressed from the tRNA Ser
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AGA-2-3 and AGA-2-5 contexts. Overall, we observed differential reductions in protein synthesis
that followed a trend of decreasing inhibition with 2-3 ~ 2-5 > 2-2 > 2-4. The results are in
reasonable agreement with the trends we predicted from K562 CHIP-sequencing and DNase
sequencing data (Fig. 5.2B,D).

Figure 5.3 Fluorescence of cells expressing tRNA-Ser-AAA-2-n variants. Plasmids encoding
mCherry and wild-type human tRNASerAGA or G35A variant tRNASerAAA with different flanking
sequence contexts from human tRNA-Ser-AGA-2-n genes were transfected in human K562 (A),
HEK 293T (B) and murine N2a (C) cells. Representative images were captured by fluorescence
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microscopy (A-C) and fluorescence was quantitated using custom Fiji/ImageJ macros (D-F; see
supplemental information) as previously described (8). Each box-and-whisker plot represents data
from at least N = 4 biological replicates (D-E). Midline represents the median, boxes represent
quartiles, and whiskers represent 1.5× the interquartile range. Dots show underlying datapoints
from individual cells. HEK 293T cell lysates from cells expressing no tRNA, tRNA-Ser-AAA-22, 2-3, and 2-5 genes were western blotted with α-RFP and α-GAPDH (G). Letters indicate
significantly different groups determined by Tukey’s Honestly Significant Different (HSD) tests
of biological replicate means, where groups sharing a letter are not significantly different and
groups not sharing a letter are significantly different (α = 0.05).
In HEK 293T cells, we observed a strong mistranslating tRNA variant-induced reduction
in mCherry fluorescence from all AGA-2-n sequence contexts (Fig. 5.3B,E), including the AGA2-4 context which had no effect in K562 cells (Fig. 5.3D). To our knowledge, this is the first known
example of identical human cytoplasmic tRNA genes being differentially regulated in different
cell types. We also observed in HEK 293T cells that the variant in the 2-5 context had a stronger
effect on mCherry fluorescence than in the 2-3 context. In N2a cells, we observed similar effects
to HEK 293T cells, where the Ser-AAA-2-5 gene variant caused the strongest reduction in cellular
mCherry fluorescence and the other contexts reduced fluorescence compared to their respective
wild-type tRNAs but not significantly differently from each other (Fig. 5.3C,F).

5.3.5 Precise detection of tRNA-dependent codon misreading with MSREAD.
Previously we demonstrated by liquid chromatography with tandem mass spectrometry
(LC-MS/MS) that the tRNA-Ser-AGA-2-3 G35A variant causes Phe to Ser mis-incorporation at
UUC codons in N2a cells (8). We hypothesized that the variant could also mistranslate UUU (Phe)
codons, and potentially UUA (Leu) codons, since wild-type tRNA-Ser-AGA tRNAs may be
modified at the A34 position to inosine (56), and A34I tRNAs can pair with codons ending in U,
C, or A (57-59). Given the strong reduction in protein synthesis that we observed was from
expressing the tRNA-Ser-AAA variant in the Ser-AGA-2-5 genetic context in HEK 293T cells,
we expected the 2-5 context to cause higher levels of mis-incorporation, allowing us to establish
exactly which codons the variant is capable of mis-coding with serine.

177

We also improved on our previous mass spectrometry approach which involved
immunoprecipitation of mCherry as a test protein for misincorporation events (8). In that approach,
we expressed wild-type or variant tRNA from the same plasmid as the mCherry test protein.
Hence, the timing of tRNA and reporter expression is coupled, and all transfected cells expressing
the reporter protein also express the tRNA variant. In this case, we fused a designer peptide
sequence (MS-READ) to mCherry to improve detection sensitivity (Fig. 5.4A). MS-READ is an
affinity purification combined with mass spectrometry approach which utilizes a designer peptide
readily detected in LC-MS/MS to identify all possible amino acid misincorporation events (43).
At the test site of the designer peptide, we cloned all UUN codons (UUA, UUC, UUG, and UUU)
and fused the peptide sequence to mCherry. The MS-READ-mCherry protein was co-expressed
with wild-type tRNA-Ser-AGA-2-5 or variant tRNA-Ser-AAA-2-5 on the same plasmid in HEK
293T cells. After 48hr transfection, we purified the MS-READ-mCherry protein by RFP-trap
immunoprecipitation (See Materials and Methods, Fig. S5.4) and analyzed the mCherry samples
by LC-MS/MS.
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Figure 5.4 tRNA-dependent Phe to Ser misincorporation detected by MS-READ. A cartoon
depicting the MS-READ reporter approach is shown (A). The MS-READ peptide-coding sequence
was mutagenized to include UUA, UUC, UUG, or UUU codons at the test position, and fused to
mCherry in a mammalian expression plasmid. From the same plasmid, we expressed wild-type
tRNASerAGA or the variant tRNASerAAA with flanking sequence context from the human tRNA-SerAGA-2-5 gene. High quality y and b ion spectra were obtained pertaining to the encoded Phe (B)
and Leu (Fig. S4), and the mistranslated Ser (C) peptide in cells expressing the tRNA variant with
UUC and UUU test codons in MS-READ (see also Table 5.5). Area-under-the-curve values from
the liquid chromatogram were used for quantitation, where mistranslated Ser peptide values were
normalized to the encoded Phe or Leu peptide value from the same sample (D), similarly to
published approaches (43). Error bars represent one standard deviation of the means of three
biological replicates.
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Table 5.5 LC-MS/MS area under the curve and spectral counts for MS-READ peptides.
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values from liquid chromatogram. bSpectral counts for number of spectra
with area > 1E6 and -10logP value > 50. cExpected amino acid refers to the amino acid encoded
by the test codon in the MS-READ peptide. dAmino acids refer to the detected amino acid in the
test position of the MS-READ peptide
aArea-under-the-curve

Complete area and spectral count results are described in Table 5.5 and exemplary y and b
ion spectra for all samples where Ser misincorporation was detected are provided in Fig. S5.5. We
observed high quality y and b ion spectra pertaining to the mistranslated Ser residue incorporated
at Phe UUC and UUU codons only when the variant tRNA was expressed (Table 5.5, Fig. S5.5),
and not in samples from any other tRNA or codon pair. In several other samples we observed a
single putative spectral count for Phe:Ser misincorporation (Table 5.5), but in these cases the y
and b ion spectra showed poor coverage of the misincorporation site (Fig. S5.5). As expected, in
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all samples we identified many high-quality peptide spectra pertaining to the properly encoded
Phe or Leu peptides (Fig. 5.4B, Table 5.5). For an estimate of mis-incorporation levels, we
normalized the abundance from the area under the chromatographic curves of the Ser peptides to
the respective Leu or Phe encoded peptide from the same sample, as others have described for
label-free quantitation using the MS-READ peptide (43). According to the estimate, the proportion
of Ser : Phe was 0.023 ± 0.002 when the variant tRNASerAAA and UUC test peptide were coexpressed and 0.036 ± 0.006 when the variant tRNASerAAA and UUU test peptide were coexpressed (Fig, 5.4D). For all other tRNA and codon pairs the Ser : Phe/Leu ratios were effectively
zero, since the un-normalized area-under-the-curve values for any putative mis-incorporation hits
were below background level (< 1x107). Hence, the tRNA-Ser-AGA-2-5 G35A variant is capable
of mistranslating both UUU and UUC Phe codons in HEK 293T cells, but Ser mistranslation at
Leu codons was not detected. These data also represent the first successful adaptation of MSREAD for detecting amino acid misincorporation in mammalian cells.

5.3.6 Cytotoxicity of a mistranslating tRNA variant expressed from different
sequence contexts.
In previous work, we demonstrated that the human tRNA-Ser-AGA-2-3 G35A variant is
cytotoxic when expressed in N2a cells, and that cytotoxicity is exacerbated by treating cells with
the proteasome inhibitor MG132 (8). To assess cytotoxicity of the tRNA variant in other sequence
contexts and cell lines, we transfected K562 (Fig. 5.5A), HEK 293T (Fig. 5.5B), and N2a (Fig.
5.5C) cells with wild-type or G35A variant tRNA-Ser-AGA in the 2-2, 2-3, 2-4, and 2-5 sequence
contexts expressed from our mCherry plasmids as above. Cytotoxicity was assessed with
CytoxGlo2.0 assays, which involved luminescent detection of cellular proteases released into the
medium by dying cells. In N2a cells, we observed significant cytotoxicity from the tRNA SerAAA
variants expressed from all sequence contexts, though we could not detect differences in
cytotoxicity when comparing the different sequence contexts to each other (Fig. 5.5C). In K562
and HEK 293T cells, we found cytotoxicity results to be highly variable and could not conclude
cytotoxic effects from any of the tRNA variants (Fig. 5.5A,B).
To further probe cytotoxicity in HEK 293T cells, we used a dye exclusion assay with
SYTOX Blue, a cell-impermeable nucleic acid stain, and subsequent treatment with a membrane
detergent (Triton X-100) to establish total cell counts, as previously described (see Chapter 4).
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Cells were assayed in the presence (Fig. S5.6B) or absence (Fig. S5.6A) of 10 μM MG132, and
after longer transfection periods (48 hr; Fig. S5.6C). Again, we were unable to detect significant
cytotoxic effects from the variant expressed from any of the sequence contexts in HEK 293T cells.
Hence, the tRNA-Ser-AGA-2-n G35A variants were not significantly cytotoxic to K562 or HEK
293T cells, but cytotoxicity was detected readily in N2a from all sequence contexts.

Figure 5.5 Cytotoxicity of tRNASerAAA variants in different cell lines and sequence contexts.
Plasmids encoding mCherry and wild-type human tRNA SerAGA or variant tRNASerAAA with
different flanking sequence contexts from human tRNA-Ser-AGA-2 genes were transfected in
human K562 (A), HEK 293T (B) and murine N2a (C) cells. Cytotoxicity was determined after 24
hr transfection using Cytotoxglo assays (see Materials and Methods). Letters indicate significantly
different groups determined by Tukey’s Honestly Significant Different (HSD) tests of at least three
biological replicates, where groups sharing a letter are not significantly different and groups not
sharing a letter are significantly different (α = 0.05).
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5.3.7 Migration kinetics of cells expressing a mistranslating tRNA variant
expressed from different sequence contexts.
Given that we could not reliably detect cytotoxicity of the tRNASerAAA variant expressed from
different sequence contexts in K562 or HEK 293T cells, we sought to test other phenotypic assays
which could be used to compare identical tRNA variants in cells. In previous work, we found that
the tRNA-Ser-AGA-2-3 G35A variant caused perturbations to protein homeostasis, reducing
protein synthesis but also reducing protein turnover rates in N2a cells (2). Others have observed
similar perturbations to protein homeostasis in yeast (60) and mammalian cells (7,29,55) that
expressed different anticodon variants of tRNASer. Since mistranslating tRNAs cause defects in
protein synthesis and degradation, we hypothesized that cellular processes that require active
protein synthesis and turnover would be sensitive to mistranslation. One such process is cell
migration. For example, others have shown that knockdown of ribosomal protein S6 (61)
suppresses migration and proliferation of ovarian cancer cells.
To assay cell migration in mistranslating cells, we devised several modifications to
standard wound healing assays that would render the assay highly sensitive to the effects of tRNAdependent mistranslation (see Materials and Methods). To track cell migration we used live cell
fluorescence microscopy, capturing images of red fluorescing cells every 30 min over a 15 hr time
course. We analyzed the data using a particle tracking software package in Fiji (TrackMate (45)).
As others have demonstrated, TrackMate can be used to quantitate migration of fluorescently
labeled cells from live-cell imaging data with single-cell resolution (46,47). With this approach,
we tracked the movement of individual HEK 293T cells transfected with plasmids expressing
mCherry and wild-type tRNASerAGA or tRNASerAAA from the -2-2, -2-3, or -2-5 sequence contexts
(Fig. 5.6A). We also assayed migration in the presence or absence of 10 µM MG132 to inhibit the
proteasome, which exacerbated tRNASerAAA cytotoxicity in N2a cells (8).
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Figure 5.6 Migration kinetics of cells expressing tRNA-Ser-AAA-2-n variants. Plasmids
encoding mCherry and wild-type human tRNASerAGA or variant tRNASerAAA with different flanking
sequence contexts from human tRNA-Ser-AGA-2 genes were transfected in HEK 293T cells.
Migration velocity of fluorescing cells was measured using a wound healing assay combined with
cell tracking in Fiji/ImageJ (A; see Materials and Methods, Supplemental appendix). Each boxand-whisker plot represents data from three biological replicates (B). Midline represents the
median, boxes represent quartiles, and whiskers represent 1.5× the interquartile range. Dots show
underlying datapoints from individual tracks detected with TrackMate. Stars indicate statistically
significant differences of biological replicate means determine by independent sample t-tests (n.s.
= not significant, * = p-value <0.05)
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In DMSO control, we could not detect significant changes to migration velocity in cells
expressing the tRNA variant in any of the tested sequence contexts (Fig. 5.6). In MG132 treated
cells, we detected a significant 1.17 ± 0.02-fold reduction (p = 0.013) in cell migration velocity in
the tRNA-Ser-AAA-2-3 expressing cells compared to cells expressing tRNA-Ser-AGA-2-3 (Fig.
5.6). Compared to cells expressing no tRNA, tRNA-Ser-AAA-2-3 reduced cell migration by 1.29
± 0.02-fold (p = 0.02). Hence, in cells treated with a proteasome inhibitor, tRNA-dependent
mistranslation suppressed cell migration. To our knowledge, this is the first example of a natural
human tRNA variant altering migration kinetics in human cells. In cells expressing the variant
from the -2-2 context and 2-5 contexts, we could not detect a significant change in cell migration
velocity (Fig. 5.6). We note that our detection sensitivity was limited in the tRNA-Ser-AAA-2-5
+ MG132 population as cellular fluorescence was severely reduced (see also Fig. 5.3B). Further
refinement of this assay may be required for optimal detection sensitivity. However, we have
shown for the first time that human tRNA variants can act as modifiers of cell migration activity
in cells treated with a proteasome inhibitor.

5.4 Discussion
5.4.1 tRNA gene copy number does not imply redundancy.
The theoretical minimum number of tRNA genes required for an organism to decode all
61 sense codons is 32, since tRNAs are capable of decoding multiple codons through G:U pairing
and modification of nucleotides in the anticodon (57,58). Most eukaryotes far exceed this
theoretical minimum, harboring hundreds to thousands of tRNA genes, many of which are
predicted to be functional (15). In humans, the most recent estimates suggest 416 functional tRNA
genes (15). Excessive tRNA gene counts provide a buffer for the occurrence of variants, which
occur commonly in tRNA genes via transcription associated mutagenesis (20). Many of these
variants exist in the genomes of healthy individuals, as we and others have revealed in sequencing
studies (1,30,31).
Despite the apparent “buffering capacity” of the tRNAome, tRNA copy numbers are not
uniform across isodecoder groups (15), so mutations in some tRNA genes with fewer equivalent
copies may be more deleterious. The most striking example of this being the single-copy human
selenocysteine tRNA gene (15,62), mutation in which has been linked to a rare disease
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characterized by abdominal pain, fatigue, muscle weakness and low plasma selenium levels (9).
Numerous links to disease have also been established with variants in mitochondrial tRNAs
(63,64), which comprise of only 22 tRNA genes (64). Remarkably, human mitochondria use an
alternative genetic code to defy the theoretical minimum number of tRNA genes established for
the standard genetic code (65). Even in cytosolic tRNA isodecoder groups with higher tRNA gene
copy numbers, tissue-specific sensitivities can exist, since some tRNA genes are only transcribed
in certain tissues (5). Transfer RNA mutation sensitivities may also arise from changes in tRNA
regulation that occur in different cell states. For example, changes in cellular tRNA pools have
been reported in differentiating versus proliferating cells (66,67).
Our work expands on our understanding of redundancy in tRNA genes by demonstrating
that even identical tRNA genes can be regulated differently in different cell lines, as others have
predicted bioinformatically (18). Hence, as our understanding of variation sensitivity in specific
human tRNA genes grows, characterization of not only specific tRNA sequences but also their
genomic context will be essential. Our work also demonstrates experimentally that data from DNA
sequence-based predictions (18), DNase hypersensitivity sequencing (34,35), and CHIPsequencing (34,54) provide a reasonable but not definitive estimation of tRNA gene activity in
human cell lines. For example, our observation that expression of the tRNA SerAAA variant in K562
cells from the tRNA-Ser-AGA-2-5 gene context had a stronger effect on mCherry fluorescence
compared to expression from the tRNA-Ser-AGA-2-4 context was in excellent agreement with our
predictions based on the K562 cell DNase hypersensitivity and CHIP sequencing data. However,
we had not predicted that expression of the variant from the tRNA-Ser-AGA-2-3 context would
have an equivalent effect to expression from the tRNA-Ser-AGA-2-5 context, and a stronger effect
than expression from the tRNA-Ser-AGA-2-2 context.

5.4.2 Using variants as tools to detect tRNA expression.
Our tRNA sequencing data demonstrate that tRNASerAAA was expressed and detectable
against a highly repetitive background of tRNA sequences in murine N2a cells. By contrast, we
were unable to discriminate expressed wild-type tRNASerAGA from identical endogenous tRNAs,
as expected. Hence, the inclusion of a variant in expressed tRNAs could represent a valuable
approach to detect expression levels of tRNAs that are encoded at multiple genomic loci. While
our ability to make quantitative comparisons was limited in transiently transfected cells, we
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anticipate that tRNAseq will be a valuable method to study tRNA variant expression in more
homogenous cell populations, such as patient-derived cells or knock-in cell lines created by
genome editing. Knowing that the tRNASerAAA variant is detectable and elicits clear phenotypes
which we have characterized in this and other works (see chapter 4, (8)), genome-integrated cell
lines expressing this variant will form the basis of future studies.

5.4.3 Detecting amino acid misincorporation by mass spectrometry.
Detecting low level amino acid mis-incorporation events caused by tRNA variants is not
trivial and requires further research. We and others have developed fluorescent reporters for this
purpose, which detect amino acid misincorporation by reversing a disabling mutation in a
fluorescent protein (29,40,68). In many cases, these fluorescent reporters have proven effective in
detecting mistranslation caused by mutant tRNA genes. However, many tRNA variants that cause
amino acid misincorporation, including the tRNA SerAAA variant studied here, also lead to severe
reductions in protein synthesis in mammalian cells (8,29,55). This limits the sensitivity of
fluorescent mistranslation reporters since higher mistranslation levels result in lower expression
of the reporter protein. Some reporters have been developed to account for this phenomenon, by
fusing the inactive fluorescent protein to a differently colored, active fluorescent protein (40). This
provides a control for reporter expression, where fluorescence of the test protein is normalized to
fluorescence of the active protein. We are currently optimizing reporters based on this design, and
the mass spectrometry data here will provide a means of validating reporter efficacy.
In this work, we improved upon current mass spectrometry methods for detecting amino
acid mis-incorporation in mammalian cells by adapting a technique developed for detecting
mistranslation in yeast and Escherichia coli (43). MS-READ is an affinity purification combined
with LC-MS/MS approach that utilizes a designer peptide optimized for detection by mass
spectrometry with any of the proteinogenic amino acids encoded at a central test residue (43). The
test peptide is fused to a readily purified fluorescent protein allowing purification in high yields.
The advantage of this method is that amino acid misincorporation events can be detected
unambiguously, and high sensitivity can be achieved by optimizing reporter purification.
In mammalian cells, large batch protein purifications are often prohibitively expensive,
especially for academic laboratories. However, we found in previous work that suitable yields of
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mCherry protein for mass spectrometry could be obtained from 20 mL cultures of N2a cells grown
on 3 x 10 cm plates (8), by immunoprecipitating mCherry with α-RFP nanobody-conjugated
agarose beads (RFP-trap; developed by Chromotek). Here we optimized this approach further, by
expressing the tRNAs and reporter in HEK 293T cells and making some adjustments to our
protocol such that complete yields could be loaded in a single SDS-PAGE well. HEK 293T cells
have been modified from their parental HEK 293 line for high expression of recombinant proteins
from plasmids using the Simian Virus 40 (SV40) promoter sequence (69). For this reason, HEK
293T cells are a preferred cell line for high expression of recombinant proteins (70). With our
improved expression and purification approach combined with MS-READ reporter proteins, we
readily detected Phe to Ser misincorporation from replicates of single 10 cm HEK 293T cell
cultures (7 mL volume). Thus, we have demonstrated a more feasible and cost-effective strategy
to detect amino acid misincorporation by mass spectrometry in mammalian cells.

5.4.4 Phenotypic assays enable high sensitivity and throughput in tRNA
variant testing.
Given the immense number of tRNA genes (15) and variants (1,30,31) in human genomes
and populations, the ability to test variants in high throughput will be essential in characterizing
which naturally occurring variants have the strongest potential to act as disease modifiers. As we
and others have shown here and previously (19,50), the ability to make quantitative inferences
about the expression of specific tRNAs and variants is limited by the highly repetitive nature of
tRNA sequences. For this reason, tRNA sequencing can only resolve changes in expression of
highly unique tRNA sequences, and multi-copy tRNAs must be discussed as a conglomerate or
pool of identical or highly similar sequences.
Another challenge associated with the study of tRNA genes is that most popular antibiotics
used to establish stably selected mammalian cell lines act on the ribosome (Table 5.6). Hence, the
use of selectable markers in tRNA studies is likely to influence physiological observations. Indeed,
the only well characterized antibiotic used to select transfected mammalian cell lines that does not
act on the ribosome is Zeocin, which others have shown induces DNA cleavage even in resistant
human cells (71). Further, selectable markers can significantly influence proteins synthesis rates
in mammalian cells (72), making it difficult to compare the effects of tRNA genes on protein
synthesis in selected cell lines. For these reasons we have general avoided the use of antibiotic
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selection markers in our previous studies on tRNA genes (8), and chose to tailor our investigations
in this work to methods which can be done in transiently transfected cells.
Table 5.6. Mechanism of action of common selectable markers used in mammalian cell line
selection.
Antibiotic

Mechanism of action

References

Blasticidin

Inhibits peptidyl-tRNA hydrolysis in the ribosome

(73,74)

Puromycin

Integrates into elongating nascent peptides, causing
premature termination of translation

(75)

G418
(geneticin)

Interferes with mRNA translation elongation

(76)

Interferes with ribosomal translocation and
aminoacyl-tRNA recognition

(77)

Intercalates DNA, inducing single and double strand
breaks

(78)

Hygromycin B
Zeocin

In this work, we demonstrated the value of using local flanking sequence from human
tRNA genes found in the genome to express a well characterized gain-of-function tRNA
mistranslator. This allowed us to probe the contributions of flanking sequence to activity of
identical tRNA genes. With this approach, we found that phenotypic effects can be used to
compare tRNA gene activity in transiently transfected cells. For example, we found that expressing
the tRNASerAAA variant from sequence context found around the human tRNA-Ser-AGA-2-4 gene
caused a reduction in protein synthesis in human HEK 293T and murine N2a cells, but not in
human K562 cells. While behaviors in cell lines are only models of the biology in real human
tissues (79), the same approach could be used in transfected primary cells (80) for a more clinically
relevant investigation. A major challenge in studies using primary cells and certain disease-model
cell lines is that transfection efficiency is typically poor compared to more commonly used cell
lines (81). Since the assays we described are fluorescence-based and can be quantitated with
automated image analysis software, they can be employed with single cell resolution even in cells
where high transfection efficiency cannot be achieved. Thus, our work opens new possibilities for
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exploring the biology of natural human tRNA variants in systems with increasing potential for
translational discoveries.
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5.7 Supplemental information
5.7.1 Supplemental methods
tRNA sequencing.
The following text describes sample prep and tRNA sequencing methods as reported by
Arraystar Inc. For transfection and cell harvesting details, see Materials and Methods.

RNA sample QC.
Integrality of total RNA samples was checked using denaturing agarose electrophoresis, in
which the 28S and 18S ribosomal bands of samples should be fairly sharped, intense bands and
the intensity of upper 28S bands should be about twice of the lower 18S bands. Quantification of
total RNA samples was done using NanoDrop ND-1000 instrument.

tRNA isolation.
tRNA was isolated from total RNA using Denaturing Urea Polyacrylamide Gel
Electrophoresis (Urea PAGE) method. Over 2µg total RNA was resolved on 7.5% Urea PAGE
gels (7M Urea) and recovered within a size window of 60-100 nt for tRNA.

tRNA demethylation.
Reagents: rtStarTM tRF&tiRNA Pretreatment Kit (Arraystar, AS-FS-005)
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Procedures: ‘Demethylation’section in rtStarTM tRF&tiRNA Pretreatment Kit was used for tRNA
m1A&m3C demethylation treatment. 50 µL demethylation reaction mixture was prepared
according to the manufacturer’s protocol and incubated at 37°C for 2 hr. Then 40 µL nuclease-free
water and 10 µL 5×Stop Buffer were added to terminate the reaction. Demethylated tRNA was
purified by phenol-chloroform extraction and ethanol precipitation.

Partial Hydrolysis of tRNA (Hydro-tRNAseq).
Demethylated tRNA was partially hydrolyzed according to Hydro-tRNAseq method with
little modification (50). tRNA was subjected to limited alkaline hydrolysis in a 15 µL buffer of
10mM Na2CO3 and 10mM NaHCO3 (pH 9.7) at 90°C for 7 min. The partially hydrolyzed tRNA
was dephosphorylated with 10 U Calf Intestinal Alkaline Phosphatase (CIP; New England Biolabs,
M0290L) in a 50 µl reaction of 100mM NaCl, 50 mM Tris-HCl (pH 7.9), and 10 mM MgCl2,
1mM DTT, 3mM Na2CO3, 3mM NaHCO3, at 37°C for 1hr. The resulting tRNA was purified
with TRIzol reagent and then re-phosphorylated with 10 U T4 polynucleotide kinase (New
England Biolabs, M0201L) in a 20 µl reaction of 70 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 5
mM DTT, and 1 mM ATP at 37°C for 1 hr. TRIzol reagent purification was performed once more.

Library preparation.
Partially hydrolyzed tRNA fragments were converted to barcoded small RNA sequencing
libraries using NEBNext® Multiplex Small RNA Library Prep Set for Illumina® kit (New
England Biolabs, E7300L/E7850L) according to manufacturer’s instructions. The procedures
generally included: 1) 3’-adapter ligation; 2) 3’-adapter blocking; 3) 5’-adapter ligation; 4) reverse
transcription; 5) PCR amplification; 6) size selection of ~140-155 bp PCR amplified fragments
(corresponding to ~19-35nt tRNA fragments) using 6% PolyAcrylamide Gel (PAGE). The
completed libraries were qualified and quantified by Agilent 2100 Bioanalyzer. Equal amount of
Hydro-tRNAseq libraries were mixed for following sequencing on Illumina NextSeq 500
instrument.
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Sequencing.
The DNA fragments in well mixed libraries were denatured with 0.1M NaOH to generate
single-stranded DNA molecules, and loaded onto the reagent cartridge (NextSeq 500/550 HighOutput v2 kit) at a loading concentration. The sequencing run was performed on Illumina NextSeq
500 system and carried out by running 50 cycles.

Data analysis.
Sequencing quality was examined by FastQC software (82) and trimmed reads (pass
Illumina quality filter, trimmed 3’-adaptor bases by cutadapt (83)) were aligned to the cytoplasmic
mature-tRNA sequence getting from GtRNAdb (15) and the mitochondrial mature-tRNA
sequences getting from mitotRNAdb (84) using BWA (85) software. For tRNA alignment, the
maximum mismatch was 2 (50). The tRNAs expression profiling was calculated based on uniquely
mapped reads and including mapped reads, respectively. The differentially expressed tRNAs were
screened based on the count value with R package edgeR (86).

5.7.2 Supplemental tables
Table S5.1. Oligonucleotide sequences
Description
tRNA-Ser-AGA-2-2 genomic
PCR (Fwd)
tRNA-Ser-AGA-2-2 genomic
PCR (Rev)
tRNA-Ser-AGA-2-2 nested
PCR with PciI cloning site
(Fwd)
tRNA-Ser-AGA-2-2 nested
PCR with PciI cloning site
(Rev)
tRNA-Ser-AGA-2-3 genomic
PCR (Fwd)
tRNA-Ser-AGA-2-3 genomic
PCR (Rev)
tRNA-Ser-AGA-2-3 nested
PCR with PciI cloning site
(Fwd)

Nucleotide sequence
AAAATGCCGTGCAAACGAG
CAATACCTGCGCTCCGTTG
CAGACTACATGTGTGTCAGGCCCAGATTTAC
CAGACTACATGTCCCCAAACTGAAAGCAAATATG
CCTGGAAGTCCGAACACC
GTGAACACAAAGATGAGAGACACC
CAGACTACATGTGTTGGCCATGACTCCCC
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tRNA-Ser-AGA-2-3 nested
PCR with PciI cloning site
(Rev)
tRNA-Ser-AGA-2-4 genomic
PCR (Fwd)
tRNA-Ser-AGA-2-4 genomic
PCR (Rev)
tRNA-Ser-AGA-2-4 nested
PCR with PciI cloning site
(Fwd)
tRNA-Ser-AGA-2-4 nested
PCR with PciI cloning site
(Rev)
tRNA-Ser-AGA-2-5 genomic
PCR (Fwd)
tRNA-Ser-AGA-2-5 genomic
PCR (Rev)
tRNA-Ser-AGA-2-5 nested
PCR with PciI cloning site
(Fwd)
tRNA-Ser-AGA-2-5 nested
PCR with PciI cloning site
(Rev)
tRNA-Ser-AGA to G35A
mutagenesis (Fwd)
tRNA-Ser-AGA to G35A
mutagenesis (Rev)
MS-READ (TTA) insert with
BamHI/EcoRI overhangs (Fwd)
MS-READ (TTA) insert with
BamHI/EcoRI overhangs (Rev)
MS-READ (TTC) insert with
BamHI/EcoRI overhangs (Fwd)
MS-READ (TTC) insert with
BamHI/EcoRI overhangs (Rev)
MS-READ (TTG) insert with
BamHI/EcoRI overhangs (Fwd)
MS-READ (TTG) insert with
BamHI/EcoRI overhangs (Rev)

CAGACTACATGTGCAATTCCGTGAGGGAAATTCG

AGTGGACATCCTTGCATCG
CTTTAATCTGCCGCCTAAGC
CAGACTACATGTTCCACTGCCAGAGCTCAG
CAGACTACATGTCTTGGACCTCTGACTAGGAC
TTATGGCACGGTGGGACTG
CTTTTCCCCTCCAATCGCC
CAGACTACATGTGTTCCTGGTTCTCTCCTGG
CAGACTACATGTGGGCTCGCGGCAGAGAAC
GCGATGGACTAAAAATCCATTGGGGTCTCCCC
CCAATGGATTTTTAGTCCATCGCCTTAACCACTC
AATTCGCCACCATGTCTAAAGGGCCAGGTAAAGTT
CCAGGAGCCGGAGTTCCTGGATTAGGGGTGCCTGG
AGTTGGAAAAGGAGGCGGCACCTCG
GATCCGAGGTGCCGCCTCCTTTTCCAACTCCAGGC
ACCCCTAATCCAGGAACTCCGGCTCCTGGAACTTT
ACCTGGCCCTTTAGACATGGTGGCG
AATTCGCCACCATGTCTAAAGGGCCAGGTAAAGTT
CCAGGAGCCGGAGTTCCTGGATTCGGGGTGCCTGG
AGTTGGAAAAGGAGGCGGCACCTCG
GATCCGAGGTGCCGCCTCCTTTTCCAACTCCAGGC
ACCCCGAATCCAGGAACTCCGGCTCCTGGAACTTT
ACCTGGCCCTTTAGACATGGTGGCG
AATTCGCCACCATGTCTAAAGGGCCAGGTAAAGTT
CCAGGAGCCGGAGTTCCTGGATTGGGGGTGCCTGG
AGTTGGAAAAGGAGGCGGCACCTCG
GATCCGAGGTGCCGCCTCCTTTTCCAACTCCAGGC
ACCCCCAATCCAGGAACTCCGGCTCCTGGAACTTT
ACCTGGCCCTTTAGACATGGTGGCG

197

MS-READ (TTT) insert with
BamHI/EcoRI overhangs (Fwd)
MS-READ (TTT) insert with
BamHI/EcoRI overhangs (Rev)

AATTCGCCACCATGTCTAAAGGGCCAGGTAAAGTT
CCAGGAGCCGGAGTTCCTGGATTTGGGGTGCCTGG
AGTTGGAAAAGGAGGCGGCACCTCG
GATCCGAGGTGCCGCCTCCTTTTCCAACTCCAGGC
ACCCCAAATCCAGGAACTCCGGCTCCTGGAACTTT
ACCTGGCCCTTTAGACATGGTGGCG

Table S5.2. tRNAseq RNA yields and purity.
Sample ID

A260/280
A260/230
Conc. (ng/μl) Quantity
1
2
Ratio
Ratio
(ng)
AGA-1
2.09
2.15
912.02
89378.1
AGA-2
2.1
1.9
655.16
64205.4
AGA-3
2.1
2.05
910.53
89231.8
AAA-1
2.1
2.08
995.49
97558.3
AAA-2
2.09
2.17
908.33
89016.2
AAA-3
2.08
2.17
1329.53
130293.8
1
A = absorbance (optical density). A260/A280 ratio should be close to 2.0 for pure RNA (ratios
between 1.8 and 2.1 are acceptable). 2A260/A230 ratio should be more than 1.8.
Table S5.3. tRNAseq read mapping summary
Sample
(tRNAreplicate)
AGA-1
AGA-2
AGA-3
AAA-1
AAA-2
AAA-3

Clean
Reads

Trimmed
Reads

Mapped
Reads

Mapped
(%)

Unique

Unique
(%)

5277545
6934385
7309565
6109477
5672373
7231950

2987367
1656226
2836550
2296773
3666402
2495504

626548
726798
1211436
738696
786928
1023582

20.97
43.88
42.71
32.16
21.46
41.02

247994
266903
416086
268425
337544
359828

8.3
16.12
14.67
11.69
9.21
14.42
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Table S5.4. UCSC genome browser data representing basal tRNA transcription initiation
complex proteins.
Gene name
(track name)1
TBP

Protein full name

Transcription
initiation
complex
TFIIIB

Data source
(lab)

Cell line

TATA-binding
ENCODE
K562
protein
(Stanford)
BDP1
Transcription factor
TFIIIB
ENCODE
K562
TFIIIB component B”
(Harvard)
homolog
BRF1
Transcription factor
TFIIIB
ENCODE
K562
IIIB 90 kDa subunit
(Harvard)
POLR3A
DNA-directed RNA
Pol III
ENCODE
K562
(RPC155)
polymerase III
(Harvard)
subunit RPC1
POLR3G
DNA-direscted RNA
Pol III
ENCODE
K562
(POL3)
polymerase III
(Stanford)
subunit RPC7
GTF3C2
General transcription
TFIIIC
ENCODE
K562
(TFIIIC110)
factor 3C polypeptide
(Harvard)
2
1
track name displayed on UCSC genome browser if different from standardized gene name.
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5.7.3 Supplemental figures

Figure S5.1. tRNA-Ser-AGA-2-n gene alignment. tRNA-Ser-AGA-2-n genes and flanking
sequences captured by our genomic PCR primers (Table 5.2, S5.1) were aligned using T-Coffee
(see Materials and Methods). Alignments were visualized and colored by sequence identity in
Jalview. Sequence encoding the identical tRNA genes is labeled (tRNA gene).
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Figure S5.2. tRNAseq transfection images. N2a cells were transfected with a plasmid encoding
human wild-type tRNASerAGA (A) or tRNASerAAA G35A variant (B; expressed from human tRNASer-AGA-2-3 gene flanking sequence context) and mCherry (see Materials and Methods).
Representative fluorescent microscopy images used for transfection efficiency counting are
shown.
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Figure S5.3. CHIP-seq and DNase-seq data for all tRNA-Ser-AGA genes. UCSC genome
browser tracks showing K562 cell CHIP-Seq and DNase-seq data from ENCODE datasets for all
high confidence human tRNA-Ser-AGA genes with ± 350 bp flanking sequence. See Results
section 5.3.3 and Table S5.4 for details on data sources. Transfer RNA gene coordinates were
found on GtRNAdb.
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Figure S5.4. Representative y and b ion spectra for Leu containing MS-READ peptides.
Detailed y and b ion spectra for MS-READ peptides containing Leu encoded by UUA (A) or UUG
(B) codons.

Figure S5.5. Representative y and b ion spectra for Ser-containing MS-READ peptides. The
highest quality y and b ion spectra containing putative Ser misincorporation from each
tRNA:codon pair tested in MS-READ LC-MS/MS experiment are shown. Expressed tRNA and
MS-READ-mCherry reporter proteins are labeled above the spectra. Numbers in brackets indicate
spectral counts for total peptides detected from the same tRNA:codon pair (see also Table 5.6).
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Figure S5.6. Supplemental HEK 293T cell cytotoxicity data. Plasmids encoding mCherry and
wild-type human tRNASerAGA or variant tRNASerAAA with different flanking sequence contexts
from human tRNA-Ser-AGA-2 genes were transfected HEK293T cells for 24 hr (A,B) or 48 hr
(C). Cells transfected for 24 hr (A,B) were also treated with 10 µM MG132 or vehicle (DMSO)
for 4 hours before assays (see Materials and Methods). Cytotoxicity was measured using dye
exclusion assays with SYTOX Blue as previously described (see Chapter 4, Materials and
Methods). Statistical significance was determined by Tukey’s Honestly Significant difference tests
(α = 0.05). No statistically significant differences were found (n.s.)
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5.7.4 Appendix: Fiji/ImageJ macros and TrackMate analysis
Fiji/Image J macros.
Fiji/ImageJ (version 1.53f51 (44); Java version 1.8.0_172 (64-bit)) scripts to measure the
fluorescence and analyze images of transfected cells. All macros were run on 16-bit, singlechannel images.

Fiji/ImageJ macros used in Figure 5.3 D-E - Mean fluorescence/cell area
plots.
Fluorescence in regions of interest was measured using the following Fiji/ImageJ macro,
which is almost identical to our previously described approach (8). Threshold values were tailored
slightly to exclude differences in background fluorescence from the different cell line images
(K562, HEK293T, N2a), but the same settings were used to analyze all images for a given cell
line. Data outputs were processed in Microsoft Excel, where means of biological replicates were
calculated and statistical differences were determined using ANOVA followed by Tukey’s
Honestly Significant Difference tests (α = 0.05). Box and whisker plots with strip plot overlays
were created in R.
//Open image. Replace “file name” with desired image directory.
open("file name");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50");
//Set threshold to exclude pixels below chosen intensity cutoff (6 in this case). Fine-tune according
to your image brightness and use same cutoff for all images in one experiment.
setThreshold(6, 255);
//Next two lines convert to black on white mask image
setOption("BlackBackground", false);
run("Convert to Mask");
//Remove noise with despeckle function.
run("Despeckle");
//Separate closely adjacent objects with watershed function.
run("Watershed");
//Create annotations covering area above threshold. Excludes objects of area under chosen size
cut-off (100 pixels in this case). Size cut-off should be adjusted depending on the magnification
of the image and the size of objects you wish to exclude (noise).
run("Analyze Particles...", "size=100-Infinity display clear summarize add");
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//Clear results. Steps so far to are to create region of interest annotations (ROIs), results will be
collected in following steps.
run("Clear Results");
//Import unmodified image again. Should be identical to line 1
open("file name");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50");
//The next two lines overlay the ROIs from the thresholded on the non-thresholded image.
roiManager("Show None");
roiManager("Show All");
//Set measurements to record area, mean, and integrated density to 3 decimal places, then measure.
“Mean” is the quotient of (integrated density) / (area).
run("Set Measurements...", "area mean integrated redirect=None decimal=3");
//Measure.
roiManager("Measure");

Fiji/ImageJ analysis of cell migration kinetics using TrackMate.
Image series were imported to Fiji/ImageJ and background-subtracted with the macro
below (A). Settings used in the TrackMate user interface for analysis are listed (B). Tracks of
duration < 3 frames were excluded (step 7). Mean speed values for each track were processed in
Microsoft Excel, where means of biological replicates were calculated and statistical differences
were determined using independent sample t-tests. Box and whisker plots with strip plot overlays
were created in R.
A) Macro for importing image sequence.
//Open image series. Replace “folder name” with desired image series directory.
run("Image Sequence...", "dir=[“folder name”] type=16-bit start=2 count=30 step=3 sort");
//Subtract background signal using rolling circle method with radius of 50 pixels.
run("Subtract Background...", "rolling=50 stack");
//Open TrackMate plugin
run("TrackMate");
B) TrackMate settings.
1)
2)

Swap Z and T
LoG detector
20 pixel
0.3 quality threshold
no median filtering
do subpixel localization
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3)
4)
5)
6)

7)
8)

Median filtering
skip
Set filters on spots
skip
Select a tracker
simple LAP tracker
Settings for tracker
20.0 pixel linking
20.0 pixel gap-closing max
2 frame gap-closing max
Set filters on tracks
track duration above 2.91
Display options
tracks --> click tracks tab on left, export to csv
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Chapter 6
6. Conclusions and future perspectives
6.1 Summary and conclusions
The existence of transfer RNAs was first predicted in 1955 (1), and by 1958 the
contribution of soluble RNAs in delivering amino acids to translating ribosomes had been
demonstrated in vitro (2). The first transfer RNA sequence was described in 1965 (3), and in the
decades that followed, extensive work would reveal how tRNAs maintain the relationship between
the genetic code and amino acid sequences in proteins (4). Despite the long history of tRNA
research, their inherent complexity and a series of challenges unique to their study have limited
the depth of our understanding of how tRNAs behave (or misbehave) in human cells — especially
in models of disease.
The subject of my thesis was inspired by a surprising discovery, where a genetic suppressor
screen in yeast revealed a tRNA variant as a suppressor of a toxic loss-of-function mutation in a
chaperone protein (Tti2L187P) (5). The tRNA mutation, characterized by Hoffman et al in 2017,
caused a yeast tRNAPro to be mis-aminoacylated with alanine by AlaRS. This resulted in low-level
(~5%) Pro to Ala amino acid misincorporation, which effectively restored a proportion of the
expressed Tti2L187P chaperone protein to a functional Tti2L187A variant. tRNAAla is a unique case in
terms of interaction with its aminoacyl-tRNA synthetase, where a single base-pair in the tRNA
acceptor stem (G3:U70) is sufficient for recognition (4,6). Indeed, early studies on the identity
determinants of tRNAAla revealed that introducing a single G3:U70 pair in other tRNAs can be
sufficient for mis-aminoacylation by AlaRS (6).
Intrigued by the work of Hoffman et al, we tested an equivalent mutation in human tRNAPro
(G3:U70) for mistranslation in mammalian HEK293 cells ((7), Chapter 2). In mammalian cells,
we found the levels of mistranslation to be generally lower than in yeast (~2%), but still detectable.
We observed this in cells deprived of serum and glucose, which acted to slow cell division and
promote accumulation of mis-made proteins. Surprisingly, despite the ~2% amino acid
misincorporation, we could not detect a significant loss of cellular viability, or induction of a heat
shock response in HEK293 cells expressing the tRNA variant, as had been observed in yeast.
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Hence, HEK293 cells tolerated the amino acid misincorporation well. This is in agreement with
other studies of tRNA variants in cancerous or embryonic cells, where toxicity of mistranslation
is not always evident (8,9), or can vary greatly depending on the type of amino acid
misincorporation (10). In Chapter 5, we showed that cell types can also be an important factor in
the toxicity of tRNA variants, where tRNA variants that mistranslate Phe to Ser had clear cytotoxic
effects in murine neuroblastoma (N2a) cells but not human HEK293 or K562 cells.
Given that human cells can tolerate, at some level, mistranslation caused by mutations in
tRNAs, we began investigating the prevalence of human tRNA variants that cause amino acid
misincorporation in the human population ((11), Chapter 1). We narrowed our search based on the
logic that: 1) most aminoacyl-tRNA synthetases recognize the anticodon during amino acid
ligation and 2) most tRNAs make multiple essential contacts with aminoacyl-tRNA synthetases
(called identity elements or identity determinants, (4)). This refined our search to several cases
where a single nucleotide variant in a tRNA could cause amino acid misincorporation, since many
variants would either render the tRNA non-functional, or be insufficient to confer novel identity
to a tRNA sequence. Firstly, tRNAs Ser, Ala, and to a lesser extent Leu, do not require specific
sequences in the anticodon for recognition by their cognate aminoacyl-tRNA synthetases (4).
Hence, non-synonymous anticodon mutations in Ser, Ala, and Leu tRNAs can read noncognate
codons without compromising aminoacylation efficiency. The second exception was the case of
tRNAAla and its single identity element, G3:U70. Since only a single base pair is required for
AlaRS to recognize tRNAs, any tRNA already possessing a G at position 3 or U at position 70
would require only a single nucleotide variant to become a potential alanine acceptor (5-7).
Our search for mistranslating tRNAs in data from the 1000 genomes project (12,13) bore
striking results. While most of the variants we highlighted were rare, some mistranslation-ready
anticodon variants were found in allele frequencies as high as 6% ((11), Chapter 1). Some also had
the potential to cause remarkably dissimilar amino acid substitutions, including a tRNA Ser variant
that mistranslates Phe codons ((14), Chapters 3-5) and is found in ~1.8% of sequenced individuals.
We also found several examples of tRNA variants that create G3:U70 pairs in non-alanine tRNAs,
the most common of which occurs in ~1.3% of sequenced individuals.
At the same time, we contributed to a DNA sequencing project that would reveal a much
greater prevalence of tRNA variants in the human population than previously understood (15). A
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major challenge in sequencing tRNA genes is their repetitive nature, with some tRNA genes
occurring in as many as 11 identical copies in the human genome (13). This creates a mapping
challenge in whole genome sequencing studies, since read lengths typically fall below 50
nucleotides in length (12), and tRNAs are >70 nucleotide sequences. Further, low sequencing
coverage in the 1000 genomes project (4x) limited the authors’ ability to determine the number of
tRNA variants occurring per individual, since many potential variant reads could not be
distinguished from sequencing errors (12).
In our study (15), we employed greater depth of coverage (>60x) and a tiled read mapping
strategy that used tRNA flanking sequence to more accurately map tRNA sequences to their correct
genomic loci. With this approach, we found ~60-70 tRNA variants per individual in a cohort of 84
individuals. Thus, variants in cytoplasmic tRNA genes occur in all individuals. Hence, individuals
likely differ in the rate and type of protein synthesis errors that occur in their cells depending on
the collection of variants present in their tRNA genes.
Despite the astounding prevalence of tRNA sequence variants in the population, very little
was known about how naturally occurring variants in human cytoplasmic tRNA genes affect
cellular physiology, especially in models of disease. Indeed, in our 2019 review ((11), Chapter 1),
we found only a single proven example of a variant in a human cytoplasmic tRNA acting as a
primary driver of disease (16). However, many examples were found of mutations in mitochondrial
tRNAs or proteins that interact with cytoplasmic tRNAs (aminoacyl-tRNA synthetases, tRNAmodifying enzymes, ribosome-associated factors, etc.) being implicated in human disease (11).
Further, studies on engineered tRNA variants expressed in mammalian cells demonstrated that
mistranslating tRNAs can cause protein folding stress (10) and have exacerbating effects in models
of cancer (8). Another study demonstrated that in mice, a cytoplasmic tRNA variant was associated
with neuronal dysfunction (17).
Based on our review, we hypothesized that human cytoplasmic tRNA variants would be
more likely to act as modifiers than primary drivers of disease. To investigate this hypothesis
further, we employed mammalian cell-based models of the neurodegenerative diseases
Huntington’s disease ((14), Chapter 3) and amyotrophic lateral sclerosis (ALS; Chapter 4). We
chose to focus on models of neurodegenerative disease since the pathogenesis of most
neurodegenerative diseases involves misfolding proteins, which challenge many of the same

210

protein folding stress responses as mistranslating tRNAs (18). There are also many examples of
mutations in mitochondrial tRNAs and proteins that interact with tRNAs being implicated in
neurodegenerative disease (11), in addition to the mentioned example of a mouse cytoplasmic
tRNA exacerbating a neurodegenerative phenotype (17). For both studies (Chapters 3 and 4), we
primarily focused on a naturally occurring non-synonymous anticodon variant in the tRNA-SerAGA-2-3 gene which occurs in ~1.8% of sequenced individuals (12,13,15,19). As we
demonstrated in Chapters 3 and 5, the tRNA causes Ser amino acid misincorporation at Phe UUC
and UUU codons. We expressed the tRNA by encoding it on a plasmid with ± 300 bp flanking
sequence, which was PCR amplified from HEK293 genomic DNA.
In our study on models of Huntington’s disease ((14), Chapter 3), we expressed exon 1
sequences from the human HTT gene with extended CAG repeats that encode an aggregationprone polyglutamine (polyQ) sequence. Conveniently, fusing this protein coding sequence to a
fluorescent protein (EGFP) enables real-time monitoring of polyQ aggregation kinetics in live cells
(20). Similarly, in the ALS study (Chapter 4), we expressed an mCherry-fused FUS protein or
R521C variant. FUS is a frequently mutated protein in ALS (21), and C-terminal fusion to
fluorescent proteins allows visualization of aggregate formation in live cells (22).
In cytotoxicity assays where the mistranslating tRNA and extended polyQ proteins were
co-expressed, we did not observe synthetic toxic effects ((14), Chapter 3). Rather, the
mistranslating tRNA had a dominant effect, exhibiting cytotoxicity in cells expressing either
typical (23Q) or disease-length (74Q) polyQ proteins. In our studies co-expressing the
mistranslating tRNA and FUS, we observed a synthetic toxic effect with the FUS(R521C) mutant,
where expressing both the mistranslating tRNA and FUS mutant had a stronger cytotoxic effect
than either component alone (Chapter 4). Further studies may be required to determine why the
mutant FUS had an exacerbating effect not seen with mutant polyQ, but it should be noted that
toxicity of HTTexon1 polyQ proteins expressed in cells can be relatively mild (23). Another
observation from our cytotoxicity experiments was that proteasome inhibition using the small
molecule MG132 was capable of exacerbating toxicity of the mistranslating tRNA ((14), Chapter
3). Hence, we demonstrated the usefulness of MG132 as an exacerbating agent to study
mistranslating tRNA toxicity.
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In our experiments on aggregation kinetics of polyQ proteins in mistranslating cells, we
found that the mistranslating tRNA caused slowed formation of aggregates ((14), Chapter 3). We
attributed this to a reduction in protein synthesis which occurred in mistranslating cells. Others
have observed a similar effect on protein synthesis when expressing engineered anticodon variants
of tRNASer in mammalian cells (9,10). We observed a comparable effect in cells expressing the
FUS-mCherry proteins (Chapter 4), where expression and aggregation of FUS-mCherry was
generally lower in mistranslating cells. However, in our FUS experiments, we monitored cells for
a longer time-course, and found that after extended expression of the mistranslating tRNA and
FUS-mCherry, the appearance of aggregates began to accelerate rapidly. In cells expressing
FUS(R521C)-mCherry, aggregation kinetics were highly sporadic in mistranslating cells and
fluctuated above and below aggregation levels in cells expressing wild-type tRNA throughout the
timecourse.
Future studies will be required in stable cell lines to assess the more long-term kinetics of
protein aggregation in mistranslating cells. However, the data suggest that suppression of protein
synthesis in mistranslating cells may be transient or fluctuate over time. Intriguingly, a study on a
ribosomal protein mutant that causes chronic amino acid misincorporation showed that protein
folding stress responses, which often signal reductions in protein synthesis, can become suppressed
in chronically mistranslating cells (24). Another study on tRNASer anticodon variants expressed in
stably transfected cells demonstrated that protein synthesis rates can vary greatly depending on
passage number of the cells and the type of amino acid misincorporation (9). In that study, in cells
expressing a tRNASer with Ala-decoding anticodon, protein synthesis increased from passages 1 to
15, then fell sharply by passage 30. By contrast, cells expressing a tRNA Ser with Leu-decoding
anticodon exhibited reduced protein synthesis at all passages after passage 1. Our observations on
FUS-mCherry aggregation (Chapter 4) further demonstrate that protein synthesis rate alterations
caused by mistranslating tRNAs can change temporally.
From a mechanistic standpoint, how mistranslating tRNAs elicit reductions in protein
synthesis is dependent on a multitude of factors. For example, inhibitory phosphorylation of
elongation initiation factor 2 alpha (eIF2α) is a converging point of numerous stress responses (25)
and has been observed in several studies of mistranslating tRNAs expressed in mammalian cells
(9,10,26). However, in our studies on the naturally occurring Phe to Ser mistranslating tRNA, we
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did not observe phosphorylation of eIF2α ((14), Chapter 3). Further, cells expressing this tRNA
were resistant to effects of the integrated stress response inhibitor (ISRIB), a small molecule
designed to promote mRNA translation initiation in cells where eIF2α is phosphorylated. It should
also be noted that this was the first published example (to our knowledge) of a naturally occurring
tRNA variant altering small molecule treatment efficacy in mammalian cells. Regarding eIF2α,
others have found that phosphorylation is not always evident in cells expressing mistranslating
tRNAs (9), and levels can vary greatly depending on the type of amino acid misincorporation (10),
and cell passage number (9). We also did not observe phosphorylation of eukaryotic elongation
factor 2 (eEF2), another major regulatory point of protein synthesis (27,28). Studies in our lab are
ongoing to better understand the mechanism of translation inhibition in cells expressing the Phe to
Ser mistranslating tRNA variant.
In our study on polyQ aggregation in mistranslating cells ((14), Chapter 3), we also
measured effects on protein turnover. Cells expressing the mistranslating tRNA exhibited reduced
turnover of polyQ protein. Thus, while polyQ aggregates formed more slowly initially, they were
also slower to degrade in mistranslating cells. This was supported by our observation that
proteasome inhibition can exacerbate mistranslation toxicity (Chapter 3). Given that mistranslating
tRNAs lead to the production of misfolded proteins, they place an increased burden on protein
turnover. The implications of this finding in patients with neurodegenerative disease are complex.
Robust protein turnover is required for cells to tolerate protein folding stress caused by misfolding
proteins (29,30). However, in aging cells, reduced protein turnover can also be beneficial, as it
helps to compensate for age-related reductions in protein synthesis (31).
Altogether, our studies on Huntington’s and ALS disease models were the first to explore
naturally occurring human cytoplasmic tRNA gene variants as modifiers of disease. Our work
demonstrates that tRNA variants have significant potential to alter disease progression since
mistranslation and the signaling events it elicits can alter the expression and degradation of
proteins, as well as alter the efficacy of small molecules designed to treat disease. These
discoveries shed new light on a potentially vast and understudied source of variability in human
disease.
Given that the human genome encodes ~400 functional tRNA genes and ~210 tRNA-like
pseudogenes (12,13,32), and each individuals harbors ~60-70 variants in these genes (15),
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characterizing which variants have potential to affect disease progression represents a significant
challenge. While some tRNA variants that cause amino acid misincorporation can be functionally
predicted based on knowledge of tRNA identity elements, many more variants can have complex
effects that are harder to predict. For example, others have shown that mutations in the T-stem of
different tRNAs can compromise tRNA function. In one case, a C65G mutation in human tRNA Sec
resulted in changes to stress-dependent modifications in the anticodon (16). Hence, mutations in
one location in the tRNA body can affect other sites in the tRNA by changing interactions with
tRNA modifying enzymes. In another case, a C50T mutation in a mouse tRNA Arg gene caused
ribosome stalling, but only in the central nervous system where the tRNA gene is exclusively
expressed (17). Thus, understanding tissue-specific differences in tRNA gene expression is critical
to predict the consequences of variants in the tRNA sequence. These examples highlight how the
relationship between tRNA sequence and function is complex. Even when mutations occur in well
characterized nucleotides in the tRNA body, it is difficult to predict how a given mutation will
alter the path of a tRNA from transcription and processing to mRNA translation. Therefore, the
rational approach of predicting tRNA variant functions has limitations.
Another tool to classify the disease-modifying potential of tRNA gene variants is to
evaluate the loci at which tRNAs are encoded (33). Individual tRNA genes vary greatly in
expression activity, and tRNA genes can be activated or silenced depending on tissue (34) or cell
states (eg. proliferation versus differentiation) (35). Hence, classifying expression activity of
individual tRNA genes could be a valuable approach to predict variants-of-concern and what
tissues might be most affected by a given tRNA variant.
Transfer RNA gene expression activity can be roughly predicted based on publicly
available gene expression data such as CHIP-sequencing (36,37) and DNase sequencing (36,38),
or based on bioinformatic scoring algorithms (33,39). In Chapter 5, we explored the use of a wellcharacterized tRNA variant as a tool to test tRNA gene activity experimentally. The Phe-to-Ser
mistranslating tRNA we characterized in Chapters 3-4 represented an interesting case to explore
the effects of loci-of-origin on tRNA gene activity. The variant is a G35A mutation in the tRNASer-AGA-2-3 gene. Intriguingly, the tRNA-Ser-AGA-2-3 is one of the six identical copies of the
same tRNA sequence (named tRNA-Ser-AGA-2-1, -2-2, …, -2-6) (13). Yet, the variant occurs
much more commonly in the -2-3 locus than any other site. In the -2-3 locus, the variant is found
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in ~1.8% of sequenced individuals. In the other tRNA-Ser-AGA-2 genes, the variant has either not
been observed, or is exceedingly rare (allele frequency < 0.0015%) (12,19,40). Given that the
genes are identical, it is not possible to compare their expression activity at the RNA level with
methods like RNA sequencing or quantitative reverse-transcription polymerase chain reaction
(qRT-PCR). Interestingly, while the sequences encoding tRNA-Ser-AGA-2 are identical, the
sequences flanking the tRNAs are highly divergent. Indeed, in Chapter 5 I aligned all six tRNA
gene loci with ± 300 bp flanking sequence and the only conserved feature outside of the tRNA
gene was a short poly-thymidine transcription termination sequence downstream of each tRNA
sequence. It has long been known that tRNA flanking sequences can alter the regulation and
processing efficiency of tRNA genes (33,41,42). Hence, we expected that the identical tRNA-SerAGA-2 loci would be expressed at different levels, and potentially in a tissue-dependent manner.
To test the functional activity of the tRNA gene in its different sequence contexts, we took
advantage of the reliable reduction in fluorescence we observed when co-expressing the Phe-toSer mistranslating tRNA with fluorescent proteins ((14), Chapters 3-4). We encoded the tRNA
variant or wild type on plasmids with flanking sequences (± 300 bp) taken from four different loci
at which copies of the gene is encoded in the human genome. With this approach, we found that
expressing the tRNA variant from different sequence contexts altered its phenotypic potency in a
cell-line dependent manner (Chapter 5). For example, expressing the tRNA variant from the tRNASer-AGA-2-4 gene context caused a significant reduction in fluorescence in two of the tested cell
lines (HEK293T and N2a), but no effect in the other cell line (K562). We also found that the effects
on fluorescence correlated well with our gene expression predictions based on CHIP-sequencing
(36,37) and DNase sequencing (36,38) data from K562 cells. Hence, our approach could be useful
for validating tRNA gene expression predictions from publicly available datasets.
We also used our plasmids to test the cytotoxicity of the tRNA variant expressed from
different sequence contexts in different cell lines. We could not readily detect cytotoxic effects
from the tRNA variant expressed from any context in HEK293T or K562 cells, but in N2a cells
we observed a significant cytotoxic effect from the tRNA expressed in all contexts (Chapter 5).
Hence, N2a cells may be more sensitive to tRNA-dependent mistranslation than HEK293T or
K562 cells. As discussed earlier, we and others have found that some mammalian cell lines
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(including HEK293) are robust to amino acid misincorporation, so it was not surprising that the
tRNA variants had no detectable cytotoxic effects in HEK293T and K562 cells.
To probe phenotypic effects further, we employed a single-cell resolution cell migration
assay. The assay uses fluorescence from transfected cells and particle tracking software to track
and measure cell migration speed. With this assay we found that, in the presence of MG132
proteasome inhibitor, the mistranslating tRNA expressed in the tRNA-Ser-AGA-2-3 context
caused a significant reduction in cell migration speed compared to cells expressing wild type
(Chapter 5). To our knowledge, this is the first demonstration that a naturally occurring tRNA
variant can alter mammalian cell migration kinetics. Further studies will be required to determine
the detailed mechanism of this phenomenon. One likely explanation is that increased errors in
mRNA translation and the reduced protein synthesis rate in mistranslating cells impede
cytoskeletal dynamics required for migration. Indeed, genetic interaction screens in yeast using
mistranslating tRNAs (43) and amino acids that misincorporate in proteins (44) have shown that
actin cytoskeleton regulation is often altered in mistranslating yeast cells.
Another observation we made in our sequence context experiments (Chapter 5) was that
one of the sequence contexts (tRNA-Ser-AGA-2-5) had an exceptionally strong effect on
fluorescence compared to the other expression contexts in HEK293T cells. We saw this as an
opportunity to improve on our methods for detection of amino acid misincorporation with a strong
mistranslating tRNA. In Chapter 3, we demonstrated that the tRNA-Ser-AGA-2-3 G35A variant
caused Phe-to-Ser amino acid misincorporation by immunoprecipitating a co-expressed mCherry
protein from cells and identifying peptides containing misincorporated amino acids by liquid
chromatography with tandem mass spectrometry (LC-MS/MS). One limitation of this approach
was that we were limited to the codons already present in the mCherry coding sequence, and the
peptides containing misincorporated amino acids varied in size and sequence composition, making
it difficult to quantitatively compare misincorporation at different codons. To improve on our
approach, we used MS-READ (45), a designer peptide-based mass spectrometry method that was
developed to quantitatively detect amino acid misincorporation events in yeast. The MS-READ
peptide was designed to have optimal characteristics for detection by LS-MS/MS with a broad
range of amino acids encoded at a central test position (45).
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To adapt MS-READ for use in mammalian cells, we fused the MS-READ peptide sequence
containing custom test codons to mCherry and co-expressed the MS-READ-mCherry protein with
wild-type or mistranslating tRNA expressed from the tRNA-Ser-AGA-2-5 gene sequence context.
We then purified the MS-READ-mCherry proteins from HEK293T cells by immunoprecipitation
with anti-RFP nanobody conjugated agarose beads. Lastly, we digested the MS-READ-mCherry
proteins with trypsin and analyzed the samples by LC-MS/MS. With this approach, we
demonstrated that the tRNA-Ser-AGA-2-5 G35A variants misincorporates Ser at Phe UUU and
UUC codons, but not Leu UUA or UUG codons. Thus, we demonstrated a highly sensitive and
codon-specific method to characterize tRNA-dependent amino acid misincorporation in
mammalian cells. We anticipate that this approach will become a valuable tool in characterizing
other human tRNA genes with anticodon and identity element mutations.
In sum, the work described in Chapter 5 demonstrated that identical tRNA gene variants
can differ in phenotypic potency and affected cell types depending on local sequence context. We
also demonstrated novel methods for phenotypic comparison of tRNA variants and detection of
amino acid misincorporation that could significantly improve our ability to study the astounding
number of tRNA variants in the human population.

6.2 Future outlook
6.2.1 Mechanisms of protein synthesis inhibition in mistranslating cells
One major outstanding question from my thesis work is how the tRNA-Ser-AGA-2-3
G35A variant causes a reduction in protein synthesis in cells. In Chapter 3, we used western
blotting to test for several markers of protein folding stress and protein synthesis inhibition that
others had observed in mistranslating yeast (43) and mammalian cells (9,10,26). Surprisingly, we
could not establish any of these responses in cells expressing the tRNA-Ser-AGA-2-3 G35A
variant (tRNASerAAA). Our laboratory is currently working to better answer this question using
methods that more broadly assay for changes in the proteome (reverse-phase protein array). I also
initiated some investigations into immunofluorescence as a method to assay both signaling
changes and changes to physiological features of mistranslating cells.
At the same time, I have initiated investigations into a working hypothesis of anticodon
loop compatibility. My hypothesis of anticodon loop compatibility is that tRNAs bearing non-
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cognate anticodons would in some cases exhibit sub-optimal decoding kinetics in the ribosome.
Since tRNA anticodon variants did not co-evolve with their anticodon sequence, they may or may
not be able to orient the anticodon for efficient pairing and unpairing with codons. If true, slowed
kinetics in the ribosome could in part reduce protein synthesis rates by physically slowing
ribosomal translocation. This would also explain why we found that the integrated stress response
inhibitor was unable to restore protein synthesis activity in cells expressing the tRNA SerAAA variant
(Chapter 3).
Interestingly, the AAA anticodon does not occur naturally in human tRNA Phe genes
(13,46). Instead tRNAPhe in humans and almost all eukaryotes exclusively utilize a GAA anticodon
to decode UUU codons (13,46). tRNAPhe also harbors a highly conserved guanine in the anticodonadjacent position 37 (46). These guanine bases are modified post-transcriptionally and ensure
accurate and efficient pairing with U-rich Phe codons (47-49). By contrast, the tRNA SerAAA variant
harbors five consecutive adenosine nucleotides spanning from the first position of the anticodon
to the first pair of the anticodon stem (positions 34-38). Others have postulated that A:U-rich
codon:anticodon pairs are prone to frameshifting and inefficient conformational sampling at the
decoding center (50,51), which could limit decoding kinetics. Thus, the variant may reduce protein
synthesis partly through physical impediment of the ribosome, which would explain the lack of
signaling associated with protein synthesis reduction. To investigate this hypothesis, I have done
some preliminary investigations introducing G34 or G37 mutations into the tRNA to better mimic
the anticodon loop sequence of tRNAPhe. I hope that these investigations will help to better
understand the mechanism of protein synthesis inhibition in cells expressing the tRNA SerAAA
variant, as well as provide insight to mechanistic studies of tRNA anticodon variants in general.

6.2.2 Fluorescent reporters of amino acid misincorporation
In Chapter 2, we used a fluorescent reporter protein to monitor Pro to Ala amino acid
misincorporation in live cells. Recently, we developed and characterized a similar reporter in E.
coli that can be used to detect mistranslation caused by tRNASer anticodon variants (52). I have
developed a version of this reporter for monitoring Ser misincorporation in mammalian cells, and
work with this reporter is ongoing in our laboratory. Given that tRNASer anticodon variants are
especially capable of causing amino acid misincorporation, I anticipate that this reporter will prove
valuable in characterizing other tRNASer anticodon variants found in the human population.
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6.2.3 Sequencing tRNA genes in disease cohorts
As noted in section 6.1, the repetitive nature of tRNA genes has contributed to a lack of
reliable sequencing data on tRNA variant frequencies in the human population, especially in
disease cohorts. Further, tRNA genes are not typically included in whole exome or genome-wide
association sequencing arrays. With increasing examples of tRNAs acting as genetic modifiers in
models of disease (8,14,17,26), promoting the further inclusion of tRNA genes in sequencing
studies will be critical to determine if our findings in cell culture-based models of disease hold true
in real patients. With sequencing data to validate disease associations of tRNA variants, tRNA
genes may become valuable markers in predicting the age of onset and severity of diseases in
humans.

6.3 Conclusion
In my thesis work, I contributed to revealing a greater prevalence of tRNA gene sequence
variants in the human population than previously understood and highlighted how many of these
variants have potential to cause amino acid misincorporation and act as modifiers of disease. As
proof-of principle, I demonstrated in mammalian cell-based models of Huntington’s disease and
ALS that a naturally occurring tRNA variant can alter the cytotoxicity, synthesis, and degradation
of aggregation-prone proteins associated with neurodegenerative disease. Finally, I developed
novel methodological approaches to study highly similar and identical tRNA genes found in the
human population, using a well characterized naturally occurring tRNA variant as a genetic tool.
I hope that this work will draw greater attention to tRNA variants as potential modifiers of human
disease, refining our ability to predict progression and treatment. Finally, the methodological
approaches described should inspire new approaches to characterize the astounding number of
tRNA sequence variants found in the human population.
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